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Reconstitution of the Final Step of Peptidoglycan Assembly in Staphylococcus aureus 
Abstract 
Bacterial peptidoglycan (PG) is an exoskeleton structure that maintains cell shape and 
protects cells from lysis. Peptidoglycan is essential in bacteria but is not found in mammalian 
cells. Therefore, it is the target for several classes of antibiotics, including the beta-lactam 
family. Beta-lactams target the transpeptidase (TP) domain of penicillin-binding proteins (PBPs), 
the enzymes responsible for the final step of peptidoglycan biosynthesis. Mutations of 
transpeptidases in Staphylococcus aureus (S. aureus) have been implicated in beta-lactam 
resistance in the clinic (commonly known as MRSA infections). Despite the fact that PBPs are 
important antibiotic targets, there have been no direct assays to monitor their enzymatic activity, 
primarily due to inaccessibility to appropriate substrates. The PG precursor, Lipid II, is required 
to study transpeptidase activity. Lipid II contains a glycopeptide attached to a pyrophosphate 
lipid containing 55 carbons. It has poor physical properties and is present in low abundance in 
bacteria. 
This thesis describes the reconstitution of peptidoglycan assembly in Staphylococcus 
aureus by the essential Class A PBP, PBP2. This was enabled by several key advances, which 
are also described. The first advance is the discovery that PBP4, a low-molecular weight PBP in 
S. aureus, can use a Lipid II analogue as a transpeptidation substrate. It can incorporate biotin-D-
Lys (BDL) and other non-canonical D-amino acids into the terminal position of the stem peptide 
in Lipid II. BDL labeling of Lipid II with S. aureus PBP4 has enabled the second advance: the 
direct detection of native Lipid II extracted from bacteria. This has facilitated elucidation of 
! iv 
cellular mechanisms of antibiotics that target cell wall biosynthesis. The third advance is a 
general strategy to accumulate and isolate native Lipid II in bacteria in useful quantities. Access 
to substantial quantities of native S. aureus Lipid II has enabled reconstitution of PBP2 
transpeptidase activity, as well as characterization of several beta-lactam antibiotics by 
monitoring enzymatic inhibition.  
In sum, this work establishes important tools for studying enzymatic mechanisms of 
bacterial transpeptidases and for characterizing inhibitors that target bacterial peptidoglycan 
biosynthesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
! v 
Table of Contents 
Abstract iii 
Table of contents v 
List of Figures viii 
List of Table xii 
List of Schemes  xii 
Glossary of Abbreviations  xiii 
Acknowledgements xv 
 
Chapter One: Introduction to peptidoglycan biosynthesis in Staphylococcus aureus 
1.1 Penicillin, the wonder drug 2 
1.2 The bacterial cell wall pathway 3 
1.2.1 Formation of the Park nucleotide 5 
1.2.2 Formation of the lipid-linked intermediates 7 
1.2.3 Peptidoglycan (PG) assembly 13 
1.3 The cellular roles of S. aureus penicillin-binding proteins (PBPs) 17 
1.4 Resistance in methicillin-resistant S. aureus (MRSA) 22 
1.4.1 An acquired resistant PBP, PBP2a in MRSA 22 
1.4.2 Factors influencing methicillin resistance 25 
1.4.3 Chemical genetic approaches to combat MRSA 27 
1.5 Lipid II is required for enzymatic studies of PBPs 27 
1.5.1 Current approaches of Lipid II preparation 28 
1.5.2 Mechanistic insights into peptidoglycan glycosyltransferase (PGT) activities 32 
1.5.3 Existing knowledge on PBP transpeptidase (TP) activities 35 
1.6 Perspectives 36 
1.7 References 38 
 
Chapter Two: Exploiting the transpeptidase activity of PBP4 to detect peptidoglycan 
precursors in cells and to elucidate the mechanism of antibiotics that target cell wall 
biosynthesis  
2.1 Introduction 59 
2.1.1 S. aureus PBP4, a peculiar PBP 59 
2.1.2 Challenges with studying the cellular pools of Lipid II in bacteria 62 
2.2 Purification and characterization of S. aureus PBP4 64 
2.3 Assessment of S. aureus PBP4 in vitro activity 65 
2.4 Assessment of S. aureus PBP4 in vivo activity 67 
2.5 Analysis of S. aureus PBP4 substrate specificity in vitro 69 
! vi 
2.6 Detection of the cellular levels of Lipid II in bacteria 73 
2.7 Elucidation of the cellular mechanism of action for lysobactin 75 
2.8 Conclusion 77 
2.9 Materials and Methods  
2.9.1 Materials 79 
2.9.2 General methods 80 
2.9.3 Plasmid construction 80 
2.9.4 Overexpression and purification of S. aureus PBP4 and mutant 81 
2.9.5 Bocillin-FL binding assay 82 
2.9.6 LC/MS protocol for muropeptide analysis 82 
2.9.7 Microscopy imaging analysis 84 
2.9.8 Preparation of BDL probe 84 
2.9.9 Incorporation of functionalized D-amino acids into Lipid I and Lipid II 84 
2.9.10 Western blot detection of BDL-Lipid II in vitro 86 
2.9.11 Extraction of cellular lipid-linked PG precursors and Western blot detection 86 
2.10 References 88 
 
Chapter Three: Preparation of native Staphylococcus aureus Lipid II   
3.1 Introduction 97 
3.2 Chemical synthesis of S. aureus Lipid II  
3.2.1 Synthesis of stem pentapeptide containing variable glycine branches 99 
3.2.2 Coupling reactions to make Lipid I and Lipid II variants 104 
3.3 A facile method to obtain native S. aureus Lipid II 106 
3.3.1 Estimation of S. aureus Lipid II quantity 111 
3.4 A general approach to obtain bacterial Lipid II 112 
3.5 Conclusion 114 
3.6 Materials and Methods  
3.6.1 Experimental details of synthesis 115 
3.6.2 Small-scale extraction of S. aureus Lipid II 130 
3.6.3 Large-scale extraction of S. aureus Lipid II 131 
3.6.4 Thin layer chromatography analysis of phospholipids 132 
3.6.5 Western blot analysis of BDL-labeled Lipid II  133 
3.6.6 LC/MS analysis of delipidated S. aureus Lipid II 133 
3.6.7 Quantifications of delipidated S. aureus Lipid II 134 
3.7 References 135 
 
Chapter Four: Reconstitution of peptidoglycan assembly by Staphylococcus aureus PBP2  
4.1 Introduction 139 
4.1.1 PBP2 is the essential Class A PBP in S. aureus 139 
4.1.2 Traditional competition binding assays to study beta-lactams 142 
! vii 
4.2 Purification of S. aureus PBP2 143 
4.3 Reconstitution of the PGT and TP activities of S. aureus PBP2 145 
4.4 Assessing the inhibitory effects of beta-lactams 148 
4.5 Investigating the substrate specificity of S. aureus PBP2 151 
4.6 Conclusion and future studies 152 
4.7 Materials and methods  
4.7.1 General methods 154 
4.7.2 Cloning of S. aureus PBP2[M59-S716] and mutants 154 
4.7.3 Overexpression and purification of S. aureus PBP2 and mutants 155 
4.7.4 LC/MS assay analysis of S. aureus PBP2 activity in vitro 156 
4.7.5 Degradation of isolated S. aureus sacculi 157 
4.7.6 Western blot analysis of S. aureus PBP2 TP activity  158 
4.7.7 Studies on beta-lactam inhibition of PBP2 TP activity  159 
4.8 References 160 
 
Appendix One: Mass spectrometry (MS) analysis for studies in Chapter Two 164 
 
Appendix Two: NMR and MS data for compounds in Chapter Three 170 
 
Appendix Three: MS data and Western blot analysis for studies in Chapter Four 192 
 
 
 
 
 
 
 
 
 
 
 
!! viii 
  
List of Figures 
 
Figure 1.1. General structure of the penicillin family of antibiotics. 2 
Figure 1.2. Structure of the Park nucleotide in S. aureus. 6 
Figure 1.3. Structure of Lipid I and Lipid II intermediates identified in the  
cell-free system using the particulate enzymes from S. aureus. 8 
Figure 1.4. The complete Lipid II structure in S. aureus. 11 
Figure 1.5. Schematic showing pepetidoglycan (PG) biosynthesis in S. aureus. 15 
Figure 1.6. The proposed mechanisms of transpeptidation (and hydrolysis) by PBPs  
and penicillin inhibition. 16 
Figure 1.7. Beta-lactams show selective binding to S. aureus PBPs. 18 
Figure 1.8. An allosteric regulation of S. aureus PBP2a activity is proposed. 25 
Figure 1.9. The synthetic route to make Lipid I by Tsukamoto and Kahne. 30 
Figure 2.1. Schematic of carboxypeptidase and transpeptidase activities 
in S. aureus PG assembly and Lipid II substrates. 60 
Figure 2.2. Protein sequence alignments of representative LMW PBPs.  61 
Figure 2.3. S. aureus PBP4 protein is purified to homogenity.  65 
Figure 2.4. S. aureus PBP4 demonstrates TP activity in vitro.  67 
Figure 2.5. S. aureus PBP4 has TP activity in vivo.  68 
Figure 2.6. S. aureus PBP4 exhibits promiscuous TP activity in vitro.  70 
Figure 2.7. LC/MS analysis of S. aureus PBP4-mediated D-amino acid exchange  
in Lipid II.  72 
Figure 2.8. Schematic showing the versatility of PBP4 TP activity.  73 
Figure 2.9. S. aureus PBP4 enables a simple assay to detect cellular Lipid II in bacteria. 75 
!! ix 
Figure 2.10. Lysobactin treatment accumulates Lipid II in S. aureus. 77 
Figure 3.1. Moenomcyin treatment accumulates Lipid II by 10-fold in S. aureus. 108 
Figure 3.2. Preparative quantities of the native S. aureus Lipid II can be obtained via  
a two-step accumulation and extraction procedure. 109 
Figure 3.3. Structural confirmation of isolated S. aureus Lipid II. 111 
Figure 3.4. Structures of deplidated Lipid II species. 112 
Figure 3.5. Structures of Lipid II species isolated from different bacteria. 114 
Figure 4.1. Schematic depiction of S. aureus PG biosynthetic pathway. 140 
Figure 4.2. Purification of S. aureus PBP2[M59-S716] construct and mutants. 144 
Figure 4.3. S. aureus PBP2 uses native Lipid II to make cross-linked PG in vitro. 146 
Figure 4.4. Beta-lactams inhibit S. aureus PBP2 TP activity. 150 
Figure 4.5. S. aureus PBP2 demonstrates substrate specificity in transpeptidation. 152 
Figure App1.1. S. aureus PBP4 shows TP activitiy in vitro. 165 
Figure App1.2. S. aureus PBP4 shows TP activitiy in vitro. 166 
Figure App1.3. Analysis of S. aureus PBP4 activities at varying concentrations of D-Tyr 
nucelophile. 167 
Figure App1.4. S. aureus PBP4 efficiently incorproate D-amino acids into  
m-Dap-Lipid II and Lys-Lipid II in vitro. 168 
Figure App1.5. S. aureus PBP4 incorporates functionalized D-amino acids into  
Lys-Lipid I and Lys-Lipid II in vitro. 169 
Figure App2.1. 1H NMR of Boc-L-Ala-D-isoGln-OH. 171 
Figure App2.2. 1H NMR and LRMS of Boc-L-Ala-D-isoGln-L-Lys(Cbz)-D-Ala- 
D-Ala-OMe (1). 172 
Figure App2.3. 1H NMR and LRMS of Boc-L-Ala-D-isoGln-L-Lys(-Gly-TFA)-D-Ala- 
!! x 
D-Ala-OMe (3). 173 
Figure App2.4. 1H NMR and LRMS of Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Cbz)- 
D-Ala-D-Ala-OMe (4). 174 
Figure App2.5. 1H NMR and LRMS of Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly- 
TFA)-D-Ala-D-Ala-OMe (5). 175 
Figure App2.6. 1H NMR and LRMS of Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly- 
Gly-Cbz)-D-Ala-D-Ala-OMe (6). 176 
Figure App2.7. 1H NMR and LRMS of Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly- 
Gly-Gly-TFA)-D-Ala-D-Ala-OMe (7). 177 
Figure App2.8. 1H NMR and LRMS of Cbz-D-isoGln(Trt)-OH. 178 
Figure App2.9. 1H NMR of Boc-L-Ala-D-isoGln(Trt)-L-Lys(-Cbz)-D-Ala-D-Ala- 
OMe (9). 179 
Figure App2.10. 1H NMR and LMRS of Boc-L-Lys(-Gly-Gly-Gly-Gly-NH2)- 
D-Ala-D-Ala-OMe (10). 180 
Figure App2.11. 1H NMR and LMRS of Boc-L-Lys(-Gly-Gly-Gly-Gly-Gly-TFA)- 
D-Ala-D-Ala-OMe (11). 181 
Figure App2.12. LRMS of protected Gly-Lipid I. 182 
Figure App2.13. LRMS of Gly-Lipid I (12). 182 
Figure App2.14. HRMS of Gly-Lipid I (12). 183 
Figure App2.15. LRMS of protected Gly3-Lipid I. 184 
Figure App2.16. LRMS of Gly3-Lipid I (13). 184 
Figure App2.17. HRMS of Gly3-Lipid I (13). 185 
Figure App2.18. LRMS of protected Gly5-Lipid I (14). 186 
Figure App2.19. HRMS of Gly-Lipid II (15). 187 
!! xi 
Figure App2.20. HRMS of Gly3-Lipid II (16). 188 
Figure App2.21. LC/MS/MS of delipidated S. aureus Lipid II. 189 
Figure App2.22. Estimation of the amount of S. aureus Lipid II isolated from cells. 190 
Figure App2.23. LC/MS analysis of delipidated Lipid II from different bacteria. 191 
Figure App3.1. The TP domain of S. aureus PBP2 is responsible for PG cross-linking. 193 
Figure App3.2. Beta-lactams inhibit S. aureus PBP2 TP activity in vitro. 194 !
 
 
 
 
 
 
 
 
 !
!! xii 
  
List of Table 
 
Table 1.1. Classification of PBPs in S. aureus.  21 
  
List of Schemes 
 
Scheme 3.1. Synthetic route of Gly1-pentapeptide (3), Gly3-pentapeptide (5),  
Gly5-pentapeptide (7). 102 
Scheme 3.2. Alternative routes attempted to avoid complication by the carboxamide 
in the stem pentapeptide.  104 
Scheme 3.3. The general reaction sequence to afford Lipid I and Lipid II variants. 106 
 
 
 
 
 
 
 
 
 !
! xiii 
 
Glossary of Abbreviations 
 
6-APA 6-aminopeicillanic acid 
Ala alanine 
Bac bacitracin 
BDL biotinylated-D-lysine 
Bo-FL Bocillin-FL 
C35 heptaprenyl 
C55 undecaprenyl 
ACN acetonitrile 
CDI 1,1-carbonyldiimidazole 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CP carboxypeptidase 
DMSO dimethyl sulfoxide 
DMTMM dimethoxytriazine-N-methylmorpholinium chloride 
ECA enterobacterial common antigen 
ER endoplasmic reticulum 
FDL fluorescent-D-lysine 
Fos fosfomycin 
Gal galactose 
GlcNAc N-acetyl-glucosamine  
Gln glutamine 
Glu glutamic acid 
! xiv 
Gly glycine 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His histidine 
HMW high-molecular weight 
HPLC high pressure liquid chromatography 
Kan kanamycin 
LC/MS liquid chromatography mass spectrometry 
LDAO N,N-dimethyldodecylamine N-oxide 
LMW low-molecular weight 
LPII Lipid II 
LPS lipopolysaccharide 
LTA lipoteichoic acid 
Lys lysine 
Lyso lysobactin 
m-Dap meso-diaminopimelic acid 
MmA moenomycin 
MS mass spectrometry 
MS/MS tandem mass spectrometry 
MurNAc N-acetyl-muramic acid 
NMR nuclear magnetic resonance 
PBP penicillin-binding protein 
penG penicillin G 
PEP phosphoenolpyruvate 
! xv 
PG peptidoglycan 
PGT peptidoglycan glycosyltransferase 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
Tar targocil 
TFA trifluoroacetic acid 
TLC thin layer chromatography 
TM transmembrane 
TP transpeptidase 
Tris tris(hydroxymethyl)aminomethane 
UDP uridine diphosphate  
UnP undecaprenyl phosphate 
Vanco vancomycin 
wt wildtype 
WTA wall teichoic acid 
  
 
 
 
 
 
 
 
 
 
 
 
!! xvi 
Acknowledgements 
 Looking back, I feel graduate school has been a swift five-year journey, although there 
were moments that it had felt like never-ending. I am thankful to a lot of people who have helped 
me in various ways on this journey. I am very fortunate to have Dan Kahne and Suzanne Walker 
as my advisors, who have helped me grow as a scientist over the years but also truly care about 
us on a personal level. From every conversation with them, no matter short or long, I can always 
gain great insights into my projects, and more often than not, I receive some words of wisdom on 
life and marriage as well! Dan and Suzanne have always been a source of inspiration for me. I 
admire their passion and enthusiasm in scientific pursuits, their optimistic and open-minded 
attitude towards challenges, and even their commitments to daily workout amid the busy 
schedule.  
My committee members, JoAnne Stubbe and Emily Balskus, have provided invaluable 
advice during my PhD. I have always enjoyed my annual committee meeting with them; our 
discussions have always challenged me to think about my research in greater depth and breadth. I 
see both of them as my female scientist role models.  
There are also many people in the Kahne and Walker labs I need to acknowledge. Tania 
Lupoli and Matthew Lebar were my two awesome mentors as I began graduate school. Tania 
taught me a lot about biochemistry, while Matt was my go-to person for any synthesis problems. 
Their cheerfulness and good humor were very contagious. Both of their work has laid important 
foundations for my projects. Early on, Yuriy Rebets helped me with protein purifications to get 
me started with my projects. Kathrin Schirner offered invaluable help on the PBP4 project and 
made a head start on a key experiment. I would also like to thank Christian Gampe, from whom I 
!! xvii 
inherited the drug discovery project. Our short business trip together to Germany (Christian’s 
home country) and England had strengthened our friendship.  
For the most time in graduate school, I have been working closely with Katie Schaefer, 
Jeep Veerasak Srisuknimit, Wonsik Lee, Fred Rubino, and Jonathan Cheng in the cell wall sub-
group in the Kahne and Walker labs. Katie and I got to know each other really well through 
many collaborations. It is always a pleasure to talk to her (about anything)! Jeep has been a great 
help with my project, his keen observation has opened up new directions for our research. Fred’s 
meticulousness and thoughtfulness in research has never ceased to amaze me. Wonsik and 
Jonathan (a former postdoc) in the Walker lab have made important contributions to the sub-
group and are fun to work with. Alan Yang and Akeem Pinnock, who worked with Jeep and I 
over the past summer, had not only contributed to the progress regarding the PBP2 project, but 
also imparted youthful enthusiasms that are much needed in lab. I also appreciate the hard work 
of Helen Correiro and Mike Quinn for making sure the lab runs smoothly every day.    
Last but not least, I want to thank my family for their unconditioned love and support. 
My husband, Xian Wang, has supported me in every way possible in my graduate school journey 
as well as our marriage journey together. He cheers me up and listens to me. My parents, 
although far away in China, have never failed to make me feel their presence and love over the 
years. I could not have made this far without the selfless and supportive parents that I have.   
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1.1 Penicillin, the wonder drug  
  
The story of penicillin discovery is not an unfamiliar one. In 1928, Alexander Fleming 
made a serendipitous observation that a penicllium mold contamination on a petri dish containing 
Staphylococcus aureus (S. aureus) inhibited the growth of the bacteria.1,2 The term, penicillin, 
was thus coined for the antibacterial substance produced by the penicillium mold.3 Subsequent 
work by Howard Florey, Ernst Chaina and Norman Heatley contributed to the extraction and 
purification of penicillin from mold culture for systematic application.4 Despite a lack of 
knowledge on its structure and mechanism of action at the time, penicillin’s phenomenal 
antibacterial activity had been realized and harnessed by the 1940s, leading to its medicinal use 
as an important class of antibiotics in man.5,6 The expeditious development of penicillin deemed 
extremely beneficial in those days when bacterial infection was the leading cause of deaths in the 
general population. Juxtaposed with the World War II, penicillin, produced in large quantities by 
several pharmaceutical companies in the United States, made an indelible mark in human history 
by saving lives of numerous people that were afflicted with wound infections in the battlefield. 
1,7 The enormous demand of the antibiotic culminated during the war and led to a staggering 
annual production of penicillin of over 600 billion units per month.8b!Penicillin has 
revolutionized modern medicine.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
a!Together with Fleming, Florey and Chain shared the Nobel Prize in Medicine in 1945 for the discovery 
of penicillin and its curative effect in various infectious diseases. !
b One unit is equivalent to 0.6 µg of penicillin. 
N
S
O OH
H
N
O
R
O
Figure 1.1. General structure of the penicillin family of antibiotics. 
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Shortly after the widespread use of penicillin in the general public, the chemical structure 
of penicillin was determined in 1945,9,10 which in turn greatly facilitated the chemical syntheses 
of penicillin and its derivatives for activity optimization (Figure 1.1).11 Semi-synthetic 
approaches making use of the natural precursor, 6-aminopenicillanic acid (6-APA), were also 
widely used to prepare diverse beta-lactam structures.12-14 Penicillin is the founding member of 
the beta-lactam family, which represents the oldest yet the most successful class of antibiotics in 
history. Currently, beta-lactam drugs comprise more than half of the commercially available 
antibiotics in the market.15    
 
1.2 The bacterial cell wall pathway 
 
In addition to its glory as a miracle drug, penicillin has been a successful chemical probe 
in illuminating our understanding of bacterial physiology. In the extended efforts to understand 
the mechanism of penicillin, the cell wall biosynthesis--- a major metabolic pathway in bacteria 
was elucidated. In 1940, Gardner A. D. first noticed the striking morphological changes in a 
variety of bacteria when grown in dilute concentrations of penicillin.16 Rod-shaped bacteria such 
as Escherichia coli (E. coli) became filamentous and grotesquely swollen, while S. aureus cells 
became spherically enlarged. 17,18 Such swelling and bulging in bacteria as a result of penicillin 
treatment led Duguid J. P. (1946) to predict that penicillin disrupts the formation of a cell surface 
structure that supports the cell,19 even before the identification of the bacterial cell wall. In 
addition, the site of action of penicillin in bacteria was proposed to be on the cytoplasmic 
membrane, since exposing bacteria to radioactive penicillin resulted in strongly radiolabeled 
membranes.20-22  
 
4 
With the development of electron microscopic techniques in the 1940s, bacterial cell wall 
was shown as an encasing structure outside of the cytoplasmic membrane in bacteria.23-25 Based 
on the observations that the isolated cell wall maintained bacterial shape, and that bacteria 
became spherical protoplasts after lysozymec treatment in hypertonic sucrose solution, it was 
proposed that the bacterial cell wall is a rigid structure protecting the cell from rapturing under 
the high internal osmotic pressure.26-29 In Gram-positive bacteria such as S. aureus, the cell wall 
is considerably thicker (~20 nm),30 while Gram-negative bacteria have a much thinner cell wall 
(5 nm) in the periplasmic space.31 Analysis of the cell wall composition revealed unusual 
features such as D-amino acids and N-acetyl-muramic acids (MurNAc), which were not observed 
in other metabolic processes in bacteria.32 In general, the cell wall, also referred to as 
peptidoglycan (PG), is composed of glycan strands made of alternating N-acetyl-glucosamine 
(GlcNAc) and N-acetyl-muramic acid (MurNAc) units, with a stem peptide attached on each 
MurNAc residue.33 The identity of the peptide moiety varies in each organism.31 In S. aureus cell 
wall, the stem peptides (L-Ala-D-isoGln-L-Lys-D-Ala-D-Ala) from adjacent glycan polymers are 
cross-linked via a pentaglycine bridge.33 The cross-link is a peptide bond formed between the 
amino terminus of the pentaglycine branch on one stem peptide to the carboxylate end of the 
penultimate D-Ala residue on another. The cross-links impart strengths to PG as a protective 
layer. In S. aureus and other Gram-positive species, PG also serves as a scaffold for covalent 
attachment of cell surface oligosaccharide polymers such as wall teichoic acids (WTAs) and 
capsular polysaccharides, as well as a number of proteins.34  
The biosynthesis of PG is a multi-step process. Much of our understanding of the reaction 
sequence in the pathway was revealed in conjunction with studies on penicillin’s mechanism of !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
c Lysozyme, another significant discovery of Alexander Fleming, is a substance found in human body 
fluids that acts as a glycosidase to kill bacteria by hydrolyzing the bacterial cell wall. 
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action in bacteria in the 1950s-1970s. The following sections summarize the three stages of PG 
biosynthesis using S. aureus as the primary example, while many of the steps are conserved in all 
bacteria.34  
 
1.2.1 Formation of the Park nucleotide 
 
In 1949, Park J. T. made a curious but seminal observation that several related nucleotide 
species were strongly accumulated in S. aureus treated with a non-lethal concentration of 
penicillin.35 The principal species, which was identified as uridine-5’-pyrophspho-N-acetyl-
muramyl-L-alanyl-D-glutamyl-L-lysl-D-alanyl-D-alanine (UDP-MurNAc-pentapeptide), was 
later named the Park nucleotide (Figure 1.2), while the other species contain incomplete peptide 
moieties.36-38 The accumulation of the Park nucleotide in S. aureus was not irreversible, since 
removal of penicillin from the culture led to its reduction. The Park nucleotide was also present 
at a low level in untreated S. aureus as well, thus excluding its possibility as a toxic byproduct 
due to penicillin treatment. Instead, the rapid accumulation of the Park nucleotide in penicillin-
treated S. aureus reflected its high flux under normal conditions, suggesting its involvement in a 
major metabolic pathway in cell.39 The striking structural similarity between the Park nucleotide 
and S. aureus PG led Strominger J. L. and coworkers in 1959 to proposes that the Park 
nucleotide is a biosynthetic precursor of the cell wall, and the accumulation of the Park 
nucleotide is a direct effect of penicillin inhibition.33 They further established that the related 
nucleotides containing shorter peptides were intermediates in the formation of the Park 
nucleotide in S. aureus.40-42 
It wasn’t until the early 1990s that the individual enzymes involved in the formation of 
the Park nucleotide were characterized, owing to the ability to overexpress and purify candidate 
 
6 
proteins. The first committed step in the pathway is the conversion of UDP-GlcNAc to UDP-
MurNAc by MurA and MurB enzymes in the cytoplasm. MurA transfers phosphoenolpyruvate 
(PEP) to UDP-GlcNAc, generating an intermediate that is further reduced by MurB reductase 
using NADPH.43,44 MurA is the target of fosfomycin (fos), a natural product inhibitor that is a 
structural analogue of PEP, which can covalently bind to the active site cysteine residue in 
MurA.45 In the subsequent steps, Mur ligases (MurC–F), which all belong to the ATP-dependent 
amide bond-forming enzyme family, catalyze the sequential attachment of L-Ala, D-isoGlu, L-
Lys (or meso-diaminopimelic acid (m-DAP) in most Gram-negative bacteria) and D-Ala-D-Ala 
onto the C3-lactoyl moiety of UDP-MurNAc to yield UDP-MurNAc-pentapeptide precursor (the 
Park nucleotide). The D-Ala-D-Ala dipeptide is synthesized by the D-Ala-D-Ala ligase (Ddl), 
another specific ATP-dependent ligase, which condenses two molecules of D-Ala.46 Vancomycin 
(vanco), an important glycopeptide antibiotic that is considered as a ‘last-resort’ antibiotic in the 
clinic, acts by specifically binding to the D-Ala-D-Ala termini in PG to kill bacteria. In 
vancomycin-resistant bacterial strains, MurF incorporates D-Ala-D-Lacd depsipeptide (a product 
of the Van ligase) into the Park nucleotide.47-49 Strains that use altered peptide termini in PG in 
place of the normal peptide can effectively evade vancomycin sequestration.  
 
 
 
 
 
 
 
 
 
 
 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
d Lac refers to a lactate residue. 
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Figure 1.2. Structure of the Park nucleotide (UDP-MurNAc-pentapeptide) in S. aureus. 
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1.2.2 Formation of the lipid-linked intermediates 
 
The involvement of the Park nucleotide in bacterial cell wall synthesis was validated  by 
several labs (1964) using S. aureus or Micrococcus luteus particulate enzymes in vitro.41,50 The 
particulate enzymes, which were crude preparations of membrane proteins, could utilize the 
radioactive Park nucleotide and UDP-GlcNAc to yield an insoluble radiolabeled product that was 
lysozyme-sensitive. The product was characterized as a linear polymer made of alternating 
GlcNAc and MurNAc units, resembling the glycan backbone in bacterial cell wall. 49 Strominger 
and coworkers uncovered the complexity of the bacterial cell wall pathway when they analyzed 
in vitro reaction mixture on paper chromatography using isobutyric acid-ammonia eluent, which 
is the prototype of in vitro PG synthesis assay that is still prevalent today.51,52 In the paper 
chromatogram, the radiolabeled polymeric PG product was immobile and retained at the origin, 
while the soluble nucleotide migrated slightly up from the baseline. However, a third fast-
moving radioactive spot appeared near the top of the paper, which was identified as a mixture of 
two species, one containing MurNAc-pentapeptide, and the other containing MurNAc-
pentapeptide and GlcNAc. The high mobility of both species on paper chromatography in the 
organic eluent implied they were lipid-linked, while their occurrence in the reaction was 
consistent with them being the reaction intermediates. These lipid-linked intermediates were 
quantitatively extracted from the reaction mixture using organic solvents of pyridinium 
acetate/n-butanol, while mild acid hydrolysis of the isolated intermediates yielded two soluble 
products, GlcNAc-MurNAc-pentapeptide and MurNAc-pentapeptide, where the composition of 
the pentapeptide was identical to that of the Park nucleotide.51 In each intermediate, a 
pyrophosphate linkage was identified connecting the reducing end of the MurNAc unit to a lipid 
moiety. While the general structures of the intermediates, MurNAc-(pentapeptide)-P-P-lipid 
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(known as Lipid I) and GlcNAc-MurNAc-(pentapeptide)-P-P-lipid (known as Lipid II) were 
determined, elucidation of the nature of the lipid moiety was complicated by the low availability 
of these materials. Remarkably, Higashi et al. managed to scale up the particulate enzyme 
reaction by nearly 100,000-fold to achieve approximately 4 !moles of the purified Lipid IIe that 
permitted structural studies.53 After removal of the soluble fragment on Lipid II by acid 
hydrolysis, the lipid moiety was purified and conclusively identified as undecaprenol (Und) by 
mass spectrometry. The Und lipid contains eight cis- , two trans-, and one terminal isoprene 
units, as characterized in nuclear magnetic resonance (NMR) studies.53,54 The chemical 
structures of Lipid I and Lipid II intermediates are shown in Figure 1.3, while the reactions 
leading to their formation are summarized below:  
 UDP-MurNAc-pentapeptide + Und-P ! UMP + MurNAc-(pentapeptide)-P-P-Und [Lipid I] 
Lipid I + UDP-GlcNAc ! UDP + GlcNAc-MurNAc-(pentapepitde)-P-P-Und [Lipid II] 
 
 
 
 
 
 
 
The essential mraY and murG genes, which encode the enzymes in Lipid I and Lipid II 
synthesis, were identified in 1991.55-58 In the first step, MraY, which belongs to the 
polyprenylphosphate N-acetyl hexosamine 1-phophate-transferase (PNPT) superfamily, transfers !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
e 4 !moles of Lipid II is equivalent of 8 mg. 
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Figure 1.3. Structures of Lipid I and Lipid II intermediates identified in the cell-free system using the 
particulate enzymes from S. aureus.  
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the phospho-MurNAc-pentapeptide moiety from the Park nucleotide to the Und-P acceptor in the 
cytoplasmic face of the membrane to form Lipid I.59 Early work by Anderson et al. using 
particulate enzymes had demonstrated that Lipid I formation was reversible in vitro.51 
Unfortunately, the complex transmembrane architecture of MraY has posed a challenge to its 
enzymatic studies. In 2004, Bouhss et al. reported the first purification of the Bacillus subtilis (B. 
subtilis) MraY protein to homogeneity in milligram quantities, which opened ways for its 
biochemical characterizations.60 Chung et al. (2013) recently solved the crystal structure of 
Aquifex aeolicus (A. aeolicus) MraY (MraYaa), which represents the first structure of the PNPT 
protein superfamily.61 In the MraYaa structure, a number of invariant residues were identified 
near the active site cleft, in which a Mg2+ was bound. Interestingly, a hydrophobic groove 
connected to the MraYaa active site was observed, which was proposed to be the binding site for 
Und-P substrate.61 In addition, MraY demonstrates promiscuous substrate specificity to lipid 
lengths and configurations in the in vitro syntheses of Lipid I analogues.62,63 
In the second reaction, the glycosyltransferase MurG catalyzes the addition of GlcNAc 
from UDP-GlcNAc donor to the C4 hydroxyl of Lipid I to yield Lipid II. Using synthetic Lipid I 
analogues containing variable lipid moieties, Walker and coworkers reconstituted MurG activity 
in 1998, and further established its intrinsic lipid preference (see Section 1.5).64 MurG reaction 
proceeds via an ordered Bi-Bi mechanism in which UDP-GlcNAc binds first, prior to the 
formation of a ternary complex.65 Consistent with the proposed mechanism, crystal structures of 
apo-MurG as well as MurG in complex with UDP-GlcNAc have been obtained.66,67 Notably, in 
Lipid II formation, the !-anomeric configuration of UDP-GlcNAc is inverted to the "-(1-4)-
glycosidic linkage in Lipid II.64 In bacteria, MurG is believed to rapidly turn over Lipid I to 
Lipid II, based on the observation that Lipid II is always in excess of Lipid I in bacteria.68  
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In addition to the conserved MraY and MurG reactions, additional modifications on Lipid 
II occur in most Gram-positive bacteria. The complete S. aureus Lipid II structure (Figure 1.4) 
was deduced by Strominger and coworkers in the late 1960s, based on the observation that the 
linear PG product formed in vitro differs from the isolated S. aureus cell wall in two aspects: one 
is amidation on the !-carboxylate group of D-isoGlu, the other is the attachment of a 
pentaglycine branch to the #-amino group of L-Lys in the pentapeptide.69-71 The enzymes 
responsible for these additional modifications in S. aureus Lipid II have been revealed and 
characterized recently. Three enzymes, FemXAB, which belong to the non-ribosomal 
peptidyltransferase enzyme family, sequentially assemble the complete pentaglycine branch 
using glycyl-tRNA as donors, such that FemX adds the first, FemA adds the second and third, 
and FemB add the last two glycines.71 Enzymatic studies of the Fem proteins showed that they 
are highly specific to the respective acceptor substrates (i.e. Lipid II for FemX, Gly-Lipid II for 
FemA and Gly3-Lipid II for FemB).72,73 The activity of each Fem protein does not require the 
presence of the other ones, but the formation of the complete pentaglycine branch is delayed in 
vitro when all three proteins are present, implying that competitive, non-productive binding 
occurs between non-cognate protein and acceptor pairs.73 While FemX is essential, FemA and 
FemB are dispensable in S. aureus but are critical for resistance in methicillin-resistant S. aureus 
(MRSA) strains (see Chapter 1.4). Homologues of Fem proteins are present in other Gram-
positive species for branch peptide formation. For instance, bppA1 and bppA2 transferases are 
responsible for the L-Ala-L-Ala branch in Enterococcus faecalis (E. faecalis), MurM transferases 
form the L-Ser-L-Ala (or L-Ala-L-Ala) branch in Streptococcus pneumoniae (S. pneumoniae).72 
On the other hand, Lipid II in Gram-negative bacteria commonly has an m-Dap at the third 
position of the stem peptide and does not have a branch peptide.72  
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Amidation of the !-D-isoGln in Lipid II is a common feature in Staphylococci, 
Streptococci and Mycobacteria, but is not observed in many Gram-negative bacteria.72 In S. 
aureus, Lipid II amidation is catalyzed by two enzymes, a glutaminase GatD and an 
amidotransferase MurT, in an ATP- and ammonia-dependent reaction.74 A decrease in the 
amidation content in PG in MRSA reduces methicillin resistance (see Chapter 1.4). In addition, 
bacterial PG amidation is shown to reduce the activation of host immune response, which may 
provide a survival advantage to bacteria during infection.75,76 Nevertheless, the in vivo sequence 
of these additional modifications on S. aureus Lipid II (i.e. pentaglycine branch and amidation) 
is yet to be determined, since both FemXAB and GatT/MurT enzymes are capable of modifying 
Lipid II independently in vitro.73,74 
 
 
 
 
 
 
 
 
Around the time when the existence of lipid-linked intermediates (Lipid I and Lipid II) in 
S. aureus PG synthesis was first established in the mid-1960s, the involvement of lipid-linked 
oligosaccharide intermediates in the lipopolysaccharide (LPS) pathway in Salmonella was 
revealed as well.77 Indeed, the use of Und lipid-linked substrates is a common strategy in the 
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Figure 1.4. The complete Lipid II structure in S. aureus. The moieties in red indicate additional 
modifications on Lipid II precursor. The pentaglycine branch is unique to S. aureus Lipid II. 
 
12 
biosynthesis of many bacterial cell surface polysaccharides,f such as LPS O-antigen, 
enterobacterial common antigen (ECA), WTA and capsular polysaccharide.78 In eukaryotes, the 
dolicol-linked oligosaccharides are precursors in the N-linked protein glycosylation in 
endoplasmic reticulum (ER).79 The membrane-bound lipid carriers provide a mean to translocate 
hydrophilic precursors across the hydrophobic cytoplasmic membrane for processes in the 
extracellular face of the membrane (or in the ER lumen in the case of the eukaryotic dolicol 
pathway). Thus, the involvement of a translocase or flippase in the membrane was envisioned to 
facilitate the energetically unfavorable translocation process. However, the translocation step in 
bacterial PG biosynthesis is poorly understood and has remained elusive, until recently, several 
candidates of Lipid II flippase in bacteria are proposed.  
In 2008, Ruiz N. first proposed MurJ (formerly MviN), an essential inner membrane 
protein in E. coli, is the Lipid II flippase.80 MurJ is conserved in PG-producing endosymbiotic 
bacteria that have lost most of their non-essential genes, but it is absent in bacteria that lack PG. 
Depletion of MurJ in E. coli results in an accumulation of PG precursors and induces cell 
rounding and blebbing, reminiscent to the morphological observations of penicillin-treated 
bacteria by Gardner and others in the 1940s that were indicative of PG synthesis inhibition.16 In 
addition, MurJ belongs to the multidrug/oligo-saccharidyl-lipid/polysaccharide (MOP) exporter 
superfamily, which also encompasses other polysaccharide transporters (PSTs) such as WzxE, 
the flippase for ECA lipid-linked precursors, and WzxB, the LPS O-antigen flippase, as well as 
the oligosasaccharidyl-lipid flippase (OLF) Rtf1p, the proposed flippase in the dolicol-
pathway.81 Since its discovery, many lines of evidence have given credence to MurJ as the Lipid 
II flippase. For instance, MurJ is predicted to have a hydrophilic cavity based on topological 
studies (such cavities are present in many multidrug exporters in the MOP family); chemical !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
f Mycobacteria are known to use decaprenyl-lipid carriers instead. 
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blockage of this cavity in MurJ leads to accumulation of Lipid II in the inner membrane in E. 
coli.82-84 In addition, the murJ orthologue, ygtP is found to be essential in S. aureus and S. 
pneumonia,85 whereas B. subtilis possesses multiple ygtP homologues that are non-essential, yet 
an unrelated amJ gene can substitute the Lipid II flipping activity in B. subtilis.86 Controversially, 
another flippase candidate, FtsW has been proposed in E. coli, which is an essential protein for 
cell division that belongs to the shape, elongation, division and sporulation (SEDS) family.87 
FtsW is shown to translocate Lipid II as well as phospholipids in vitro using vesicle assays, but 
its role as a flippase has not been validated in vivo.88   
 
1.2.3 Peptidoglycan (PG) assembly  
 
After translocation of Lipid II to the outer leaflet of the cytoplasmic membrane, it is 
polymerized by peptidoglycan glycosyltransferases (PGTs) to form long glycan strands that 
contain "-(1,4)-glycosidic linkages between the C4 of GlcNAc and the C1 of MurNAc units. The 
formation of linear PG polymers has been demonstrated in early works on PG synthesis.41,50 
However, unlike the nascent PG product in vitro, the isolated S. aureus cell wall is a highly 
cross-linked material, in which the amino end of the pentaglycine branch on one stem peptide is 
attached to the carboxylate group of the penultimate D-Ala residue on another. Thus, it was 
interpreted that nascent PG must undergo a transpeptidation reaction in the final stage of PG 
assembly, the enzymes that carry out this step are named transpeptidases (TPs).89 The major 
steps in S. aureus PG biosynthesis are shown in Figure 1.5. However, due to the difficulties in 
obtaining the complete S. aureus Lipid II (see Chapter 1.5), transpeptidation in S. aureus has not 
been demonstrated in vitro.  
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With the recognition of the complete reaction sequence in PG biosynthesis, penicillin’s 
mechanism of action was visited by Tipper and Strominger in 1965.89 Since penicillin did not 
inhibit the formation of nascent PG in the particulate cell-free reactions, its involvement in the 
final transpeptidation reaction was highly likely. Based on the structural similarities between the 
6-APA core of penicillin (which is in essence an acylated cyclic dipeptide of L-Cys and D-Val) 
and the D-Ala-D-Ala terminus in PG, Tipper and Strominger proposed that penicillin inhibits 
transpeptidation by acting as a substrate analogue.89,90 It was postulated that in the 
transpeptidation step, a TP recognizes the D-Ala-D-Ala terminus of the stem peptide and cleaves 
the terminal D-Ala residue to form an acyl-enzyme intermediate, then the incoming pentaglycine 
branch attacks the covalent intermediate to form a cross-link, thus freeing the TP enzyme (Figure 
1.6). Transpeptidation does not require any ATP input, consistent with a lack of ATP in the 
extracytoplasmic space in bacteria. Penicillin contains a highly reactive amide bond in the beta-
lactam ring that could be viewed as the equivalence of the amide bond in D-Ala-D-Ala terminus. 
Thus, when the TP enzyme attacks the beta-lactam ring in penicillin instead, a penicilloyl-
enzyme adduct is yielded, inactivating the TP enzyme (Figure 1.6). Consistent with the proposed 
mechanism of penicillin, uncross-linked nascent PG polymers were significantly accumulated in 
penicillin-treated S. aureus.90  
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In efforts to identify the cellular target(s) of penicillin in bacteria, the old observation of 
penicillin binding to bacterial membrane was examined in greater detail in the 1960s-1970s. The 
intricacy of the biosynthetic enzymes in the final step of bacterial PG assembly was then 
revealed.91,92 Multiple penicillin-binding proteins (PBPs), defined as proteins that covalently 
interact with penicillin, were detected when the radiolabeled penicillin was incubated with either 
whole cells or particulate membranes from bacteria. Radiolabeled PBPs, which could be 
separated on sodium dodecyl sulfate (SDS) gel electrophoresis and detected by fluorography, 
were numbered in order of descending molecular weights in each organism.93-97 In S. aureus, 
there are four native PBPs, PBP1-4, while MRSA has acquired an additional one, PBP2a (see 
Chapter 1.4).93,97 PBPs can also be classified into high-molecular weight (HMW) Class A and 
Figure 1.6. The proposed mechanisms of transpeptidation (and hydrolysis) by PBPs and penicillin 
inhibition. In this model, the beta-lactam ring in penicillin (highlighted in brown) resembles the 
conformation of the D-Ala-D-Ala terminus in a stem pentapeptide (in crimson color). In PG assembly, 
PBPs reacts with the D-Ala-D-Ala terminus on a donor strand to form an acyl-enzyme intermediate, with 
the concomitant release of the terminal D-Ala. The intermediate is attacked by the pentaglycine branch on 
an acceptor strands to form a cross-link (transpeptidation). Alternatively, in the case of carboxypeptidase, 
the acyl-enzyme intermediate is resolved by water. Penicillin inhibits PG biosynthesis by covalently 
acylating the PBP active site.  
 
17 
Class B PBPs, and low molecular weight (LMW) PBPs. HMW Class A PBPs, such as S. aureus 
PBP2, contain both TP and PGT domains, while HMW Class B PBPs, such as S. aureus PBP1, 
2a and 3, contain TP domain and an N-terminal domain of unknown function. In S. aureus, PBP4 
is the only LMW PBP.98 In addition, S. aureus also contains two nonessential monofunctional 
PGTs, SgtA and SgtB.99  
 
1.3 The cellular roles of S. aureus penicillin-binding proteins (PBPs)  
The detection of multiple PBPs in bacteria unequivocally validated the proposed 
inhibition mechanism of penicillin, in which a stable penicilloyl-enzyme adduct is formed.89 
However, the observation also raised several questions: which of the PBPs are the lethal targets 
of penicillin? How do the activities of multiple PBPs differ in bacteria and what are their cellular 
roles? It was soon realized that PBPs in a given organism display widely different sensitivities to 
penicillin and other beta-lactams.100 In general, LMW PBPs appear less sensitive to penicillin, 
and are capable of releasing the bound penicillin either spontaneously or by exogenous 
hydroxylamine nucleophiles, while HMW PBPs are relatively more sensitive. The binding 
affinity of a non-radiolabeled beta-lactam for PBPs is usually assessed in a competition assay, in 
which the concentration of the beta-lactam required to block the binding of labeled penicillin is 
determined.95,96 However, quantitative analysis of binding affinity depends on many variables 
such as temperature, incubation time, and protein concentrations of the assay.100,101 Beta-lactams 
that selectively bind to individual PBPs in S. aureus have been identified.  For instance, as 
reported by Okonog et al. and shown in Figure 1.7, cloxacillin, ceftizoxime, cephalexin and 
cefoxitin are specific binders to S. aureus PBP1, PBP2,g PBP3, and PBP4 respectively at !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
g The binding of ceftizoxime to PBP2 was not complete at concentrations used in the experiment (ref. 
102). 
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concentrations that do not affect other PBPs.102 Together with genetic approaches, studies using 
beta-lactams as chemical probes to inhibit specific PBPs have shed light on the physiological 
roles of individual PBPs in bacteria. 
 
S. aureus PBP1 is an essential HMW Class B PBP,103 whose function was initially 
elucidated by Okonog et al. using cloxacillin as a probe.102 Selective inhibition of PBP1 by 
cloxacillin caused S. aureus cells to swell and become irregularly shaped, while manifesting 
aberrant septum formation. Similar abnormal septa formation was observed in a PBP1-deficient 
MRSA mutant, in which the expression of PBP1 was under the control of an inducible 
promoter.104 Thus, S. aureus PBP1 is proposed to play an essential role in regulating cell 
division. Subsequently, the specific function of the PBP1 TP domain was addressed by Pereira et 
al., using a S. aureus mutant strain in which the TP catalytic residue of PBP1 was specifically 
mutated.105 The strain was viable but showed separation defects after a few rounds of normal cell 
divisions, and demonstrated decrease in PG cross-linking. Taken together, the TP activity of S. 
Figure 1.7. Beta-lactams show selective binding to S. aureus PBPs. Figure a) is modified from ref.102. 
Briefly, growing S. aureus cells were incubated with cloxacillin (0.06 !g/mL) (i), ceftizoxime (0.1, 0.6 
!g/mL) (ii-iii), cephalexin (0.08 !g/mL) (iv), and cefoxitin (0.05 !g/mL) (v), or in the absence of  an 
antibiotic (vi). The cells were disrupted and incubated with 14C-penicillin G, and were subjected to 
SDS-PAGE and fluorography. The concentrations of the beta-lactams in use were above the in vitro 
inhibitory concentrations. b) Structures of beta-lactams used are shown. 
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aureus PBP1 is not essential for viability, but is required for cell separation at the end of 
division.105 PBP1 was proposed to be part of a regulatory circuit that ensures proper PG synthesis 
and degradation in S. aureus, although the underlying mechanism remains elusive.105 
S. aureus PBP2 is a HMW Class A PBP that has both PGT and TP domains. Using 
genetic strategies to selectively inactivate the catalytic residue in PBP2 PGT or TP domain, 
Pinho et al. investigated the essentiality of each domain in PBP2.106,107 The TP domain, which is 
essential in methicillin-susceptible S. aureus (MSSA), becomes dispensable in MRSA in the 
presence of an additional PBP2a (see Chapter 1.4).106 On the other hand, the inactivation of 
PBP2 PGT domain does not normally affect S. aureus viability, but strongly sensitizes MRSA to 
beta-lactams.107 Taken together, these observations imply that PBP2 is the major TP for PG 
cross-linking in S. aureus, but it can be replaced by PBP2a in MRSA; whereas PBP2 PGT 
activity is required to cooperate with PBP2a to maintain PG synthesis in MRSA in the face of 
beta-lactams. However, when grown in the absence of beta-lactams, S. aureus PBP2 PGT 
activity can be replaced by the monofunctional PGT, SgtB.108h S. aureus PBP2 is the lethal target 
of moenomycin, a natural product PGT inhibitor, since a resistant mutant that bears a point 
mutation in the PBP2 PGT active site cleft has been isolated. The mutant displays an increase in 
moenomycin resistance by 25-fold.109 In addition, the TP domain of PBP2 was thought to be 
responsible for its localization at the division septum in S. aureus by interacting with the D-Ala-
D-Ala termini in PG, since either acylation of PBP2 TP domain by oxacillin or modification of 
the PG termini by D-cycloserine and vancomycin results in delocalization of PBP2.110 In 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
h S. aureus has two monofunctional PGTs, SgtA and SgtB, both of which are nonessential when PBP2 is 
present. However, only SgtB can compensate the PGT activity when PBP2 PGT domain is mutated (ref. 
108). The transglycosylase activity of SgtB has been reconstituted in vitro (ref. 171), but the activity of 
SgtA has not been reconstituted in vitro.  
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addition, a spontaneous ceftizoxime-resistant mutant of S. aureus was identified with a point 
mutation in the PBP2 TP domain, suggesting that PBP2 is the lethal target of ceftizoxime.111 
S. aureus PBP3 is another HMW Class B PBP, which can be deleted without causing 
detectable change in S. aureus cell growth or PG composition,112 contrary to the previous 
interpretation that PBP3 is essential in the competition binding assays.113 However, treating the 
S. aureus $PBP3 mutant with a sub-lethal concentration of methicillin results in abnormal cell 
shape and size, indicating that inhibition of other PBPs in the absence of PBP3 is deleterious to 
S. aureus cell morphology.112  
Aside from the HMW PBPs in S. aureus, PBP4 is the only LMW PBP. Because of its 
reversibility in penicillin binding by hydroxylamine, S. aureus PBP4 was purified and 
characterized by Kozarich and Strominger in 1978.114 PBP4 did not only hydrolyze the terminal 
D-Ala in the Ac2-L-Lys-D-Ala-D-Ala tripeptide, indicating its carboxypeptidase activity, but also 
incorporated Gly or hydroxylamine acceptors in place of the terminal D-Ala, demonstrating TP 
activity. Under prolonged incubation with a high amount of penicillin, S. aureus PBP4 also 
demonstrated penicillinase activity in vitro, although it was not considered physiologically 
relevant.114 Its dual activities as a CP and TP in vitro were quite perplexing. Like other LMW 
PBPs, S. aureus PBP4 is non-essential for cell viability, thus it is not a lethal target of 
penicillin.115 However, S. aureus $PBP4 mutant manifests a drastic reduction in the level of PG 
cross-linking, suggesting the cellular role of PBP4 in PG secondary cross-linking.116 S. aureus 
PBP4 and PBP2 are proposed to cooperate in vivo to produce the highly cross-linked cell wall in 
S. aureus.111 The inactivation of PBP4 in S. aureus causes intermediate vancomycin resistance in 
several laboratory and clinical isolates,117,118 while an overproduction of PBP4 in certain S. 
aureus strains leads to an increase in beta-lactam resistance.119-121 However, the effect of S. 
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aureus PBP4 on antibiotic resistance can be variable depending on the strain background.122 In 
the community-acquired MRSA (CA-MRSA) strains, PBP4 is essential for the expression of 
beta-lactam resistance.123 Inactivation of PBP4 strongly sensitized the CA-MRSA to oxacillin 
and nafcillin. Cefoxitin, a selective inhibitor of S. aureus PBP4, strongly synergizes with 
oxacillin at killing CA-MRSA, which may provide a potential therapeutic strategy against CA-
MRSA infections. Furthermore, WTAs are proposed to ensure proper localization of PBP4 at the 
division septum in S. aureus,124 although recently, it is shown that S. aureus PBP4 can display 
extraseptal cross-linking activity as well.125  
 
Table 1.1. Classification of PBPs in S. aureus. PBP1-4 are native PBPs in S. aureus, PBP2a is an 
acquired PBP in MRSA.  
S. aureus 
PBPs 
       Class Cellular roles       Essentiality Biochemical 
characterization 
 
PBP1 
 
HMW 
(Class B) 
 
Cell division; 
PG cross-linking 
 
Yes (but not the TP 
domain) 
 
No 
PBP2 HMW 
(Class A) 
Major PBP in 
PG polymerization 
and cross-linking 
PGT not essential if 
SgtB is present; 
TP is essential, but 
can be replaced by 
PBP2a in MRSA 
Only PGT126, 
not TP 
PBP2a 
(MRSA) 
HMW 
(Class B) 
Confers resistance Requires PBP2 PGT 
domain to function 
No 
PBP3 HMW 
(Class B) 
Unclear Not essential No 
PBP4 LMW PBP Secondary PG 
cross-linking 
Not essential, but is 
required for 
resistance in CA-
MRSA 
CP/ TP/ beta-
lactamase 
 
A combination of genetic, microscopic and chemical approaches has been useful to 
dissect the cellular roles of individual PBPs in S. aureus. However, their TP activities have not 
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been demonstrated in vitro (Table 1.1). This thesis focuses on the development of tools to study 
TP activities of two S. aureus PBPs (PBP4 and PBP2). Biochemical characterizations of 
bacterial PBPs will not only contribute to our understanding of their redundant and 
interdependent activities, but also may facilitate the discovery of potential antibiotics. 
 
1.4 Resistance in methicillin-resistant S. aureus (MRSA) 
 
Since the first introduction of penicillin in the 1940s, which marks the dawn of an 
antibiotic era, antibiotics have been frequently misused and overused. As a result, antibiotic 
resistance in bacteria has emerged rapidly and has become alarming in recent years. CDC 
estimated that at least two million people are infected with resistant bacteria each year and at 
least 23,000 people die as a direct result of such infections in the United States.127 At the current 
rate, it is projected that 10 million deaths worldwide will be attributed to resistant bacterial 
infections each year by 2050.128 Among the most threatening resistant pathogens, MRSA is one 
that is widespread and causes the most number of deaths each year.129 Although new antibiotics 
have been developed to target MRSA, including the fourth and fifth generations of 
cephalosporins, resistance against these new drugs has also emerged.130 In order to develop new 
strategies to combat MRSA, understanding the mechanism of resistance in MRSA is of 
paramount importance.  
 
1.4.1 An acquired resistant PBP, PBP2a in MRSA 
 
A defining characteristic of MRSA is the presence of staphylococcal cassette 
chromosome mec (SCCmec) in the chromosome.i SCCmec is a mobile genetic element about 40-!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
i In some cases, S. aureus strains may have other genetic determinants for low-level resistance in the 
absence of the mecA gene.  
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60 kb in length and includes a mecA gene.131 The transcription of mecA is normally repressed by 
the regulatory elements mecI and mecRI that are also part of the SCCmec, its repression can be 
alleviated by certain beta-lactams.132 However, many clinical MRSA isolates have mutations in 
the regulatory elements such that mecA is constitutely expressed.133 SCCmec is proposed to 
originated from Staphylococcus sciuri (which contains homologous genes), but the mechanism 
of acquisition is not clear.134 The MRSA mecA gene encodes PBP2a, a HMW Class B PBP, 
which displays low affinity to penicillin and other beta-lactams in the competition binding 
assay.135,136 PBP2a is assumed to continue PG cross-linking in MRSA under conditions that 
native PBPs are inhibited by beta-lactams. However, MRSA manifests a decrease in PG cross-
linking when grown in the presence of beta-lactams.107 This observation implies that PBP2a 
activity cannot entirely compensate for other native PBPs but is enough for MRSA survival in 
the face of beta-lactam inhibition. 
Kinetic binding studies have shed light on the intrinsic resistance of PBP2a against beta-
lactams. S. aureus PBP2a displays a slow acylation rate (k2) and a low affinity to most beta-
lactams (high Kd) (Figure 1.8a), both of which work in concert to contribute to its intrinsic 
resistance.137,138 The poor acylation rate (k2) of S. aureus PBP2a by beta-lactams can be 
rationalized by its having a distorted TP active site that needs to undergo an unfavorable 
conformational change for acylation, as perceived in the apo- and acylated-PBP2a crystal 
structures.139 Cephalosporins, which possess extended substituents on the beta-lactam core, can 
make significant Van der Waal interactions in the narrow active site groove of PBP2a. Such non-
covalent interactions are thought to contribute to cephalosporins’ enhanced affinity to PBP2a 
(reduced Kd) and hence potent antibacterial activities. In light of this, non-covalent inhibitors that 
exhibit strong affinity to PBP2a may represent promising anti-MRSA strategies.139  
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S. aureus PBP2a’s intrinsic resistance to acylation offers MRSA an advantage to beta-
lactam inhibition. However, it must be overcome during transpeptidation, in which PBP2a 
presumably forms an acyl-enzyme intermediate with the stem peptide in PG. Mobashery and 
coworkers established that the presence of cell wall fragments can stimulate beta-lactam 
acylation of PBP2a in vitro.140 In the recent crystal structures of S. aureus PBP2a by the same 
group, ligands (i.e. muramic acid, cell wall fragment or ceftaroline) bound in a location 60 Å 
distal from the TP active site in PBP2a were identified (Figure 1.8b).141 This observation led to 
the proposal of an allosteric regulation in S. aureus PBP2a TP activity: binding of a ligand in the 
allosteric domain in PBP2a may allow the TP active site to open up for catalysis.141 The 
allosteric model awaits validation in a TP activity assay of S. aureus PBP2a. Nevertheless, such 
allostery may have been exploited by ceftaroline, the recently approved fifth-generation 
cephalosporin, to re-sensitize S. aureus PBP2a to beta-lactam inhibition.142,143 Ceftaroline’s 
interaction with PBP2a allosteric domain in addition to acylation of the TP active site suggest an 
unprecedented inhibitory mechanism.141 Binding of ceftaroline in the allosteric site is thought to 
trigger a series of salt bridge interactions in PBP2a that spans from the allosteric to the TP 
domain, predisposing the TP active site for acylation. In the clinical isolates of ceftaroline-
resistant MRSA, several point mutations in the allosteric site of PBP2a have been identified.144 
These mutations were shown to disrupt the interaction network in the allosteric site responsible 
for the stimulation of the TP active site, leading to resistance.144 However, such mutations are 
expected to disturb PBP2a TP activity as well. The TP activities of PBP2a and its variants are yet 
to be demonstrated. In addition, a similar allosteric domain is present in the crystal structure of 
Enterococcus faecium PBP5, but whether allosteric regulation applies is yet to be determined.141 
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1.4.2 Factors influencing methicillin resistance 
Although mecA is the primary resistant gene in MRSA, it alone is not enough to confer 
resistance and additional genes are required for the full expression of resistance. Many of these 
genes, named fem (for factors essential for methicillin) or aux (auxiliary) factors, were identified 
in transposon mutagenesis studies of MRSA mutants that display reduced methicillin resistance. 
In particular, the femA and femB inactivation produced the most significant reduction in 
methicillin resistance in MRSA.145,146 As mentioned in Chapter 1.2.2, FemA and FemB are 
Figure 1.8. An allosteric regulation of S. aureus PBP2a is proposed. a) The equation representing the 
chemical reaction of beta-lactam acylation of PBP and release. E represents PBP, EI is the non-covalent 
pre-acylation complex, E-I is the covalent acyl enzyme species, and P denotes the product of hydrolysis 
of the beta-lactam antibiotic. Kd is the dissociaton constant for the formation of the non-covalent 
complex, k2 is the first-order rate constant for the acylation reaction, and k3 is the first-order rate 
constant for deacylation. b) Ribbon representation of crystal structure of S. aureus PBP2a bound with 
ceftarolines both in the allosteric site and TP active site. Figure modified from ref. 141.   
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enzymes responsible for pentaglycine branch formation in Lipid II in S. aureus PG pathway. S. 
aureus $femA and $femB mutants both demonstrate a drastic reduction in cross-linking and 
glycine contents in PG, with monoglycine branch predominantly found in the former and 
triglycine branch in the latter.147,148 It is hypothesized that PBP2a has a stringent substrate 
requirement for the complete pentaglycine branch in PG cross-linking, while shorter branches in 
$femA and $femB mutants abolish its TP activity and re-sensitize MRSA to beta-lactams.149 
Therefore, targeting FemA or FemB protein in combination with beta-lactams may provide a 
novel therapeutic strategy against MRSA. Reportedly, a small molecule FemA inhibitor, 
cyslabdan that effectively potentiates beta-lactams against MRSA has been recently 
identified.150,151 The substrate specificity of PBP2a needs to be validated in order to establish a 
mechanistic basis for such re-sensitization strategy in MRSA. 
In addition, several genes that are either directly or indirectly involved in the formation of 
native S. aureus Lipid II were found to affect beta-lactam resistance in MRSA. For instance, 
inactivation of the glutamine synthetase repressor, glnR, which reduces the amidation on D-
isoGln on PG, results in lowering of beta-lactam resistance in MRSA.152 Moreover, genes 
involved in other aspects of the cell surface can also contribute to beta-lactam resistance in 
MRSA, such as, fmtA, a predicted membrane protein with sequence homology to PBPs that is 
recently identified as a D-alanyl esterase of teichoic acids,153,154 as well as a large number of 
genes including tarO, tarA, tarD, tarS and ltaS in the WTA pathway and in the lipoteichoic acid 
(LTA) pathway.155-157 Global regulators, agr and sar, which control the expression of many cell 
surface proteins were identified as well.158 Since many of these factors play important roles in S. 
aureus cell division, growth and autolysis, their inactivation also sensitizes MSSA to methicillin 
instead of directly influencing the activity of PBP2a in MRSA per se.159 
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1.4.3 Chemical genetic approaches to combat MRSA 
The diverse fem and aux factors identified in transposon mutagenesis studies represent 
potential points of intervention. Inhibition of these targets by small molecules may phenocopy 
the effects of their genetic inactivation to re-sensitize MRSA against beta-lactams. The 
combination of such inhibitors with beta-lactams holds great promise as a novel therapeutic 
strategy against MRSA. In recent years, many groups have performed high-throughput screening 
of chemical libraries to identity compounds that can potentiate beta-lactam activity in 
MRSA.150,160-162 As mentioned earlier, a potential FemA inhibitor, cyslabdan, was identified as 
an imipeniem potentiator.150 Similarly, Huber et al. reported two related compounds CDFI and 
DMPI that act to potentiate imipenem activity in S. aureus COL. The inhibitors were proposed to 
target SAV1754 that is the proposed Lipid II flippase in S. aureus,162 representing a new class of 
inhibitors in S. aureus. A recent study demonstrates that a collateral application of beta-lactams 
(carbapenem/penicillin/beta-lactamase) is effective at killing MRSA in vitro and clearing MRSA 
infections in a mouse model.163 In conclusion, chemical genetic screenings prove useful in 
identifying novel beta-lactam potentiators as well as establishing new cellular targets of 
inhibition in MRSA.   
 
1.5 Lipid II is required for enzymatic studies of PBPs  
Although bacterial PBPs have been identified as the cellular targets of beta-lactams since 
the 1970s, characterizations of their enzymatic activities (i.e. PGT and TP) have lagged behind 
for several decades, due to challenges in purifying these membrane-bound proteins and in 
obtaining the complex Lipid II substrates. The cell-free system using particulate enzymes for 
Lipid II production was laborious and inefficient; the direct isolation of Lipid II from bacteria 
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was challenging given their natural low abundance in bacteria.68 It has been estimated that there 
are no more than 700 copies of Lipid I molecules and 2000 copies Lipid II molecules per E. coli 
cell;68 while the numbers are generally higher in Gram-positive bacteria, Lipid II molecules still 
represents less than 1% of the total phospholipids in the membrane.164 Since the early 2000s, 
advance in synthetic and enzymatic preparations of Lipid II and analogues64,165-168 accompanied 
with the development of specific activity assays168-170 have enabled mechanistic studies of 
bacterial PBPs. Many PBPs from different organisms have been overexpressed and purified to 
homogeneity in full-length and/or soluble forms, whose activities were characterized in vitro 
using defined substrates.126,171-175 The following sections will discuss current methods for Lipid 
II preparations, and key understanding of PGT and TP catalysis. 
 
1.5.1 Current approaches of Lipid II preparation 
In 1998, Walker and coworkers synthesized a citronellol-Lipid I (C10) analogue using a 
convergent approach to assemble the three building blocks of the molecule: the MurNAc 
derivative, the pentapeptide, and the lipid tail.64 In particular, the pyrophosphate linkage that 
connects the reducing end of the MurNAc residue to the lipid was constructed using the diphenyl 
chlorophosphate activation method. This work represents the first chemical synthesis of a lipid-
linked PG precursor. Using synthetic Lipid I analogues, the authors investigated the enzymatic 
activity of MurG in vitro, which laid the foundation for a facile chemoenzymatic strategy to 
prepare Lipid II. Subsequently, utilizing the 1,1’-carbonyldiimidazole (CDI) coupling method 
that is tolerant of the allylic phosphate ester in pyrophosphate formation, Kahne, Walker and 
coworkers (2001) prepared the natural undecaprenyl-Lipid I and a number of Lipid I derivatives 
of varying lipid lengths and double bond geometries, and converted to them to the corresponding 
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Lipid II derivatives using MurG.168 The accessibility to various Lipid II derivatives of different 
lipid moieties shed light on the substrate preference of E. coli PGTs for the very first time (see 
Chapter 1.5.2). In the same and following years, two groups reported the total chemical 
syntheses of Lipid II, both utilizing a CDI-catalyzed coupling of undecapenyl phosphate to the 
appropriately protected GlcNAc-MurNAc-pentapeptide moiety at the late stage of the multi-step 
synthetic scheme.165,167 While milligram quantities of Lipid II could be obtained from synthesis, 
the overall yield was quite low; for instance, only 0.7% overall yield was obtained after a 12-step 
synthesis, as reported by Schwartz et al.165 In addition, several fluorescent Lipid II derivatives 
have been synthesized as well.176-178 Most of the synthetic Lipid II contains the L-Ala-D-isoGlu-
L-Lys-D-Ala-D-Ala pentapeptide, which resembles the common Lipid II precursor in most 
Gram-positive bacteria, can be used as a substrate by bacterial PGTs in vitro; they are not 
suitable for studying bacterial TPs since they lack the canonical peptide branch.179  
Recognizing the formation of the allylic pyrophosphate in Lipid I and Lipid II via the 
phophorimidazolidate intermediate is rather sluggish, Tsukamoto and Kahne improved the 
reaction rate by adding an efficient catalyst, N-methylimidazolium chloride, which significantly 
reduced the reaction time from a few days to 12 hours.180 In the new synthetic route to make 
Lipid I (Figure 1.9), Tsukamoto and Kahne first introduced the pyrophosphate bond to form the 
MurNAc-PP-lipid, which is the conserved moiety among all bacterial Lipid I, followed by the 
addition of the peptide. Lipid I could then be quantitatively converted to Lipid II by MurG 
chemoenzyamtically.64 Given that the peptide portion of Lipid II is varied in bacteria, the new 
route that introduces the peptide late in the synthesis allows easier preparations of diverse Lipid 
II. Via this route, the native E. coli and B. subtilis Lipid II substrates, which contain an m-Dap 
and an amidated m-Dap residue at the third position of the stem peptide respectively, were 
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synthesized and used for characterizations of the corresponding bacterial PBPs.179,181,182 In 
addition, the more complicated Lipid IV substrate, which represents an elongated product of two 
Lipid II molecules, has been chemically synthesized to probe the activity of PGTs.183,184 
 
In addition to the above mentioned synthetic routes, another well-established approach to 
prepare Lipid I and Lipid II molecules involves biochemical reconstitutions. This approach has 
its origin in the particulate enzyme reactions for studying PG synthesis, by which Lipid I and 
Lipid II intermediates were initially identified (see Chapter 1.2.2).51 In such reactions, the Park 
nucleotide, UDP-GlcNAc and the particulate enzymes, which contain membrane proteins MraY 
and MurG as well as the Und-P precursors, were incubated. However, the low availability of 
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Figure 1.9. The synthetic route to make Lipid I by Tsukamoto and Kahne (ref. 175). In this route, the 
conserved moiety MurNAc-PP-lipid precursor (3) is prepared first, prior to the coupling of the peptide 
portion, which is variable in different bacteria. 
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Und-P in the membrane has rendered Lipid II production rather inefficient.68 Breukink et al. 
(2003) overcame the technical hurdle by supplying exogenous polyisoprenol phosphate to the 
reaction, improving the yield of the reaction by at least a 100-fold.63 In particularly, the 
substrates used in the reaction are isolated from various natural sources.185 For instance, the Park 
nucleotide is usually extracted from bacteria that are treated with vancomycin, which allows 
cellular accumulation of the Park nucleotide.186 Depending on the bacteria source, the peptide 
composition in the isolated Park nucleotides may vary.j The polyisoprenoids can be isolated from 
plant leaves and are phosphorylated by undecaprenol kinase (UK) in vitro.185 In addition, MraY 
exhibits broad substrate specificity to a large number of isoprenyl phosphates, including the 
dolichol-type isoprenyl phosphate, yielding a number of Lipid I variants.62,63 Although relatively 
large amount of Lipid II (50-100 mg) can be obtained with ease from biochemical productions, 
preparations of native Lipid II containing the canonical branch peptide (in Gram-positive 
bacteria) are significantly more challenging since multiple additional enzymes are required for 
reconstitution. Remarkably, the in vitro assembly of the pentaglycine branch in S. aureus Lipid II 
has been achieved by Schneider T et al., involving a complex reaction mixture that includes 
purified FemXAB proteins, glycyl-tRNA synthease, staphylococcal tRNA pool, as well as 
purified Lipid II precursors obtained from the particulate enzyme system.73 The small amount of 
pentaglycine-Lipid II formed in the reaction could be conveniently detected on thin layer 
chromatography (TLC), but its isolation and purification was not possible, thus obviating its 
utility as a substrate for studying S. aureus PBPs TP activities. Similarity, the GatD/MurT 
enzymes responsible for amidation in S. aureus Lipid II have been recently reconstituted in vitro, 
but the amidated Lipid II product could not be achieved in useful quantities.74,175 The amidated !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
j S. aureus is used for extraction of the L-Lys containing Park nucleotide, and Bacillus cereus is a good 
source for the m-Dap containing Park nucleotide. 
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Lipid II in S. penumoniae has been obtained and shown to be important for efficient PG cross-
linking.174,175 Conceivably, the exquisite features of S. aureus Lipid II are pre-requisites for 
studying S. aureus PBPs TP activities. However, obtaining the native S. aureus Lipid II 
containing both the pentaglycine branch and amidation is deemed the bottleneck to such studies. 
 
1.5.2 Mechanistic insights into peptidoglycan glycosyltransferase (PGT) activity 
The accessibility to various Lipid II analogues has enabled enzymatic studies of bacterial 
PGTs.k Kahne, Walker and coworkers (2001) investigated the substrate preference of E. coli 
PBP1b (a HMW Class A PBP) using various synthetic Lipid II substrates.168 It was found that 
the presence of a cis double bond at the allylic position in Lipid II is critical for PGT activity. In 
addition, a shorter heptaprenyl Lipid II analogue was identified as a better substrate than the 
natural undecaprenyl Lipid II for E. coli PBP1b activity in vitro, presumably due to its less 
tendency to aggregate.168,187 In general, the PGT activity of a bifunctional PBP does not depend 
on its TP activity, since the PGT domain can be isolated, overexpressed and purified, and 
demonstrate comparable activities as the full-length protein.188 Following the development of a 
high-resolution SDS-PAGE assay that can resolve long glycan polymers according to their 
lengths, Walker and coworkers showed that bacterial PGTs are processive enzymes that catalyze 
multiple rounds of polymerization without releasing the glycan strands.169 Interestingly, PGTs 
from different organisms produce glycan polymers of distinct lengths in vitro,171 implying a 
possible intrinsic control of product length. By preparing a number of short PG oligomers that 
are blocked with an galactose (Gal) at the non-reducing end, Perlstein et al. established that the 
nascent PG glycan chains elongate with the addition of Lipid II acceptors to the reducing end of !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
k!The absence of native branch peptide in Lipid II substrate does not affect PGT activity. Therefore, Lys-
Lipid II is suitable for studying PGT activity in vitro. !
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the growing polymer, solving a fundamental question regarding PGT activities.170 The ability to 
differentiate donor and acceptor substrates in PG polymerization led to the recognition that PGTs 
demonstrate different requirements for substrate lipid lengths at the two (donor and acceptor) 
sites.189 While PGTs are promiscuous to the length and geometry of the acceptor lipid, they 
require a lipid of at least 20 carbons in the donor site. The donor lipid is also the major 
determinant of the processivity of polymerization. In addition, time course analysis of the in vitro 
PGT reaction revealed a prolonged lag phase, which was attributed to the slow initial coupling of 
two Lipid II molecules in the donor and acceptor sites. This rate-limiting step in PG 
polymerization could be bypassed by pre-incubating PGTs with a Gal-Lipid IV analogue, which 
mimics the initial coupling product and serves as the ‘donor-only’ substrate.190 Thus, it was 
proposed that PGTs may undergo different conformational states. A glycan strand containing at 
least four sugars bound in the donor site may facilitate the reorganization of PGT to an activated 
conformation for PG elongation. While the structure of PGT in complex with Gal-Lipid IV still 
awaits, a number of crystal structures of bacterial PGTs that are either in the apo-forms or bound 
with inhibitor (moenomycin) or Lipid II analogue are available, providing important structural 
information of PGT activities.188,191-194 
The crystal structures of bacterial PGTs reveal a unique globular domain that is 
composed of mainly alpha helices representing a structural class of glycosyltransferase.191 
Despite little sequence homology, PGTs bear some structural resemblance to the bacteriophage 
"-lysozyme, the lytic glycosidase that cleaves the "-1,4-glycosidic bond between the C1 of 
MurNAc and the C4 of GlcNAc residues in PG with a catalytic glutamic acid residue. Sequence 
alignments show that bacterial PGTs contain five conserved motifs containing a number of 
invariant residues with the glutamic acid in the first motif being the catalytic residue.188 The 
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putative glutamic acid residue in the PGT domain is proposed to abstract the C4-OH proton of 
GlcNAc in Lipid II, which then attacks the reducing C1 position on MurNAc in the donor strand, 
forming a new "-1,4-glycosidic bond in the PG product.188 The reaction is facilitated by another 
conserved residue in the PGT active site that stabilizes the released undecaprenol pyrophosphate. 
Mutagenesis studies have confirmed the essentiality of these residues for PGT activity.188  
Several interesting features regarding the PGT active site are revealed in the crystal 
structures of PGTs bound with moenomycin, a natural product inhibitor of PGTs.188,191-193 
Moenomcyin binds in an extended conformation that makes a large hydrogen-bonding network 
with PGT, which is proposed to be the donor substrate binding site.192 The donor site in PGT 
appears more positively charged and is capable of forming numerous hydrogen-bond 
interactions, providing strong binding energy to translocate the elongated PG polymer.194 Crystal 
structure of S. aureus PBP2 in complex with moenomycin showed a dramatic conformational 
rearrangement in its jaw subdomain when compared to the apo-enzyme structure;191 whereas 
moenomycin binding did not elicit noticeable changes in the PGT domain of A. aerolicus PBP1a 
and in S. aureus SgtB.188,192-194 Such conformational difference in PGTs may reflect their 
structural dynamics during PG synthesis. A crystal structure of S. aureus SgtB in complex with a 
Lipid II analogue was reported recently, in which the polar portion of the analogue was observed 
in the PGT acceptor site, providing a new snapshot of the PG polymerization process194. Going 
forward, structural information on how a growing glycan strand interacts with the donor site of 
PGT is attractive to study. 
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1.5.3 Existing knowledge on PBP transpeptidase (TP) activities  
In contrast to the wealth of information on bacterial PGT activities, mechanistic studies 
of TPs are limited, since the specific Lipid II substrates are required for studying TP activities of 
PBPs from different organisms.l The E. coli Lipid II, which contains an m-Dap at the third 
position of the stem peptide, has been prepared either by biochemical production or chemical 
synthesis and used for characterization of E. coli HMW PBPs, PBP1a and 1b.172,173,179 The TP 
activity of a HMW PBP is coupled to its PGT activity, and cannot act alone.195 A general 
strategy is used to study HMW PBP TP activity: purified E. coli PBP1A or PBP1B is incubated 
with m-Dap Lipid II, the product is then digested by a glycosidase to disaccharide units, which 
could be separated and analyzed on liquid chromatography (LC). The presence of cross-linked 
muropeptides indicates successful transpeptidation by the PBP.172,173,179 In addition, E. coli PBPs 
are capable of attaching nascent PG polymers formed in vitro to the isolated sacculi via 
transpeptidation.172,173 Most existing knowledge on TP activities come from HMW Class A 
PBPs, while TP activities of Class B PBPs have not been demonstrated. Banzhaf et al. has 
inferred the activity of E. coli PBP2 (a Class B PBP) based on its stimulatory effects on E. coli 
PBP1a cross-linking activity in vitro, but the direct evidence of PBP2 TP activity is lacking.196 
The activities of PBPs are thought to cooperate during PG synthesis in bacteria.107,111,196 For 
instance, S. aureus PBP2 and PBP4 are thought to cooperate together to produce the highly 
cross-linked PG.110 However, the inaccessibility of native Lipid II substrates in useful quantities 
has hampered mechanistic studies of PBPs TP activities in Gram-positive bacteria.  
Using synthetic Lys-Lipid II that cannot act as an acceptor in the transpeptidation 
reaction, Lupoli et al. (2011) showed that E. coli PBP1a could incorporate D-amino acid into the 
terminal stem peptide position in PG.195 The D-amino acid incorporation by TP can be perceived !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
l!The tripeptide substrate has been used to study the TP activities of LMW PBPs, but not HMW PBPs.!!
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as the reverse of the activation step in transpeptidation, in which the terminal D-Ala is released 
(Figure 1.6). However, the tolerance of PBP to a wide range of D-amino acids as acceptors in 
vitro is unexpected.195 On the other hand, it has been observed that a variety of bacteria can 
uptake and incorporate exogenous D-amino acids into PG during growth, although the positions 
and mechanisms of incorporation vary.197,198 In E. coli, exogenous D-amino acids are exclusively 
incorporated into the fourth position of the stem peptide in PG in vivo and the L,D-
transpeptidases (Ldts) are responsible for such incorporation.198 In B. subtilis, HMW PBPs 
mediate D-amino acid incorporation into PG in vivo.198,199 In S. aureus, exogenous D-amino 
acids are incorporated into the terminal peptide position in PG,199 but the mechanism of 
incorporation was not clear at the time when we initiated the project described in Chapter Two. 
In addition, several intracellular pathogens, including Chlamydia trachomatis and Listera 
monocytogenes, incorporate exogenous D-amino acid into PG via the cytoplasmic Ddl and MurF 
ligases.200-202 Many research groups have harnessed the power of D-amino acid incorporation to 
develop fluorescent D-amino acid probes, which have provided new insights into PG synthesis in 
various organisms.125,199-203 
 
1.6 Perspectives 
Although penicillin-binding proteins (PBPs) have been exploited by beta-lactams for over 
seventy years, it is remarkable that the transpeptidase (TP) activities of PBPs in many bacteria, 
including S. aureus, have not been directly demonstrated. In particular, the activities of PBPs in 
S. aureus form the basis of resistance in methicillin-resistant S. aureus (MRSA), a major threat to 
public health. This thesis discusses our efforts on studying the TP activities of major PBPs in S. 
aureus. A major challenge is the preparation of useful quantities of native S. aureus Lipid II 
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substrate. Chapter Two describes the studies of S. aureus PBP4 and the development of a simple 
and sensitive assay to evaluate the cellular pools of Lipid II in bacteria. This observation has led 
to a facile method to accumulate and extract Lipid II from S. aureus culture (Chapter Three). 
Although our work is focused on S. aureus, the approach can be generalized to other bacterial 
organisms as well. Lastly, we have reconstituted the TP activity of S. aureus PBP2 and assessed 
its inhibition by a panel of beta-lactam antibiotics (Chapter Four). The biochemical tools 
prepared in this work should be useful for studies of resistance in MRSA and facilitate the 
development of better therapeutic strategies against MRSA.  
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2.1 Introduction 
This chapter describes work to characterize the activity of a low-molecular weight 
(LMW) penicillin-binding protein (PBP) in Stapylococcus arureus, PBP4. Unlike previously 
characterized LMW PBPs in the literature that act as carboxypeptidases (CPs), we showed that S. 
aureus PBP4 has transpeptidase activity. Moreover, unlike previously characterized high-
molecular weight (HMW) PBPs, we demonstrated that PBP4 can use Lipid II as a substrate 
rather than depending on the concomitant peptidoglycan glycosyltransferase (PGT) activity. We 
exploited the unexpected transpeptidase activity of S. aureus PBP4 to develop a facile assay for 
detection of cellular Lipid II in bacteria. We demonstrated that the assay is useful for studying 
the mechanisms of action for cell wall-targeting antibiotics and identified conditions that 
accumulate Lipid II in bacteria, laying the foundation for work described in Chapter Three. 
 
2.1.1 S. aureus PBP4, a peculiar PBP 
Bacterial growth and division require coordinations between peptidoglycan (PG) 
assembly and degradation.1 PBPs, the major players in the final stages of PG biosynthesis, are 
involved in both processes.2,3 The TP domain in HMW PBPs is responsible for peptide cross-
linking between adjacent glycan strands to rigidify PG; LMW PBPs, most of which are also 
known as D, D-carboxypeptidases (CPs)a, mediate the removal of the terminal D-Ala residue in 
the stem peptide in PG (Figure 2.1a).4 Since a stem tetrapeptide can no longer be activated by 
TPs for cross-linking, LMW PBPs are thought to regulate the degree of PG cross-linking in 
bacteria.5 While LMW PBPs are not essential for cell viability many still play important cellular 
functions in bacteria such as governing cell morphology and contributing to antibiotic !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
a A small number of LMW PBPs are endopeptidases (EPs), which catalyze the cleavage of an internal 
amide bond in the stem peptide in PG. 
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resistance.4 As mentioned in Chapter 1.2.3, the name penicillin-binding protein reflects the fact 
these proteins were identified in radioactive penicillin binding studies. Sequence alignment 
reveals that PBPs contain three conserved signature motifs: SXXK, [S/Y]X[N/C] and 
[K/H][T/S]G, where the underlined serine is the catalytic residue.6 These motifs adopt a 
strikingly similar conformation in all PBPs. In both TP and CP reactions, the first step involves 
the catalytic serine attacking the amide bond between D-Ala-D-Ala terminus of a stem peptide to 
form an acyl-enzyme intermediate with the concomitant release of the terminal D-Ala. 
Subsequently, the covalent intermediate is resolved by a nucleophile, the identity of which varies 
in TP and CP reaction. In the case of a CP, the nucleophile is water, and a tetrapeptide product is 
formed.7 In the case of a TP, the nucleophile is the terminal amine from a stem peptide on an 
adjacent PG glycan polymer, and a cross-linked PG product is formed (Figure 2.1a).8-14  !
 
Figure 2.1. Schematic of carboxypeptidase (CP) and transpeptidase (TP) activities in S. aureus PG 
assembly (a) and Lipid II substrates (b). !
PBP4 is the sole LMW PBP in S. aureus, which has been previously annotated as a CP 
based on sequence alignment to other characterized LMW PBPs in different organisms.6 Like 
many LMW PBPs, S. aureus PBP4 has a predicted transmembrane helix at the C-terminus. S. 
! 61 
aureus PBP4 has two structural domains: an N-terminal domain with a beta-
lactam/transpeptidase fold which contains the conserved motifs at the active site, and a C-
terminal domain that is composed of mainly beta-sheets.15 While the functional role of the C-
terminal domain remains to be elucidated, it is also present in several other PBP4-like proteins 
such as E. faecalis D,D-carboxypeptiase, and E. coli PBP5.16  
 
Figure 2.2. Protein sequence alignments of representative LMW PBPs. Signature motifs are highlighted 
in red, the asterisk indicate the predicated catalytic serine residue. Abbreviations for each organism are as 
follows: S. aureus (SAUR), B. subtilis (BSUB), P. aeruginosa (PAER) and E. coli (ECOL). Alignment is 
done using Clustal Omega, based on work by Massova and Mobashery (1998).  
 
As mentioned in Chapter 1.3, the biochemical activities of S. aureus PBP4 were 
investigated by Kozarich and Strominger in 1978 initially using a tripeptide substrate (Ac2-L-
Lys-D-Ala-D-Ala), which mimics the terminal portion of the stem peptide in Lipid II (Figure 
2.1b).17 Unlike most other LMW PBPs that behave solely as CPs, S. aureus PBP4 demonstrates 
CP, TP and beta-lactamase activity in vitro.17 In the presence of a high concentration of the 
acceptor, such as glycine or hydroxylamine, the hydrolysis of the tripeptide was suppressed with 
the concomitant formation of the transpeptidation product. A new peptide was formed in which 
the terminal D-Ala was replaced by the acceptor. It was pointed out that the weaker nucleophile, 
glycine, was a better acceptor than hydroxylamine suggesting that S. aureus PBP4 recognized 
glycine as a preferred acceptor for transpeptidation. In addition, S. aureus PBP4 also 
demonstrated penicillinase activity upon incubation with penicillin. The ability of S. aureus 
PBP4 to carry out multiple reactions was intriguing.  However, kinetic studies revealed that the 
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tripeptide substrate has a high Km (100 mM),17 suggesting it may not be an optimal substrate for 
analyzing S. aureus PBP4 activity in vitro. In addition, analysis of S. aureus PG reveals that over 
90% of the stem peptides are cross-linked, with more than 50% being involved in high degree 
cross-linking, while no uncross-linked tetrapeptide stems are identified.2,18 Genetic inactivation 
of S. aureus PBP4 leads to a drastic reduction in the higher levels of PG cross-linking, 
suggesting PBP4’s physiological role in secondary PG cross-linking.19 Taken together these 
studies did not resolve the physiological activities of PBP4. 
To better understand the activity of S. aureus PBP4, we set out to reconstitute its activity 
using synthetic Lys-Lipid II as a substrate, which closely resembles native S. aureus Lipid II 
(Figure 2.1b). In this chapter, we showed that PBP4 has transpeptidase activity in vitro, which is 
distinct from other LMW PBPs that act as CPs solely. We next showed PBP4, the primary 
transpeptidase in S. aureus is responsible for fluorescent D-amino acid incorporation in PG in 
vivo. Upon investigation of its substrate specificity, we revealed a unique transpeptidase activity 
of PBP4: it can mediate D-amino acid exchange in Lipid II. S. aurueus PBP4 is the first 
transpeptidase demonstrated to activate Lipid II. 
 
2.1.2 Challenges with studying the cellular pools of Lipid II in bacteria  
The cellular pool of Lipid II in bacteria is a poorly addressed question, primarily due to 
the lack of a facile analysis method.20 Scattered reports have addressed the number of Lipid I and 
II molecules in E. coli and have relied on intensive and laborious protocols.21-23 In such studies, 
the cellular PG precursors were first radiolabeled by feeding the auxotrophic E. coli strain with 
radioactive m-Dap, followed by organic extraction of the lipid intermediates. The isolated 
radiolabeled lipid intermediates were then hydrolyzed with mild acid to release the 
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corresponding muropeptides, whose relative amount was compared to UDP-MurNAc-
pentapeptide (the Park nucleotide) on HPLC. It was estimated that the ratio of the Park 
nucleotide: Lipid I: Lipid II in E. coli is approximately 300: 1: 3 or 140: 1: 3.24,25 The ratios of 
Lipid II to Lipid I was found to be constant during the cell cycle.24 Since the amount of the Park 
nucleotide is approximately 100,000 molecules per cell, there would be no more than 700 
molecules of Lipid I and 1000 to 2000 molecules of Lipid II per cell in E. coli.21  
In general, Gram-positive bacteria appear to have more Lipid II than Gram-negative 
bacteria.22-26 In several Gram-positive bacteria, antibiotics (that act as binders to lipid-linked 
peptidoglycan intermediate) have been used to estimate the pool levels of lipid intermediates, 
where the number of antibiotics bound to cell membrane was taken as the number of Lipid II 
present.20 For instance, binding of ramoplanin to S. aureus cells estimated that 50,000 molecules 
of lipid intermediates are present per cell.27b The amount of precursors estimated in such studies 
can vary considerably depending on the antibiotic and the bacteria.28 Overall, Lipid II content 
accounts less than 1% of total phospholipids in bacteria.29 The naturally low abundance of the 
lipid-linked PG precursors in bacteria renders them challenging to account for. Despite the fact 
that Lipid I and Lipid II are key intermediates in PG synthesis, how their pool levels change in 
bacteria under various pharmacological and genetic conditions has not been studied.  
We exploited the unexpected transpeptidase activity of S. aureus PBP4 to develop a 
facile method to detect the cellular level of Lipid II in bacteria,30 addressing a longstanding 
challenge in the field (see Chapter 2.6). We demonstrated that the assay is useful for elucidating 
the cellular mechanism of action for cell wall-targeting antibiotics. In a separate demonstration 
of the utility of these tools, we elucidated the mechanism of action of the antibiotic lysobactin. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
b Ramoplanin is a lipoglycodepsipeptide that binds to Lipid II substrate to prevent PG polymerization. 
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We also identified conditions that lead to Lipid II accumulation in bacteria, which are important 
for studies in Chapter Three. 
 
2.2 Purification and characterization of S. aureus PBP4  
S. aureus PBP4 gene was cloned into an expression vector for heterologous 
overexpression in the E. coli host. Two C-terminally His6-tagged PBP4 constructs were prepared 
initially.c One is a full-length construct (Mw is 48 kD); the other is a [Y21-Q383] truncated 
version that lacks the predicted N-terminal signal sequence and the C-terminal transmemrbane 
segment (Mw is 42 kD). Initial overexpression tests showed that the full-length PBP4 did not 
overexpress, but the truncated PBP4 protein was soluble and overexpressed well. The C-terminal 
transmembrane helix, a common feature in most LMW PBPs is likely to complicate the 
expression and localization of the full-length PBP4 construct. Therefore, we focused on the 
PBP4[Y21-Q383]-His6 construct for purification and characterization, which will be denoted as 
PBP4 throughout the chapter. The soluble PBP4 construct was purified from the cytosolic 
fraction in E. coli by Ni-NTA (nitrilotriacetic acid) affinity column chromatography. PBP4 was 
purified to homogeneity after one step purification as observed on SDS-PAGE gel (Figure 2.3). 
The yield of purification is approximately 10 mg/L culture. A small amount of detergent (0.1% 
reduced triton-X) was added in the elution and storage buffer of PBP4 protein. Notably, the high 
concentration of imidazole in the elution buffer did not affect PBP4 stability and activity. 
The Bocillin-FL binding assay was used to establish that the active site of PBP4 was 
properly folded.31 In this assay, PBP4 was pre-incubated with various concentrations of non-
labeled penicillin G (PenG), followed by the addition of a saturating amount of Bocillin-FL (Bo-
FL), a fluorescent penicillin derivative to the reaction mixture. As shown in Figure 2.3, PenG !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
c A former postdoctoral researcher, Yuriy Rebets, prepared the constructs. 
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inhibited Bo-FL labeling of PBP4 in a dose-dependent manner, implying that active site of PBP4 
is properly folded. However, such competition binding assays do not directly monitor activity of 
the PBPs, which will be discussed in more detail in Chapter Four.  
 
Figure 2.3. S. aureus PBP4 is purified to homogeneity. a) Structure of Bocillin-FL (Bo-FL), a fluorescent 
derivative of penicillin. b) Coomassie stained SDS-PAGE gel of purified PBP4 (left) and fluorescent 
image of Bo-FL-bound PBP4 in the presence of varying concentrations of penicillin (right). 1667 units 
(U) of penicillin equals to 1 mg.  
 
2.3 Assessment of S. aureus PBP4 in vitro activity   
        To investigate the in vitro activity of S. aureus PBP4, we used synthetic Lipid II, Lys-Lipid 
II (Figure 2.1b).32 As mentioned earlier, the Ac2-L-Lys-D-Ala-D-Ala tripeptide has been used 
primarily to study LMW PBPs, including S. aureus PBP4;15,17 however, the tripeptide substrate 
only contains a small portion of the Lipid II, which may affect the enzymatic activity.d In 
contrast, Lys-Lipid II shares the general lipid-linked disaccharide peptide structure with native S. 
aureus Lipid II except for a few distinctions. Lys-Lipid II lacks the pentaglycine branch peptide 
and contains a D-iso-Glu instead of D-isoGln at the second position of the stem peptide. Lys-
Lipid II also has a shorter heptaprenyl lipid (C35) instead of the natural undecaprenyl lipid 
(C55). It has been demonstrated that heptaprenyl Lipid II analogues is a better substrate for PGT 
activity in vitro, due to its reduced tendency to aggregate.33 The absence of pentaglycine branch 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
d The turnover number of PBP4 transpeptidase activity using tripeptide substrate was 20 min-1 (ref. 17).  
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in Lys-Lipid II for transpeptidation was overcome by the addition of exogenous oligoglycines as 
acceptors in the reaction (see below). 
To evaluate the activity of S. aureus PBP4, we adopted a liquid chromatography-mass 
spectrometry (LC/MS) assay that was previously used to study HMW PBPs in E. coli and B. 
subtilis.12,13 In this assay, PG polymer formed in vitro was digested with mutanolysin, a 
glycosidase into disaccharide muropeptides. The muropeptides were then treated with NaBH4 to 
resolve the anomers at the reducing end of MurNAc prior to LC/MS analysis. Since mutanolysin 
can only digest PG polymer containing a few disaccharide-repeating units and does not digest the 
monomeric Lipid II, formation of a PG strand is a pre-requisite in this assay. S. aureus PBP4 is a 
LMW PBP that does not have PGT activity, therefore, we coupled PBP4 with a monofunctional 
glycosyltransferase, SgtB to make nascent PG polymers.34e To evaluate if PBP4 has TP activity, 
we also added glycine oligopeptides (Glyx: Gly1, Gly2, Gly3 and Gly5) to the reaction mixture to 
mimic the acceptor strands in cross-linking. The resulting muropeptide fragments were analyzed 
via LC/MS. As shown in Figure 2.4, SgtB alone gave only unmodified fragment A, confirming 
its involvement in nascent PG formation only (Figure 2.4b, trace i); SgtB and PBP4 produced 
two products in the absence of Glyx: unmodified fragment A, and the hydrolysis product B 
(Figure 2.4b, trace ii). When Glyx was added, S. aureus PBP4 preferentially incorporated the 
exogenous nucleophile to product Cx even though the concentration of water is many orders of 
magnitude higher (Figure 2.4b, trace iii-iv, and Figure App1.1). In addition, we also observed 
efficient D-amino acid incorporation when D-Ser, D-Phe or D-Tyr (1mM) was added. While 
mutating the PBP4 catalytic serine residue abolished all activity (Figure App1.2). The ability of 
PBP4 to discriminate against water and incorporate glycine oligopeptide and D-amino acids !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!"!Previous studies have shown that SgtB polymerized Lys-Lipid II in vitro to long glycan polymers of 
approximately 50 disaccharide units.!
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shows that it acts as a TP in vitro, unlike most other LMW PBPs, which possess CP activity 
exclusively.35  
 
 
2.4 Assessment of S. aureus PBP4 in vivo activity 
To assess if S. aureus PBP4 has TP activity in cells, we investigated the ability of 
wildtype S. aureus and the !pbp4 mutant strains to incorporate a fluorescent D-Lys probe 
(FDL).36 We observed that wildtype S. aureus cells were brightly labeled with FDL, with 
fluorescence concentrated at the crosswall where the bulk of PG synthesis takes place (Figure 
2.5a).37 The !pbp4 strain showed only faint labeling, but complementation of pbp4 gene restored 
efficient labeling. Monitoring fluorescence signals in S. aureus that were incubated with FDL for 
various periods of time (1min, 10min and 30min) indicates that FDL incorporation is efficient 
and the signal intensity increases over time (Figure 2.5). These results support that PBP4 acts as 
Figure 2.4. S. aureus PBP4 demonstrates TP activity in vitro. (a) Schematic of assay to monitor PBP4 
activity. The PBP4-activated substrate adduct can be attacked by water or Glyx. Three possible 
degradation products are yielded: A represents the unreacted muropeptide, B is the hydrolysis product, 
and C is a TP product with Gly2 or Gly5 incorporated. (b) LC/MS extracted ion chromatograms (EICs) 
of a control reaction without PBP4 (i), a reaction with PBP4 (ii), and reactions containing PBP4 and 
Gly2 (iii) or D-Ser (iv). (M+2H)/2 ions: A, 485.2; B, 449.6; C(Gly2), 506.7; C(Gly5), 592.3. (See 
materials and methods for detailed protocols). 
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a TP in cells and is primarily responsible for catalyzing D-amino acid exchange into PG in S. 
aureus.f Previous findings have shown that the level of PG cross-linking in S. aureus is 
drastically reduced in !pbp4 mutant, implying its cellular function as a TP.19 Our observation is 
consistent with this. 
 
 
Using fluorescent D-amino acid derivatives to study bacterial PG synthesis has been of 
great interest in recent years.38,39 Different mechanisms are responsible for D-amino acid 
incorporation into PG in different bacteria. For instance, the L,D-transpeptidases in E. coli are 
primarily responsible for exogenous D-amino acid incorporation at the fourth position of the 
stem peptide;40 whereas in B. subtilis, exogenous D-amino acids are incorporated by TPs into the 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#!The faint labeling associated with !pbp4 strain indicates that other PBPs or pathways may play a role in 
FDL incorporation as well.!
Figure 2.5. S. aureus PBP4 has TP activity in vivo. a) Chemical structure of fluorescent D-lysine probe 
(FDL). b) S. aureus wildtype strain incorporates FDL efficiently, but the !pbp4 strain shows dramatic 
decrease in FDL incorporation. Complementation with pbp4 gene restores the incorporation efficiency 
(Scale bar: 2 µM). Sample preparation is described in materials and methods. 
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fifth position exclusively, but are rapidly hydrolyzed by CPs, and deletion of dacAg is necessary 
to retain fluorescent labels in PG.36,40 In addition, Chlamydia trachomatis, a species whose PG is 
only recently appreciated, can incorporate fluorescent analogues of D-Ala-D-Ala dipeptide 
probes in PG via the intracellular ligase MurF.39 In the case of S. aureus, the fluorescent D-
amino acid was incorporated into the fifth position in the stem peptide in PG. Our work 
demonstrates that S. aureus PBP4 is the primary PBP responsible for D-amino acid incorporation 
in PG.30 Two recent works also illustrate the importance of S. aureus PBP4 in fluorescent 
labeling of PG.41,42  
 
2.5 Analysis of S. aureus PBP4 substrate specificity in vitro    
For certain HMW PBPs, TP activity requires either ongoing PG synthesis or preformed 
uncross-linked PG polymers.8,9,43 All previously studied LMW PBPs have less stringent substrate 
requirements that only require a tripeptide mimic for their CP activity.44,45 In order to assess the 
substrate requirements of S. aureus PBP4, we modified the in vitro assay by adding enzymes 
sequentially. To determine if preformed PG is a PBP4 substrate, Lys-Lipid II was polymerized 
with SgtB, which was heat-inactivated prior to adding PBP4 and D-Tyr.h In a parallel set of 
experiments to test if Lipid II could be a substrate, Lys-Lipid II was first incubated with PBP4 
and D-Tyr and then heat-inactivated prior to adding SgtB to polymerize the modified Lipid II. 
LC/MS analysis of the reaction products showed that D-Tyr was incorporated efficiently in both 
sets of reactions (Figure 2.6). Thus PBP4 uses both nascent PG and Lipid II monomers as 
substrates in vitro. This is the first demonstration of a TP capable of activating monomeric Lipid 
II. PBP4 has been suggested responsible for the formation of highly cross-linked PG in S. !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
g B. subtilis DacA encodes PBP5, a LMW PBP that acts as a carboxypeptidase. 
h D-Tyr was chosen as an example here; other D-amino acids could be incorporated as well.  
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aureus.19 We believe the promiscuity of S. aureus PBP4 in substrate recognition has important 
ramifications for its cellular functions.46,47 The ability of S. aureus PBP4 to act on both glycan 
strands and Lipid II, independent of glycan polymerization, may allow it to add cross-links to 
partially cross-linked PG and to repair defects in cells. This role may be particularly important 
under stress conditions.48   
 
 
 
 
 
 
 
 
 
 
S. aureus PBP4 exchanges D-amino acid into Lys-Lipid II efficiently. We found that the 
presence of an increasing concentration of D-Tyr (at 0 µM, 20 µM, 400 µM, and 1mM) in the 
assay favors the formation of D-Tyr containing muropeptides. Approximately, a 10-fold excess 
of D-Tyr (400 µ") over Lys-Lipid II (40 µM) led to the complete exchange of the terminal D-
Ala over one hour of reaction (Fig. App1.3). PBP4 can also efficiently incorporate other D-
amino acids (such as D-Ser, D-Phe, D-Lys and so on) into Lys-Lipid II. To investigate if 
Figure 2.6. S. aureus PBP4 exhibits promiscuous TP activity in vitro. (a) Schematic for analyzing 
PBP4 substrate tolerance. (b) LC/MS EICs of PBP4 reactions with preformed PG (i) and Lipid II (ii) 
both show the D-Tyr-containing muropeptide peak C. (M+2H)/2 ions were extracted: A: 485.2, B: 
449.6, C: 531.2. (See materials and methods for detailed protocols). 
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different acceptors behave differently during incorporation, we set up a competition experiment 
where two nucleophiles, D-Ala(d3) and Gly-Gly dipeptide were added to the reaction mixture in 
equal concentrations (at 1 mM each).i At various time points, the reaction was subjected to 
analysis on LC/MS (Figure 2.7). In this experiment, D-Ala(d3), which resembles the terminal D-
Ala but can be distinguished on MS, was used to probe the reverse reaction of activation; Gly-
Gly dipeptide was used to represent the glycine branch in cross-linking. We observed that D-
Ala(d3) was quantitatively incorporated within the first 15 min of the reaction (Figure 2.7b, peak 
C), but was replaced by Gly-Gly as reaction proceeded (Figure 2.7b, peak D). As illustrated in 
Figure 2.7c, the incorporation of D-Ala(d3) and Gly-Gly into Lipid II both involves the formation 
of a common acyl-enzyme intermediate. D-Ala(d3) attacks the intermediate rapidly, forming a 
modified D-Ala-D-Ala(d3) terminus in Lipid II, which can then be re-activated by PBP4 to yield 
the covalent intermediate again. Thus, the incorporation of D-Ala(d3) is reversible. On the other 
hand, Gly-Gly incorporation occurs slower but is irreversible, since re-inactivation of the 
modified terminus with Gly-Gly by PBP4 was not observed. As a result, Lipid II was 
quantitatively incorporated with Gly-Gly after prolonged incubation. This observation is in 
accordance with the fact that PG cross-links are not hydrolyzed by PBPs. 
Prompted by the promiscuous TP activity of S. aureus PBP4, we further examined the 
scope of synthetic Lipid I and Lipid II analogues as substrates. We found that PBP4 can act on 
canonical E. coli Lipid II, which contains an m-Dap in place of L-Lys in the stem peptide (Figure 
App.1.3). In addition, Lipid I analogues could be readily modified by PBP4 via D-amino acid 
exchange and then converted to the corresponding Lipid II analogues in the chemoenzymatic 
MurG reaction (Figure 2.8). Using biotinylated D-Lys (BDL), we readily obtained BDL-Lipid I 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!$!The reaction contains 2 µM of S. aureus PBP4 and 40 µM of Lys-Lipid II.!
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and Lipid II. A number of Lipid I and II analogues with unnatural D-amino acid in the terminal 
stem peptide position, such as D-propargylglycine and D-7-azatryptophan were prepared 
similarly (Figure App1.4 and 1.5). However, incorporation of D-amino acid derivatives with 
bulky side chains that are close to the alpha carbon (C#), such as D-Ala-7-amino-4-
mehtylcoumarin (AMC), was impeded, whereas derivatives with the bulkiness further away from 
C# (such as BDL) was well tolerated by S. aureus PBP4. 
 
Figure 2.7. LC/MS analysis of S. aureus PBP4-mediated D-amino acid exchange in Lipid II. (a-b) 
Schematic and EICs of PBP4 reactions with Lys-Lipid II in the presence of an equal amount of D-Ala(d3) 
and Gly-Gly as acceptors. D-Ala(d3) incorporated muropeptide (C) was observed wihin 15 min of 
incubation, but D-Ala(d3) was replaced by Gly-Gly (D) after prolonged incubation (3 h). (M+2H)/2 ions 
were extracted: A: 485.2, B: 449.6, C: 486.7, D: 506.7. (c) Schematic showing differences between 
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(Continued) D-Ala(d3) and Gly-Gly incorporations into Lipid II based on experimental data in (b). D-
Ala(d3) incorporation is faster but reversible; whereas Gly-Gly incorporation is slower but stable. (See 
materials and methods for detailed protocols). 
 
 
 
Figure 2.8. Schematic showing the versatility of PBP4 TP activity. PBP4 can incorporate a variety of 
functionalized D-amino acids into either Lipid I or Lipid II in vitro. 
 
2.6 Detection of the cellular levels of Lipid II in bacteria 
  The unexpected TP activity of PBP4 to label Lipid I and Lipid II may facilitate 
development of assays to study PG processes. We wondered if PBP4’s ability to biotinylate 
Lipid II precursors can be used to detect the cellular Lipid II in bacteria, which has been a 
longstanding challenge, since previous assays were laborious and involved the use of 
radioactivity.21-23 As shown in Figure 2.9, we extracted cellular lipids from a small S. aureus 
culture (2mL) at mid-log phase (O.D.= 0.4-0.5) using chloroform and methanol solvents in a 
Bligh-Dyer extraction similar to the report by Guan et al.49 To selectively biotinylate Lipid II in 
the lipid extract, we incubated S. aureus PBP4 and BDL with the extract (which was 
resuspended in a DMSO solution) for one hour. After reaction, the mixture was quenched and 
subjected to gel electrophoresis, followed by blotting with a streptavidin-HRP conjugate. 
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Remarkably, biotinylated Lipid II species were readily detected after a brief exposure (~2 
seconds). We note that both cellular Lipid I and Lipid II may be labeled by PBP4, but since 
bacteria has an excess of Lipid II than Lipid I, we assumed that the signal mainly came from 
labeling of cellular Lipid II. MS analysis described in Chapter Three confirms that only Lipid II 
was extracted from S. aureus in our studies. 
To demonstrate the utility of our assay, we assessed the cellular levels of Lipid II in S. 
aureus when treated with different antibiotics. As shown in Figure 2.9, moenomycin (MmA) and 
vancomycin (Vanco) treatments increased the Lipid II pool levels, presumably because Lipid II 
is no longer consumed by PGTs and therefore accumulates on the external surface of the cell 
membrane. Our observation was consistent with previously studies on the accumulation of 
radiolabeled PG precursors in moenomycin (MmA)- and vancomycin (Vanco)- treated 
bacteria.23 In contrast, fosfomycin (Fos), targocil (Tar) and bacitracin (Bac) treatment all reduced 
the pool levels. Fosfomycin inhibits MurA activity, which is an early step in Lipid II synthesis,50 
thus is expected to decrease the cellular Lipid II level. Targocil (Tar) targets TarGH, the wall 
teichoic acid (WTA) flippase, and inhibits the translocation of WTA precursors across the 
membrane,51-53 leading to an accumulation of WTA intermediates in the inner leaflet of the 
membrane in cells. Since both Lipid II and WTA use undecaprenyl phosphate (Und-P) as the 
lipid carrier, accumulation of WTA precursors would limit the availability of Und-P for Lipid II 
synthesis.54 Bacitracin, which specifically binds to the undecaprenyl pyrophosphate (Und-PP) in 
the outer leaflet of the membrane, prevents dephosphorylation and hence recycling of the lipid 
carrier to the inner leaflet for Lipid II biosynthesis,55 thus depleting the cellular Lipid II levels in 
S. aureus. However, a minimal change in Lipid II level was observed in S. aureus treated with 
kanamycin (kan), a non PG-targeting antibiotic (Figure 2.9). Therefore, using PBP4-mediated 
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biotinylation, we developed a simple and sensitive assay to study the cellular Lipid II levels in S. 
aureus. This assay should facilitate studies on the mechanism of action of potential PG-targeting 
antibiotics. 
 
Figure 2.9. S. aureus PBP4 enables a simple assay to detect cellular Lipid II in bacteria. Antibiotic 
treatments cause changes in the pool levels of Lipid II in S. aureus, which are consistent with their 
mechanisms of action. 
 
2.7 Elucidation of the cellular mechanism of action for lysobactin 
In collaboration with a postdoctoral researcher in the Walker lab, Wonsik Lee, we 
applied the Lipid II detection assay described above to characterize the cellular mechanism of 
lysobactin. Lysobactin is a macrocyclic depsipeptide natural product that is produced by a 
species of Lysobacter (ATCC 53042).56 It displays excellent antibacterial activity against a 
number of drug-resistance bacteria, including MRSA, vancomycin-resistant enterococci (VRE), 
as well as Mycobacterium tuberculosis (TB) with its MICs being significantly lower than that of 
vancomycin (2- to 50- fold lower depending on the strains). While several total syntheses of 
lysobactin and its biosynthetic pathway have been reported,57-61 its mechanism of action of is still 
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poorly investigated. Lysobactin was originally identified as a binder to the crude preparations of 
S. aureus cell wall; however, its mechanism appeared distinct from vancomycin since lysobactin 
did not bind to the lysozyme-solubilized cell wall (whereas vancomycin did).62 In 
macromolecular synthesis assays, lysobactin inhibited [14C]-m-Dap incorporation into PG but 
had no effects on either [14C]-uridine or [14C]-thymidine incorporation in RNA or DNA 
synthesis. However, the exact mechanism of action of lysobactin has remained unclear when this 
project was initiated in the Walker and Kahne labs. 
In the in vitro activity assays of several enzymes involved in PG synthesis (i.e. MurG, 
SgtB, TagB), lysobactin demonstrated enzymatic inhibition with a characteristic substrate-
binding curve.63j Unlike previous known substrate-binding inhibitors such as ramoplanin64 and 
teixobactin65 that have a stoichiometry of 2:1 (drug: cell wall precursors), lysobactin gives a 
distinctive 1:1 stoichiometry in the in vitro assays. We learned that lysobactin binds to the sugar-
pyrophosphate moiety in several cell wall precursors in vitro, including Lipid I, Lipid II and 
WTA precursors; however, identifying the cellular targets of lysobactin responsible for its 
antibacterial activity in vivo requires cellular assays. The S. aureus PBP4-enabled detection of 
cellular Lipid II in bacteria (see Chapter 2.6) allows us to elucidate the cellular effects of 
lysobactin. We treated S. aureus culture (2 mL) with lysobactin at 1.5 µg/mL or 3 µg/mL (i.e. 2x 
or 4x of its MIC) for 10 min, extracted the cellular lipids and labeled with BDL using S. aureus 
PBP4. As shown in Figure 2.10, a dramatic accumulation of Lipid II was observed upon 
lysobactin treatment. The higher bands were products of PBP4 cross-linking of Lipid II during 
BDL labeling, which disappeared upon treatment with lysostaphin, an endopeptidase that 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!%!In such inhibition curves, the enzymatic reaction rate is negligible at low substrate concentration because 
of no free substrate but jumps soon as substrate becomes available. Wonsik Lee performed the in vitro 
enzymatic assays. Wonsik Lee and I performed the in vivo Lipid II accumulation assays.!
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specifically cleaves cross-linked pentaglycine bridges.63 Therefore, we conclude that lysobactin 
preferably binds to Lipid II in cells, contributing to its cellular mechanism of action. Although 
lysobactin has the ability to bind to WTA precursors in vitro, WTA substrates are not the cellular 
targets of lysobactin. Given that only one in nine MurNAc residue in PG is modified with WTA, 
the precursor flux is substantially higher through the PG pathway in bacteria.66 Lipid II is the 
cellular target of lysobactin. 
 
2.8 Conclusion 
In conclusion, through studies of S. aureus PBP4 activity in vitro using Lys-Lipid II and 
various oligoglycines or D-amino acids as acceptors, we have established that PBP4 is a 
transpeptidase (TP) with unique activity to act on monomeric Lipid II substrate. Since its TP 
activity is remarkably different from other previously characterized PBPs, it is possible that other 
LMW PBPs possess similar TP activity as S. aureus PBP4. While most LMW exhibit solely 
carboxypeptidase or endopeptidase activities, Streptomyces LMW PBPs (R61 and R39) have 
been also characterized as TPs in vitro with Ac2-L-Lys-D-Ala-D-Ala tripeptide substrate.35 In 
Streptomyces, the PG cross-link is made of a Gly attached to the amino side chain of LL-DAP at 
Figure 2.10. Lysobactin treatment accumulates Lipid II in S. aureus. a) Structure of lysobactin (lyso). b) 
Western blot of BDL-labeled Lipid II in S. aureus showed the accumulation of cellular Lipid II in 
lysobactin-treated S. aureus. The multiple bands were due to PBP4 crosslinking of concentrated Lipid II. 
c) Lysostaphin treatment of multiple bands resulted in collapsing of the bands. 
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the third position of the stem peptide. Stretomyces R61 and R39 were shown to incorporate a 
dipeptide acceptor (Gly-L-Xaa) into the tripeptide substrate, yielding a tetrapeptide product. In 
addition, R61 displayed weak reversible TP activity (i.e. hydrolysis) with the tetrapeptide (Ac2-
L-Lys-D-Ala-Gly-L-Xaa).67 In our case, S. aureus PBP4 did not hydrolyze the transpeptidation 
product.k In addition, for S. aureus PBP4 activities, the presence of a free carboxylate at C# in 
the acceptor is not an absolute prerequisite, since we observed that the methyl ester derivatives of 
oligoglycines could be incorporated by PBP4; however, the effects of the carboxylate 
modification may depend on the acceptor structure, since the carboxamide derivatives were 
discriminated by PBP4 in vitro. The acceptor substrate specificity of S. aureus PBP4 in our 
studies is similar to that of R61 reported previously.67 
Exploiting the unexpected transpeptidase activity of S. aureus PBP4, we developed a 
simple and sensitive assay to detect the cellular levels of Lipid II in bacteria, addressing a 
longstanding challenge. We observed that treatment of various cell wall-targeting antibiotics led 
to changes in the cellular pools of Lipid II in S. aureus, consistent with their known mechanisms 
of action. In particular, antibiotics such as moenomycin and vancomycin that inhibit late steps in 
PG synthesis resulted in an accumulation of Lipid II, whereas antibiotics that either target an 
earlier step in the pathway (e.g. fosfomycin) or interfere with the carrier lipid (Und-P) recycling 
(e.g. bacitracin and targocil) deplete Lipid II. Hence, we now have a method to determine the 
cellular mechanisms of potential antibiotics based on their effects on Lipid II levels. As a 
demonstration, we have established that lysobactin, a macrocyclic depsipeptide natural product 
inhibitor, strongly accumulates Lipid II in S. aureus. This observation is in line with the 
proposed mechanism of lysobactin as a Lipid II binder in cells. We are currently using this assay !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
k Except when D-Ala(d3) and Gly2 acceptors were both present in the reaction, D-Ala(d3) was 
incorporated and re-activated, followed by Gly2 incorporation (Figure 2.7). 
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to profile the effects of potential PGT inhibitors on Lipid II levels in S. aureus. In closing, we 
note that the Lipid II detection assay using S. aureus PBP4 can also be applied to other 
organisms, including E. coli, E. faecalis, B. subtilis and Acinetobacter baumannii, opening up the 
possibility to study PG-related processes in various organisms. 
 
2.9 Materials and Methods 
2.9.1 Materials 
Lys-Lipid I, Lys-Lipid II, and m-Dap-Lipid II were prepared as previously 
described.13,32,43 N-terminus truncated S. aureus SgtB were purified as reported previously.68,69 
Fluorescein D-Lysine (FDL) was prepared as described.36 S. aureus PBP4 deletion strain 
(!pbp4) and the complementation strain (!pbp4 complemented with pbp4 gene) were obtained 
from the Cheung Lab.70 Primers were purchased from Integrated DNA Technologies. Restriction 
endonucleases were purchased from New England Biolabs. Vectors and expression hosts were 
obtained from Novagen. Non-stick conical vials and pipette tips used for enzymatic reactions 
were purchased from VWR. H-Gly-Gly-OH and H-Gly-Gly-Gly-OH were purchased from TCI. 
H-Gly-Gly-Gly-Gly-Gly-OH was purchased from Bachem. D-7-Azatryptophan was purchased 
from Santa Cruz Biotechnology Inc. Fmoc-D-Lys(biotinyl)-OH was purchased from VWR. D-
Propargylglycine (DPG) was purchased from Peptech Corporation. D-Alanine-3,3,3-d3 (D-Ala-
d3) was purchased from CDN Isotopes. Bocillin-FL penicillin, Na salt (Bo-FL) was purchased 
from Invitrogen. Moenomycin A was isolated from flavmoycin feedstock as previously 
reported.71 All other chemicals were purchased from Sigma Aldrich unless otherwise noted.  
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2.9.2 General Methods 
Low-resolution mass spectra chromatograms were obtained on an Agilent Technologies 
1100 series LC-MSD instrument using electrospray ionization (ESI). High-resolution mass 
spectra data was obtained on an Agilent 6520 LC-MS Q-TOF mass spectrometer instrument 
using ESI. Microscopic images were acquired with a Hamamatsu digital camera model ORCA-
ER connected to a Nikon Eclipse TE2000-U microscope with X-cite 120 illumination system.  A 
typhoon phosphorimager (GE Healthcare) was used to capture fluorescent SDS-PAGE gels. 
ImageJ was used to analyze microscopy images and western blots. 
 
2.9.3 Plasmid construction 
The pbp4[Y21-Q383] gene encoding truncated S. aureus PBP4[Y21-Q383], lacking the 
predicted transmembrane segments was PCR purified from S. aureus Newman strain using the 
following primer pair: 5’-CCTAGCTAGCTATGCACAAGCTACTAAC-3’ and 5’-
GCAGGGATCCTTACTGATGAACTTCTAC-3’. After digestion with NheI and BamHI (the 
restriction sites are underlined), the PCR fragment was ligated into pET28a(+) to produce 
pPBP4[Y21-Q383] as a N-terminal His6 fusion. The inserted pbp4[Y21-Q383] gene was 
confirmed by sequencing (Genewiz or Beckman Sequencing Facility). E. coli novablue strain 
was used for cloning. 
The catalytic serine residue (S75) of the transpeptidase domain of S. aureus PBP4 has 
been identified by sequence alignment with other PBPs.72 The S75A mutation was made in the 
parent plasmid pPBP4[Y21-Q383] using techniques described in the QuickChange site-directed 
mutagenesis kit (Stratagene) to make the mutant plasmid pPBP4[Y21-Q383] S75A with the 
forward primer 5’-CTAAGTGGAATCCAGCGGCAATGACTAAATTAATGAC-3’ and the 
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reverse primer 5’-GTCATTAATTTAGTCATTGCCGCTGGATTCCACTTAG-3’ (mutagenized 
codon is underlined).  
 
2.9.4 Overexpression and purification of S. aureus PBP4 and mutant  
Plasmid pPBP4[Y21-Q383] encoding for soluble S. aurues PBP4 and plasmid 
pPBP4[Y21-Q383] S75A encoding for S. aureus PBP4 TP* were collected from the cloning 
strains, and were transformed into E. coli BL21(DE3) cultures respectively for overexpression 
and purification. E. coli BL21 (DE3) cultures (LB medium supplemented with 50 µg/ mL 
kanamycin) were used to inoculate 1 L of LB medium (1:100) supplemented with 50 µg/mL 
kanamycin at 37 °C and grown to OD600 = 0.4-0.5 with shaking. Cells were cooled to 17 °C 
before induction with 0.5 mM IPTG for 17 h with shaking. Cells were harvested by 
centrifugation (5250 x g, 20 min, 4 °C) and pellets were resuspended on ice with 30 mL of 
Buffer A (20 mM Tris (pH = 7.5), 400 mM NaCl) with 1 mM phenylmethylsulfonyl fluoride 
(PMSF).  Cells were lysed by three passages through a cell disrupter (3 x 10,000 psi, 4 °C). The 
cell lysate was then pelleted by ultracentrifugation (90,000 x g, 30 min, 4 °C). The resulting 
supernatant containing PBP4 protein was added to 1.5 mL washed Ni-NTA resin (Qiagen) and 
rocked at 4 °C for 40 min. After loading the column, the resin was washed with wash buffer (20 
mL Tris (pH = 7.5), 40 mM NaCl, 0.1 % Triton-X-100, 40 mM imidazole). The protein was 
eluted with 200 mM imidazole in 10 mL of elution buffer (20 mM Tris (pH = 7.4), 500 mM 
NaCl, 0.1% reduced Triton-X-100, 200 mM imidazole). The eluent containing His6-PBP4 was 
concentrated to < 1 mL using 30 kD MWCO Amicon Ultra Centrifuge Filter Devices 
(Millipore). The yield of purified protein was found to be ~ 8 mg/mL by DC protein assay 
(Biorad). Proteins were stored at -80 °C.  
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2.9.5 Bocillin-FL binding assay 
Purified S. aureus PBP4 protein (250 nM) was incubated with varying concentrations of 
penicillin G (penG) (1000, 100, 0 U/mL) in a buffer containing 20 mM potassium phosphate (pH 
= 7.5) and 140 mM NaCl (to reach a volume of 9 µL). The mixture was incubated at 37 °C for 1 
h with shaking. Bocillin-FL (1 µL of 100 µM stock) was added to the mixture (total reaction 
volume is 10 µL),73 which was then incubated for 30 min at 37 °C with shaking. The reaction 
was quenched by adding 2x SDS loading dye, and heated for 20 min at 95 °C. The samples were 
loaded onto a SDS-PAGE gel, which was then scanned using Typhoon (fluorescence scan, 
excitation 488 nm, emission 526 nm). The scanned image was then analyzed using ImageJ 
(Figure 2.3).  
 
2.9.6 LC/MS protocol for muropeptide analysis 
The procedure was modified from a recent report by Lebar et al.12 Lys-Lipid II (40 µM) 
was incubated with SgtB (1 µM) and PBP4 (2 µM) in reaction buffer (12.5 mM HEPES (pH = 
7.5), 2 mM MnCl2, 20% DMSO, and 250 µM Tween-80) in a total of 10 µL reaction volume for 
1 h at 25 °C in the absence or presence of glycine oligopeptides or various D-amino acids (all 
solutions were used at 1 mM; except for Gly3 and Gly5 solutions that were acidified with 0.01 N 
HCl to facilitate solubility, and were used at a final concentration of 5 mM). The reaction was 
quenched at 95 °C for 5 min, and then treated with mutanolysin (from Streptomyces globisporus, 
Sigma, 1 U) for 1.5 h at 37 °C followed by another 1 U aliquot for 1.5 h. The resulting 
disaccharides were reduced with sodium borohydride (10 mg/mL, 30 min) to resolve the 
MurNAc anomers. Phosphoric acid (20%, 1.2 µL) was then added to adjust the pH to ~ 4. The 
reaction mixture was the lyophilized, redissolved in 12 µL H2O and subjected to LC/MS 
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analysis, conducted with ESI-MS operating in positive mode. The instrument was equipped with 
a Waters Symmetry Shield RP18 column (5 µM, 3.9 x 150 mm) with a matching column guard. 
The fragments were separated using the following method: 0.5 mL/min H2O (0.1% formic acid) 
for 5 min followed by a gradient of 0% acetonitrile (ACN) (0.1% formic acid)/H2O (0.1% formic 
acid) to 20% ACN (0.1% formic acid)/H2O (0.1% formic acid) over 40 min. Molecular ions 
corresponding to expected disaccharide fragments were extracted from chromatograms (Figure 
2.4 and Figure App1.1).  
To analyze the ability of PBP4 to use polymeric PG and monomeric Lipid II as 
substrates, the above procedure was modified slightly. To analyze PBP4 activity on preformed 
PG polymer, Lys-Lipid II (40 µM) was incubated with SgtB (1 µM) for 1 h at 25 °C, prior to 
inactivation of SgtB at 95 °C for 5 min. PBP4 (2 µM) and D-Tyr (1 mM) were added to the 
reaction mixture which was incubated for another h at 25 °C before heat quenching. The 
digestion procedure was identical to that discussed above. To analyze PBP4 activity on Lipid II 
monomer, Lys-Lipid II (40 µM) was incubated with PBP4 (2 µM) and D-Tyr (1 mM) for 1 h at 
25 °C, prior to inactivation of PBP4 at 95 °C for 5 min. SgtB (1 µM) was added to the reaction 
mixture which was incubated for another h at 25 °C before heat quenching. The digestion 
procedure was identical to above. Molecular ions corresponding to the expected disaccharide 
fragments were extracted from chromatograms (Figure 2.6). To analyze PBP4 activity to 
exchange unnatural D-amino acids into Lipid II monomers, the respective D-amino acid 
acceptors (1 mM) were used (Figure 2.7 and Figure App1.2). 
To analyze PBP4 activity on D-amino acid incorporation into Lipid II at varying 
concentrations of the D-amino acid, D-Tyr (0 µM, 20 µM, 400 µM and 1 mM) was used in the 
reaction as discussed above (Figure App1.3). 
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2.9.7 Microscopy imaging analysis  
S. aureus strains (MW2 wildtype, !pbp4, and !pbp4 complemented with pbp4 gene)74 
were grown for 4 h in TSB at 37 °C to stationary phase. The cultures were then diluted to reach 
OD600 = 0.1 and allowed to grow for an additional 30 min to reach mid-log phase. To 0.5 mL of 
S. aureus culture, 1 µL of FDL probe (2 mM in DMSO) was added (giving a final concentration 
of 4 µM). The cultures were incubated briefly for 10 min at 37 °C with shaking, and fixed with 
ice cold 70% ethanol immediately. The fixed cells were then incubated on ice for 15 min, before 
washing with PBS buffer for three times. The washed cell pellet was resuspended in 30 µL PBS, 
and 2 µL liquid was mounted on PBS pads containing 2% agarose. The samples were imaged 
using BODIPY-GFP channel. Images were adjusted to the same intensity scale to allow 
comparison on ImageJ (Figure 2.5).  
 
2.9.8 Preparation of BDL probe 
To Fmoc-D-Lys(biotinyl)-OH (0.016 mmol, 10 mg) in a glass vial, 2 mL of 20% 
piperidine/DMF and 0.3 mL toluene were added. The mixture was stirred to dissolve for 30 min 
at room temperature, and then concentrated to remove solvent in vacuo. The crude concentrated 
mixture was diluted in H2O leaving a white precipitate (deprotected Fmoc byproduct), which was 
removed via filtration. The filtrate was concentrated, and the product was analyzed by MS direct 
injection in positive mode. Pure BDL probe was prepared as a stock solution of 10 mM in H2O. 
 
2.9.9 Incorporation of functionalized D-amino acids into Lipid I and Lipid II  
An aliquot of C20-Lys-Lipid I analogue (50 nmol) in DMSO (20 µL) was briefly 
sonicated and then diluted with 20 µL of 10x reaction buffer (125 mM HEPES pH = 7.5, 20 mM 
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MnCl2, and 2.5 mM Tween-80). Biotinylated D-Lysine (BDL) (5 mM, final concentration) and 
PBP4 (20 µM, final concentration) were then added to the reaction mixture to reach a final 
volume of 200 µL. The reaction was incubated for 3 h at 25 °C, and then kept on ice before 
purification. The reaction mixture was loaded onto a pre-equilibrated Strata C18-E SPE column 
(Phenomenex), then eluted with ACN/25 mM NH4HCO3 using a step gradient of 0% to 100% 
ACN (500 µL each, 10% increment). The collected fractions were analyzed by MS direct 
injection in negative mode. The modified-Lipid I analogue was eluted in 30%-40% ACN 
fractions. HRMS data was obtained for the fractions contain pure BDL-incorporated Lipid I 
analogue (Figure App1.3-1.4). D-propargylglycine (DPG)-modified Lipid I analogue was 
obtained using DPG in place of BDL following the same protocol (Figure App1.3-1.4). 
The fractions that contained pure BDL-incorporated Lipid I analogue were combined and 
concentrated by speed-vac. Lipid I to Lipid II conversion was carried out as previously 
described.75,76 Briefly, the dried Lipid I analogue (50 nmol) was re-dissolved in MeOH (24 µL), 
and then added 23 µL of 7 x MurG buffer (350 mM HEPES pH 7.9, 35 mM MgCl2), 5 µL UDP-
GlcNAc (10 mM), and 96 µL H2O. The mixture was vortexed before adding 8 µL alkaline 
phosphatase (20U/ µL, Roche) and 4 µL purified MurG (20 mg/mL) to reach a total final volume 
of 160 µL. After incubation at 25 °C for 1 h, another aliquot of 4 µL MurG (20 mg/mL) was 
added to the reaction to incubate for another 1 h. Cold H2O (160 µL) was added to quench the 
reaction. The quenched mixture was loaded onto a pre-equilibrated BAKERBOND SPE C18-
extraction column (J. T. Bakers), and washed with H2O/ 0.1% NH4OH (500 µL x 7), and then 
eluted with MeOH/ 0.1% NH4OH (500 µL x 7). The fractions were analyzed by MS direct 
injection in negative mode. The modified-Lipid II analogue was eluted in the initial MeOH/ 
0.1% NH4OH fraction (500 µL). HRMS data was also obtained for the pure BDL-modified Lipid 
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II analogue. DPG-modified Lipid II analogue was converted from DPG-Lipid I following the 
same protocol (Figure App1.3-1.4). 
 
2.9.10 Western blot detection of BDL-Lipid II in vitro 
To a non-stick reaction vial, 3 µL H2O and 1 µL of 10x reaction buffer (125 mM HEPES 
pH = 7.5, 20 mM MnCl2, and 2.5 mM Tween-80) was added with 3 µL of BDL probe (10 mM in 
H2O). The mixture was vortexed before adding 1 µL of Lys-Lipid II (200 µM in DMSO), 1 µL of 
DMSO, and 1 µL of PBP4 (40 µM) to reach a total volume of 10 µL. The reaction was incubated 
at 25 °C for 1 h. To quench the reaction, 10 µL of 2x SDS loading buffer was added and the 
samples were heated at 95 °C for 5 min. 3 µL of the final mixture was loaded onto a 15% SDS 
polyacrylamide gel. The products were transferred to Immun-Blot PVDF membrane (BioRad). 
BDL-Lipid II was detected by blotting with streptavidin-HRP (1:10000 dilution, Pierce), and 
visualized using ECL Prime Western Blotting Detection Reagent (GE Ambersham) and Biomax 
Light Film (Kodak). To confirm the presence of PBP4, the membrane was also blotted with anti-
His5-HRP (1:10000 dilution, Qiagen).  
 
2.9.11 Extraction of cellular lipid-linked PG precursors and Western blot detection 
The extraction of cellular lipids has been modified from a previously published 
protocol.49 An overnight culture of S. aureus RN4220 was diluted to an OD600 = 0.1, and allowed 
to grow to mid-exponential phase at 37 °C. The culture was divided into 2 mL aliquots 
subsequently which were treated with antibiotics (concentrations of antibiotics were about 2x of 
their respective MICs against S. aureus RN4220). Following 10 min of growth at 37 °C, cells 
were harvested by centrifugation for 10 min at 5,000 x g. The amount of cell pellet collected was 
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normalized by OD600, and resuspended in 500 "L PBS (pH 7.4). The resuspended pellet was 
transferred to a glass tube alongside 500 "L CHCl3 and 1 mL MeOH. The mixture was vortexed 
repetitively for 10 min at 25 °C, and cell debris was removed with centrifugation for 10 min at 
4,000 x g. The supernatant was collected and transferred to a new glass tube with 500 "L CHCl3 
and 500 "L PBS. The mixture was vortexed for 10 min, and centrifuged for 1 min at 4,000 x g to 
achieve phase separation. 1 mL of the organic layer was collected and concentrated in vacuo. 
The dried fractions were resuspended in 12 "L DMSO. Each fraction (2 "L) was used (in place 
of Lipid II and DMSO) in a BDL labeling reaction as described earlier. Reactions were further 
analyzed on Western blot with HRP-streptavidin conjugate (Figure 2.9 and 2.10).  
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Chapter Three: Preparation of native Staphylococcus aureus Lipid II 
 
 
 
 
 
 
 
 
 
 
 
Data contributed by collaborators: 
 
Jeep Veerasak Srisuknimit and I performed studies on large-scale extraction of native Lipid II 
from bacteria. 
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3.1 Introduction 
The inaccessibility to native Lipid II substrate has hampered enzymatic studies on the 
transpeptidase (TP) activities of bacterial PBPs. The structure of native Lipid II varies in 
bacteria; therefore, it is impossible to prepare a ‘universal’ Lipid II substrate and it is onerous to 
prepare new Lipid II variants by either chemical synthesis or enzymatic reconstitution. In this 
chapter, I first describe my attempts to synthesize Staphylococcus aureus (S. aureus) Lipid II, 
and then describe a general strategy to accumulate and isolate Lipid II from bacteria. Using the 
second approach, we can obtain useful quantities of native Lipid II from different bacteria within 
a day of work, greatly easing the challenges with Lipid II preparation. This facile strategy for 
Lipid II preparation was developed based on our findings described in Chapter Two, and in turn 
enables biochemical characterization of S. aureus PBP2 that is described in Chapter Four.  
 S. aureus Lipid II has one of the most complex structures among all bacteria Lipid II, 
bearing a pentaglycine branch connected to the L-Lys side chain as well as a carboxamide at the 
D-isoGln on the stem peptide (Figure 1.4).1 Although Strominger and co-workers have correctly 
predicted the complete structure of S. aureus Lipid II in the 1960s, obtaining useful amount of 
native Lipid II has not been possible for several decades,2 posing a major challenge for 
biochemical characterizations of S. aureus PBPs. There are only two previous reports on 
preparations of the pentaglycine-containing Lipid II. Schneider el al. (2004) reported the in vitro 
assembly of the complete pentaglycine branch on Lipid II using purified FemXAB proteins and 
glycyl-tRNA donors.3 More recently, Patin et al. (2012) reported chemical installation of the 
pentaglycine onto the Park nucleotide using activated glycines: Fmoc-Gly-OSu and Fmoc-Gly2-
OSu (twice) successively, after which the modified nucleotide was converted to Lipid I and 
Lipid II using coupled MraY and MurG reactions in vitro.4 While both works provided valuable 
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information on the formation of the pentaglycine branch, the carboxamide on the D-isoGln at the 
second position of the stem pentapeptide was omitted. In 2012, Munch et al. identified and 
reconstituted GatD/MurT enzymes, which are responsible for amidation on D-isoGln of Lipid II 
in S. aureus. However, the native Lipid II substrate was obtained only in small amounts for 
analytical studies.5 The proper amidation on D-isoGln in Streptococcus pneumoniae (S. 
pneumoniae) Lipid II has been shown to be necessary for S. pneumoniae PBP transpeptidase 
(TP) activity.6,7 Conceivably, both pentaglycine and carboxamide on S. aureus Lipid II are 
required for reconstitution of S. aureus PBPs’ TP activities. 
As mentioned in Chapter 1.5, the Kahne lab has developed a new synthetic route to 
achieve Lipid I, which involves independent preparations of the conserved N-acetyl-muramyl-
pyrosphopho-lipid (MurNAc-PP-lipid) precursor and the peptide moiety.8 The synthetic Lipid I 
can then be quantitatively converted to Lipid II using the MurG chemoenzymatic reaction.9,10 It 
has been shown previously that the heptaprenyl-Lipid II (C35) analogue has better solubility than 
the native undecaprenyl-Lipid II (C55), hence is a better substrate for studying PBP activities in 
vitro.11 Hiro Tsukamoto, a former postdoctoral researcher in the Kahne lab, has synthesized 
approximately 80 mg of the MurNAc-PP-hetaprenyl precursor after a 22-step synthesis for future 
preparations of Lipid I and Lipid II variants. With the precursor available, the challenge with 
chemical synthesis of bacterial Lipid II now shifts to obtaining various peptide moieties since the 
identity of the peptide is distinct in each organism. Therefore, for each new substrate of interest, 
the peptide portion needs to be synthesized first prior to coupling to the conserved MurNAc-PP-
hetaprenyl precursor to yield Lipid I. Using this general synthetic route, three different Lipid I 
substrates have been prepared and converted to the corresponding Lipid II variants, including 
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Lys-Lipid II (the Lipid II precursor in Gram-positive bacteria), m-Dap-Lipid II (E. coli Lipid II), 
and amidated m-Dap-Lipid II (B. subtilis Lipid II).8,12,13 
In 2012, we set out to apply this general synthetic route to prepare native S. aureus Lipid 
II that contains both a carboxamide and a pentaglycine branch in the peptide, as well as its 
monoglycine- and triglycine- variants. Having access to these Lipid II analogues would allow us 
to investigate the substrate specificity of S. aureus PBPs in the transpeptidation reaction. In this 
chapter, my efforts to synthesize three glycine-variants of L-Ala-D-isoGln-L-Lys-D-Ala-D-Ala 
pentapeptide (in short, Gly-pentapeptide, Gly3-pentapeptide and Gly5-pentapeptide) were 
discussed. While small quantities of Gly-Lipid II and Gly3-Lipid II substrates were obtained via 
this synthetic route, the synthesis was inefficient and had low overall yield.  
On the other hand, we established a direct Lipid II accumulation and isolation strategy 
that came about from our studies with S. aureus PBP4 described in Chapter Two. We show that 
useful quantities of native S. aureus Lipid II can be obtained over a day of work, circumventing 
the need for laborious synthesis. We also demonstrated that the strategy is suitable for obtaining 
Lipid II from other bacteria as well, including S. aureus !femA and !femB mutants, Bacillus 
subtilis (B. subtilis), Enterococus faecalis (E. faecalis) and Escherichia coli (E. coli). The Lipid 
II substrate provides essential tools for biochemical reconstitution of S. aureus PBP2 TP activity 
described in Chapter Four.  
 
3.2 Chemical synthesis of S. aureus Lipid II 
3.2.1 Synthesis of stem pentapeptide containing variable glycine branch 
In the synthetic scheme to Lipid I, the highly acid-sensitive pyrophosphate linkage that is 
both glycosidic and allylic is introduced into the MurNAc-PP-lipid precursor separately from the 
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synthesis of the peptide.8 Nevertheless, the peptide moiety should still be appropriately protected 
with base-labile protecting groups that are compatible with the pyrophosphate linkage. As with 
previous Lipid I and Lipid II syntheses, we chose a methyl ester group to protect the carboxylate 
end of the D-Ala-D-Ala terminus in the stem pentapeptide,8,12,13 and a trifluoroacetic acid (TFA) 
group to mask the nucleophilic amine at the N-terminus of the glycine branch. Both protecting 
groups were installed during peptide synthesis and could be subsequently removed after Lipid I 
coupling in a global deprotection reaction. With the need to install different versions of the 
glycine branch onto the stem peptide, we used solution-phase synthesis to prepare the peptide 
moiety. Following a similar scheme reported by Tsukamoto and Kahne (2011),8 we prepared the 
linear stem pentapeptide (1), Boc-L-Ala-D-isoGln-L-Lys(Cbz)-D-Ala-D-Ala-OMe using standard 
peptide coupling synthesis. However, the presence of an unprotected carboxamide in the stem 
peptide led to several undesirable outcomes, including slow and incomplete coupling reaction 
and low yield of the product. Alternative attempts to avoid the complications of the unprotected 
carboxamide in peptide synthesis are discussed below. Hydrogenation of 1 revealed the !-amine 
of the L-Lys side chain in 2 for attachment of the glycine branch. The Gly-pentapeptide (3), Boc-
L-Ala-D-isoGln-L-Lys(-GlyTFA)-D-Ala-D-Ala-OMe was afforded in a reaction with 2 and the 
commercially available TFA-Gly-OH (Scheme 3.1). We envisioned a parallel approach to yield 
the Gly3- and Gly5-pentapeptide variants. However, preparations of TFA-Gly3-OH and TFA-
Gly5-OH from commercial reagents H-Gly3-OH and H-Gly5-OH using ethyl trifluoroacetate 
were not successful due to the insoluble nature of the oligoglycines. Thus, direct installations of 
the Gly3- and Gly5-branch onto 2 were not possible. In particular, Patin et al. encountered similar 
difficulties during pentaglycine synthesis, and turned to an iterative coupling approach instead.4 
As a result, we revised the synthetic route to add glycines onto 2 in a stepwise manner. As shown 
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in Scheme 3.1, the stem pentapeptide (2) was first coupled with an appropriately protected N-
succinimidyl ester activated diglycine, Cbz-Gly-Gly-OSu (Cbz is caboxybenzyl) to afford 
intermediate (4), followed by hydrogenation and then addition of TFA-Gly-OH to yield the Gly3-
pentapeptide (5), Boc-L-Ala-D-isoGln-L-Lys(-GlyGlyGlyTFA)-D-Ala-D-Ala-OMe. To make the 
Gly5-pentapeptide (7), Boc-L-Ala-D-isoGln-L-Lys(-GlyGlyGlyGlyGlyTFA)-D-Ala-D-Ala-OMe, 
the coupling of Cbz-Gly-Gly-OSu and the subsequent hydrogenation were performed twice 
successively, prior to the final attachment of TFA-Gly-OH. However, this strategy had several 
notable disadvantages. First, the coupling of Cbz-Gly-Gly-OSu became less efficient as the 
glycyl branch grew longer, requiring extended reaction time. Unfortunately, prolonged 
incubation under basic aqueous solution subjected the methyl ester protecting group on the stem 
pentapeptide to potential hydrolysis. In addition, purification of the product from the solution 
mixture was problematic. The insolubility of the glycyl-peptides defied traditional work-up using 
common organic solvents. Therefore, I loaded the reaction mixture (in water) onto a C-18 solid 
phase extraction column, and washed the column with a step gradient of acetonitrile and water 
mixture. Although this purification method afforded low amount of the pure peptide product, the 
recovery yield was significantly reduced (approximately 20% recovery yield). Given that two 
successive coupling and deprotection steps were required for the synthesis of 7, this strategy 
deemed considerably inefficient and tedious. Furthermore, the final step in the syntheses of both 
5 and 7 was the addition of TFA-Gly-OH. This reaction was also very sluggish, requiring 
multiple rounds of addition of excess reagents to facilitate reaction progression. In the case of 7, 
the coupling was incomplete after a 72-hour reaction with approximately 20-equivalent of the 
TFA-Gly-OH added. Overall, only less than 10 mg of 7 was obtained by combining the products 
from several rounds of syntheses after a few months of work. 
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Scheme 3.1. Synthetic route of Gly-pentapeptide (3), Gly3-pentapeptide (5), Gly5-pentapeptide (7). As 
shown in the box, trifluoroacetylation of the N-terminal amine in H-Gly-Gly-Gly-OH and H-Gly-Gly-
Gly-Gly-Gly-OH did not work due to insolubility of the oligoglycine starting materials. Thus, a direct 
coupling of the oligoglycine branch to the stem pentapeptide was not possible; instead, an iterative 
method was taken. a: H2, Pd(OH)2/C, MeOH; b: TFA-Gly-OH (5-10 equivalent), HOBt, EDC, DIEA, 
DCM/DMF, r.t. 12-72 h; c: Cbz-Gly-Gly-OSu (2-5 equivalent) 1M NaHCO3, DME, r.t., 2-12 h. 
 
To improve the synthetic efficiency of the glycyl-pentapeptide compounds, I attempted 
several modifications of the synthetic route, which are summarized here. As mentioned earlier, 
the presence of an unprotected carboxamide is known to cause complications in peptide 
synthesis, such as slow, incomplete coupling reactions and by-product (i.e. pyroglutamate) 
formation. In addition, peptides with an unprotected carboxamide often display low solubility 
and aggregation due to hydrogen bonding.14 In this regard, I sought to protect the carboxamide 
with a triphenylmethyl group, which was used in the previous synthesis of B. subtilis Lipid II 
which contains an amidated m-Dap residue.13 Since the D-isoGln(Trt)-OH reagent was 
prohibitively expensive, I had to prepare it in-house following tritylation protocols. The direct 
tritylation of D-isoGln-OH by triphenylmethanol did not work, possibility due to the low 
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solubility D-isoGln-OH and the potential formation of a pyroglutamate as reported by Sieber and 
Riniker (1991).14 Therefore, I used an indirect tritylation protocol instead: first protecting the N-
terminal amine on D-isoGln-OH with a Cbz group prior to tritylation to afford Cbz-D-
isoGln(Trt)-OH, followed by hydrogenation to yield the desired D-isoGln(Trt)-OH (Scheme 
3.2a). However, additional protection and deprotection steps were introduced for tritylation in 
this manner, and the overall yield was far from optimal (18%). As a proof of concept, the trityl-
protected pentapeptide (9), Boc-L-Ala-D-isoGln(Trt)-L-Lys(Cbz)-D-Ala-D-Ala-OMe was 
prepared, to which a triglycine branch was appended in the stepwise fashion as discussed above 
(Scheme 3.2a). Masking the carboxamide with a trityl protecting group indeed improved the 
solubility of the intermediates and eased the purification steps, and the trityl group was readily 
removed with TFA. Using this route, the Gly3-pentapeptide (5) was obtained. Conceivably, it 
could be used to prepare the Gly5-pentapeptide (7) as well. On the other hand, another route that 
involves the introduction of the carboxamide at the late step in the synthesis was attempted. The 
pentaglycine branch was installed onto the tripeptide precursor Boc-L-Lys-D-Ala-D-Ala-OMe to 
afford 11 using the similar sequential reactions (Scheme 3.2b).  
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3.2.2 Coupling reactions to make Lipid I and Lipid II variants 
To obtain Lipid I, the MurNAc-PP-lipid precursor was coupled with the respective 
peptide moiety, 3, 5 or 7 using the dimethoxytriazine-N-methylmorpholinium chloride 
(DMTMM) as a coupling reagent (Scheme 3.3).8 Because of difficulties in obtaining large 
amount of the peptide and the limited availability of the MurNAc-PP-lipid precursor, this 
reaction was usually performed in small scale using 3-5 mg of the MurNAc-PP-lipid only. The 
reaction progression was monitored by the appearance of the corresponding Lipid I peak on MS. 
In these coupling reactions, Gly-Lipid I and Gly3-Lipid I products were obtained, but the Gly5-
Lipid I was detected at a low level after prolonged reaction. While the amount of Gly5-
pentapeptide (7) diminished in the reaction over time, there was still an excess of the unreacted 
Scheme 3.2. Alternative routes attempted to avoid complication by the carboxamide in the peptide. In a), 
a trityl protecting group was installed to protect the carboxamide in D-isoGln-OH in the early step of the 
synthesis. As shown, a direct triylation did not work, instead reactions a-c were performed. The D-
isoGln(Trt)-OH was used to make the stem pentapeptide, followed by the attachment of the glycyl 
branch. a: benzyl chloroformate, r.t. 12 h; b: triphenylmethanol, acetic anhydride, conc. sulfuric acid, 
glacial acetic acid; c: H2, Pd(OH)2/C, MeOH. In b), the glycyl branch was coupled to the tripeptide Boc-
L-Lys-D-Ala-D-Ala-OMe to ensure introduction of the carboxamide in a late step in synthesis.  
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MurNAc-PP-lipid, indicating possible degradation of 7 to result in incomplete reaction. 
However, the Gly5-Lipid I might be difficult to detect on MS since it ionizes poorly, as reported 
by Schneider et al.3 Upon purification of the reaction, I obtained approximately 1 mg each for 
the protected Gly-Lipid I and Gly3-Lipid I products. To remove protecting groups on the peptide 
moiety, the protected Lipid I was subject to hydrolysis in a basic solution. The base hydrolysis 
reaction should be closely monitored since long incubation time (more than 5 h) may result in 
cleavage of the glycine branch. Gly-Lipid I (12) and Gly3-Lipid I (13) were obtained in small 
quantities. Subsequently, Lipid I was converted to Lipid II using the MurG chemoenzymatic 
reaction with a recovery yield of approximately 50%. We note that our in vitro reaction sequence 
is the opposite of the in vivo sequence in S. aureus, where MurG reaction occurs prior to the 
addition of the glycyl branch by FemXAB proteins.15,16 Hence the Gly-Lipid I and Gly3-Lipid I 
substrates might not be the optimal substrates for MurG in vitro, limiting the conversion yield. 
Small amounts of Gly-Lipid II (15) and Gly3-Lipid II (16) were yielded from these reactions.  
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3.3 A facile method to obtain native S. aureus Lipid II 
Given the challenges encountered with the chemical synthesis of the pentaglycine 
containing Lipid II, we sought an alternative strategy to obtain the substrate. As described in 
Chapter Two, we developed a simple and sensitive Western blot assay to detect the cellular 
levels of Lipid II in bacteria.17 In that study, we observed that moenomycin treatment in S. 
aureus accumulates Lipid II in cells. Moenomycin is a natural product inhibitor that targets 
bacterial PGTs to prevent monomeric Lipid II from being polymerized,18 hence accumulating 
Scheme 3.3. The general reaction sequence to afford Lipid I and Lipid II variants. a: 4 M HCl in 
dioxane; b: DMTMM, DIEA, MeOH; c: 1M LiOH, THF/H2O; d: MurG, UDP-GlcNAc. 
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Lipid II. Thus, we wondered whether it would be possible to obtain enough Lipid II substrate by 
directly isolating from moenomycin-treated S. aureus culture. 
To better characterize Lipid II accumulation caused by moenomycin, we performed a 
time course analysis to monitor levels of Lipid II in S. aureus after moenomycin treatment. 
Consistent with the bacteriostatic effect of moenomycin in Gram-positive bacteria,19 S. aureus 
growth stopped immediately after the addition of moenomycin to the culture (Figure 3.1a). At 
the indicated time point (15 min, 60 min, 120 min), an aliquot (1 mL) was collected from either 
untreated or moenomycin-treated S. aureus culture respectively, and was subjected to Lipid II 
analysis using previously described protocol.17 As shown in Figure 3.2b, the level of Lipid II in 
S. aureus increased within 15 min of moenomycin treatment and remained elevated for at least 2 
h. The amount of Lipid II in S. aureus increased by approximately 10-fold after treating with 
moenomycin for 15 min (Figure 3.1c).  
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The strong and stable accumulation of Lipid II observed in moenomycin-treated S. 
aureus culture gave us a window to perform a large-scale Lipid II extraction. We treated 6 L (4 x 
1.5 L) of S. aureus treated with moenomycin (0.6 µg/mL) for 20 minutes, pelleted down cells, 
and extracted the cellular lipids with CHCl3/MeOH. In a large-scale extraction, the total volume 
of organic solvent used per cell culture volume was less than that in the previous small-scale 
extraction, giving rise to more concentrated cellular lipids. We observed a white emulsion in the 
interfacial layer between the aqueous and organic layers at the end of the extraction, which was 
 1         2                            3         4                              5        6  
 no MoeA (1) Serial ! dilution of MoeA treated sample (2) 
Total dilution  
0            1/2          1/4           1/8         1/16       1/32 
a) 
b) 
c) 
Figure 3.1. Moenomycin treatment accumulates Lipid II by 10-fold in S. aureus. (a) Growth curves of 
untreated and moenomycin-treated S. aureus. An aliquot from each culture was collected at the indicated 
time for analysis in b. (b) Western blot analysis of biotinylated-Lipid II in each sample. The Lipid II level 
increased within 15 min of moenomycin treatment and remained elevated for at least 2 h. (c) A serial 
dilution estimation that Lipid II level increased 10-fold after treating S. aureus with moenomycin for 15 
min.  
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not observed in the small-scale extraction. To analyze contents in the interface, we collected the 
interface separately from the organic layer by pipetting out each layer. As shown in the thin layer 
chromatography (TLC) analysis in Figure 3.2b, the majority of phospholipids were found in the 
organic layer but little was present in the interface. We next evaluated the presence of Lipid II in 
the interface and organic layers by PBP4-enabled biotinylation and Western blot. Surprisingly, in 
contrast to phospholipids, Lipid II was concentrated in the interface layer. The formation of the 
third interface layer that contains Lipid II and is clean of abundant phospholipid contaminants 
was intriguing. We hypothesized that the amount of accumulated Lipid II in large-scale 
extraction exceeded its solubility in the organic phase, giving rise to an interfacial layer between 
the aqueous and organic fractions. In a previous report Guan et al., E. coli Lipid II was observed 
to partition into the aqueous phase at neutral pH during extraction.20 The authors took advantage 
of the unusual pH-dependent solubility of E. coli Lipid II to enrich for Lipid II from the abundant 
phospholipids. Our observation of the third interfacial layer in large-scale extraction of S. aureus 
also enabled us to selectively enrich S. aureus Lipid II. Therefore, we collected the interface as 
the source of Lipid II. 
Figure 3.2. Preparative quantities of native S. aureus Lipid II can be obtained via a two-step 
accumulation and extraction procedure. (a) Schematic of the extraction procedure. White materials at 
the interface were observed after CHCl3/MeOH extraction from an S. aureus culture treated with 
moenomycin. The interface was collected and further extracted with pyridinium acetate/n-butanol to 
obtain Lipid II in the organic layer. (b) Thin layer chromatography showed that phospholipids are 
predominantly in the organic layer after CHCl3/MeOH extraction. (CL: cardiolipin; PG: 
phosphatidylglycerol; LPG: lysyl-phosphatidylglycerol) (c) Western blotting showed that Lipid II is 
predominantly in the interface layer after CHCl3/MeOH extraction. 
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In order to establish the structure of the Lipid II species in the interface, we cleaved the 
pyrophosphate linkage by boiling the material in a weakly acidic buffer.a After mild acid 
hydrolysis,21,22 the sample was subjected to MS analysis. As expected, we observed a peak 
corresponding to the monophosphate muropeptide, which is the cleaved product of S. aureus 
Lipid II. However, a major peak corresponded to the Park nucleotide was present as well (Figure 
3.3). It is known that many cell wall-targeting antibiotics including moenomycin can result in 
accumulation of the Park nucleotide in bacteria.23,24 As described in Chapter 1.2, the observation 
that the Park nucleotide accumulates in S. aureus as a result of penicillin treatment led to the 
initial discovery of the cell wall pathway.25 Since the Park nucleotide is a precursor of Lipid II 
and its peptide portion closely resembles that of Lipid II, we reasoned that the Park nucleotide 
should be removed from the sample to avoid any complications in using S. aureus Lipid II as a 
substrate. Therefore, we performed an additional extraction of the interface layer using a mixture 
of 6 M pyridinium acetate and n-butanol (Figure 3.2). This solvent system was initially reported 
by Strominger and coworkers for Lipid II extraction.26,27 In this step, S. aureus Lipid II 
selectively partitioned into the organic phase, while the soluble Park nucleotide was in the 
aqueous phase. We collected the organic fraction that contains S. aureus Lipid II. The structural 
assignment of the delipidated Lipid II after mild acid hydrolysis was confirmed by LC/MS/MS 
analysis. The species contains a pentaglycine branch and a carboxamide in the stem peptide; we 
did not detect any related species such as the ones lacking some of the glycines or the 
carboxamide. TLC analysis of the isolated S. aureus Lipid II showed one major spot, which has 
comparable Rf value as synthetic Lys-Lipid II (Figure 3.3b). Therefore, we conclude that native 
S. aureus Lipid II was obtained from S. aureus by direct isolation.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
a Since direct injection of the sample did not yield any mass corresponding to Lipid II, we reasoned that 
! 111 
 
 
3.3.1. Estimation of S. aureus Lipid II quantity 
In order to determine the amount of S. aureus Lipid II obtained by extraction, we used 
synthetic Lys-Lipid II as a standard for estimation. We subjected a mixture of Lys-Lipid II and S. 
aureus Lipid II to mild acid hydrolysis for cleavage of the pyrophosphate linkage, and then 
compared the ion counts of muropeptide 1 (from the synthetic Lys-Lipid II) and muropepitde 2 
(from S. aureus Lipid II) on LC/MS (Figure 3.4). A standard curve was made based on the counts 
of muropeptide 1 at different concentrations, and was used to calculate the concentration of 
muropeptide 2. It was estimated that approximately 300 µg of S. aureus Lipid II was obtained 
from 1 L of moenomycin-treated S. aureus culture. In addition, an orthogonal quantification 
Figure 3.3. Structural confirmation of the isolated S. aureus Lipid II. a) EICs showing both delipidated S. 
aureus Lipid II and the Park nucleotide were detected in the interface (top), and only deplipidated S. 
aureus Lipid II was observed in the organic phase after the additional extraction using pyridinium 
acetate/n-butanol (bottom). The samples were boiled in a weak acidic buffer prior to LC/MS analysis. The 
structures of the species are shown. b) TLC analysis of the isolated S. aureus Lipid II and synthetic Lys-
Lipid II. 
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method to determine the amount of S. aureus Lipid II was performed. Densitometry analysis of 
the biotinylated synthetic Lys-Lipid II and S. aureus Lipid II led to approximately 800 µg of S. 
aureus Lipid II from 1 L of moenomycin-treated S. aureus culture (Figure App2.22). While the 
quantitative measurement of S. aureus Lipid II extracted is still ongoing, we note that the 
estimated amount of Lipid II is sufficient for a large number of enzymatic assays (see Chapter 
Four). Taken together, useful quantities of native S. aureus Lipid II was obtained by direct 
isolation from moenomycin-treated S. aureus culture. This method can be accomplished in one 
day of work without the need for special equipment or synthetic expertise, greatly expanding the 
accessibility to the complex molecules. 
 
3.4 A general approach to obtain bacterial Lipid II 
In contrast to chemical syntheses of Lipid II, where a new synthetic route needs to be 
developed for each new Lipid II variant, our accumulation and isolation strategy presents a 
universal solution to obtain native Lipid II from different bacteria. Up to date, we have 
demonstrated the utility of this approach for a number of strains, including S. aureus "femA and 
"femB mutants, B. subtilis, E. faecalis and E. coli. Since B. subtilis is intrinsically resistant to 
Figure 3.4. Structures of delipidated Lipid II species. The species were yielded after acid hydrolysis of 
synthetic Lys-Lipid II (1) and S. aureus Lipid II (2). 
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moenomycin,b we chose vancomycin for Lipid II accumulation. In the case of E. coli, a Gram-
negative bacteria which has an impermeable outer membrane that presents an entry barrier to 
both moenomycin and vancomycin antibiotics, we resorted to a mutant E. coli strain (Imp), 
which has an defective outer membrane and restores the susceptibility to both antibiotics for 
Lipid II extraction. In addition, blocking the Lipid II flippase, MurJ with (2-
sulfonatoethyl)methanethiosulfonate (MTSES) in a MurJA29C mutant strain of E. coli28,29 
provides an alternative route to accumulate Lipid II. Notably, an interfacial layer was obtained 
during large-scale Lipid II extraction for each strain examined, suggesting the formation of the 
interface containing concentrated Lipid II is a common phenomenon.  
We analyzed the isolated Lipid II by S. aureus PBP4-enabled BDL labeling, and found 
that short glycan polymers (of approximately 3-5 disaccharide repeats) in addition to Lipid II 
monomers were accumulated in B. subtilis as a result of vancomycin treatment. This observation 
reflects a possible mechanism of vancomycin in sequestering both short nascent PG polymers as 
well as Lipid II in B. subtilis. Nevertheless, the short glycan polymers could be completely 
removed by treating the interface sample with mutanolysin. Furthermore, we determined the 
structure of the isolated Lipid II species by LC/MS after mild acid hydrolysis. We confirmed that 
Gly-Lipid II and Gly3-Lipid II were obtained from S. aureus "femA and "femB mutants 
respectively, and both substrates were used in biochemical studies of S. aureus PBP2 in Chapter 
Four. Isolated Lipid II from B. subtilis was identified to contain an amidated m-Dap in the stem 
peptide, whereas Lipid II from E. faecalis showed an L-Ala-L-Ala branch with either a 
carboxamide or a carboxylate at the second position of the stem peptide (Figure 3.5 and Figure 
App. 2.23). The two species of E. faecalis Lipid II were present in comparable quantities. The !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!"!Treatment of B. subtilis with a sub-lethal concentration of moenomycin still leads to an accumulation of 
Lipid II.!
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amidation state on Lipid II in certain bacteria may vary with the growth phase of the organism.30 
For instance, Lipid II species in mycobacteria is highly heterogeneous with multiple 
modifications;22 however, the heterogeneity in E. faecalis Lipid II has not been reported 
previously.  
 
 
 
 
 
 
 
 
 
3.5 Conclusion 
In summary, the chemical synthesis of S. aureus Lipid II faced significant challenges due 
to insolubility of the pentaglycine branch and the D-isoGln in the stem peptide. Although Lipid II 
variants with mono- and tri-glycine branch were made, the overall yields were low. Instead, we 
developed a facile extraction method to obtain native S. aureus Lipid II from moenomycin-
treated S. aureus culture. Previously, direct isolation of Lipid II from bacteria has been 
considered impractical due to low levels (2000 molecules/cell) of Lipid II in bacteria.2 However, 
our studies showed that treatment of moenomycin in S. aureus led to a 10-fold increased in Lipid 
Figure 3.5. Structures of Lipid II species isolated from different bacteria. The Lipid II accumulation 
and extraction protocol was used. 
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II relative to untreated S. aureus, providing an opportunity for its direct extraction. In the large-
scale Lipid II extraction, we noted that the accumulated Lipid II concentrated at an interface 
layer, allowing its effective enrichment and removal from the abundant phospholipids. The 
interface was collected and extracted with organic solvents to remove the Park nucleotide and 
afforded the relatively pure Lipid II. The isolated S. aureus Lipid II contains both a pentaglycine 
and a carboxamide in the peptide portion. Our work represents the first preparation of native S. 
aureus Lipid II.  We estimated that 500 µgc of S. aureus Lipid II can be obtained from 1 L of 
moenomycin-treated S. aureus culture, sufficient for more than 1000 biochemical assays 
described in Chapter Four. In addition, this strategy is also suitable for obtaining Lipid II from 
other bacteria, including S. aureus mutants, B. subtilis, E. faecalis and E. coli. This direct 
isolation approach to yield Lipid II can be accomplished over a day without the need of 
expensive starting materials and synthetic expertise, greatly lowering the barriers to obtain 
various bacterial Lipid II.  
 
3.6 Materials and Methods  
3.6.1 Experimental details of synthesis 
 
Boc-L-Ala-D-isoGln-OH. To a stirring mixture of Boc-Ala-OSu (573 mg, 2.00 mmol) and H-D-
Glu-NH2 (293 mg, 2.00 mmol) in DME (6 mL) was added 1 M NaHCO3 (12 mL) at room 
temperature. Vigorous stirring was needed to ensure proper mixing of the solids. After reaction 
for 15 h, the mixture was concentrated in vacuo until it became clear. The mixture was cooled at 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#!!The average of the numbers from two estimation methods (see Chapter 3.3.1) was taken. !
N
H O
CONH2
O
BocHN
OH
! 116 
0 °C and acidified with 10 % aqueous citric acid (24 mL, 12 mmol). The mixture was extracted 
twice with EtOAc and the combined organic phases were washed with brine (12 mL), dried over 
Na2SO4, and then concentrated in vacuo to afford Boc-L-Ala-D-isoGln-OH as a white crystalline 
product (365 mg, 57.5%). "H (500 MHz; CD3OD), 4.09 (1 H, d, J 7.1), 2.37 (2 H, d, J 7.5), 2.17-
2.24 (1 H, m), 1.87-1.91 (1 H, m), 1.43 (9 H, s), 1.22-1.31 (3 H, m) (Figure App2.1). 
 
 
Boc-L-Ala-D-isoGln-L-Lys(Cbz)-D-Ala-D-Ala-OMe (1). To a stirring solution of HCl NH2-L-
Lys(Cbz)-D-Ala-D-Ala-OMe (174mg, 0.37 mmol) in dry DCM (10 mL) was added Boc-L-Ala-
D-isoGln-OH (129 mg, 0.41 mmol), HOBt-H2O (67.8 mg, 0.44 mmol), DIEA (77.2 #L), and 
EDC (84.9 mg, 0.43 mmol) at room temperature under N2. After reaction for 7 h, the mixture 
was concentrated and partitioned between EtOAc (40 mL) and 10% citric acid (20 mL). A small 
amount of MeOH was added to enhance the solubility of the product. The organic phase was 
subsequently washed with H2O (10mL), 5% NaHCO3 (10mL), brine (10mL), and dried over 
Na2SO4, and concentrated in vacuo to afford Boc-L-Ala-D-isoGln-L-Lys(Cbz)-D-Ala-D-Ala-
OMe as a yellow solid (231.6 mg, 85.4%). "H (500 MHz; CD3OD) 7.34 (5 H, d, J 4.2), 5.06 (2 H, 
s), 4.35-4.40 (3 H, m), 4.01-4.20 (2 H, m), 3.68 (3 H, s), 3.12 (2 H, t), 2.25- 2.36 (2 H, m), 2.15-
2.23 (2 H, m), 1.80-1.90 (2 H, m), 1.66-1.82 (2 H, m), 1.48-1.56 (2 H, m), 1.43 (s, 9H), 1.38-
1.41 (3 H, d, J 7.3), 1.35-1.37 (3 H, d, J 7.3), 1.27-1.32 (3 H, d, J 7.3); LMRS (m/z) 736.3 
(M+H) (Figure App2.2). 
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Boc-L-Ala-D-isoGln-L-Lys(-Gly-TFA)-D-Ala-D-Ala-OMe (3). To a solution of 1 (120 mg, 
0.22 mmol) in dry MeOH (15 mL) was added Pd(OH)2/C (30 mg). The mixture was let stir under 
N2 for 20 min before applying a H2 atmosphere at room temperature. After stirring under H2 for 
2 hr, the reaction mixture was filtered using a PDVF syringe filter. The filtrate was concentrated 
in vacuo to afford Boc-L-Ala-D-isoGln-L-Lys-D-Ala-D-Ala-OMe (2) (85 mg, quantitative) as a 
white solid. To dried 2 (20 mg, 0.03 mmol) in a clean RBF, TFA-Gly-OH (6.84 mg, 0.04 mmol), 
HOBt-H2O (6.12 mg, 0.04 mmol) in a mixture of dry DCM/DMF (2 mL/0.5 mL) was added, 
followed by DIEA (7 #L, 0.04 mmol) and EDC (7.7 mg, 0.04 mmol). After the reaction was 
stirred at room temperature under N2 for 15 h, the mixture was concentrated and resuspended in 
water (~ 2 mL) and purified using reverse phase C18 silica column using a step gradient: 0%, 
10%, 25%, 50%, 75% acetonitrile (ACN)/ 0.1% formic acid (3 mL each). The product was 
eluted in 10% and 25% fractions, which were pooled and concentrated in vacuo to afford Boc-L-
Ala-D-isoGln-L-Lys(-Gly-TFA)-D-Ala-D-Ala-OMe (3) as a colorless film (9.7 mg, 50%). "H 
(500 MHz; CD3OD) 4.35-4.40 (3 H, m), 4.19-4.22 (1 H, m), 4.03-4.05 (1 H, m), 3.91 (2 H, s, J 
4.4), 3.70 (3 H, t, J 4.1), 3.21-3.23 (2 H, m), 2.34 (2 H, s), 2.20-2.23 (1 H, m), 1.86-1.88 (2 H, 
m), 1.69-1.70 (1 H, m), 1.54 (2 H, dd, J 4.3 and 2.8), 1.44-1.45 (9 H, m), 1.41 (3 H, ddd, J 7.1, 
4.6 and 2.2), 1.37 (3 H, dd, J 6.4 and 3.6), 1.31-1.33 (3 H, m); LMRS (m/z) 755.3 (M+H) 
(Figure App2.3). 
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Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Cbz)-D-Ala-D-Ala-OMe (4). To a stirred solution 
containing 2 (70 mg, 0.12 mmol) and Cbz-Gly-Gly-OSu (126.7 mg, 0.35 mmol) in DME (4 mL) 
and 1 M NaHCO3 (12 mL) at room temperature. Vigorous stirring was necessary to ensure 
proper mixing of reagents. After the reaction was completed after stirring for 4 h, an excess 
amount of water was to dissolve the white solids before the mixture was concentrated in vacuo. 
The product was purified on reverse phase C18 silica using a step gradient: 0%, 10%, 10%, 20%, 
30%, 40%, 60% ACN/ 0.1% formic acid (3 mL each). The 20% and 30% fractions were pooled 
and concentrated in vacuo to afford Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Cbz)-D-Ala-D-Ala-
OMe (4) as a colorless film (57.4 mg, 56%). "H (500 MHz; CD3OD) 7.29-7.39 (5 H, m), 5.12 (2 
H, d, J 5.2), 4.35-4.40 (2 H, m), 4.20 (1 H, s), 4.05 (1 H, t, J 7.0), 3.84 (4 H, d, J 12.5), 3.69 (2 
H, d, J 5.7), 3.20 (2 H, d, J 6.0), 2.35 (1 H, t, J 6.7), 2.20-2.21 (1 H, m), 1.86-1.89 (1 H, m), 
1.75-1.80 (1 H, m), 1.66-1.72 (1 H, m), 1.54 (1 H, d, J 6.0), 1.42-1.45 (9 H, m), 1.42 (3 H, t, J 
5.0), 1.38 (3 H, t, J 5.6), 1.33 (3 H, d, J 7.1); LMRS (m/z) 850.3 (M+H) (Figure App2.4). 
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Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly-TFA)-D-Ala-D-Ala-OMe (5). To a mixture of 4 (50 
mg, 0.059 mmol) in dry MeOH (10 mL) was added Pd(OH)2/C (10 mg). The mixture was stirred 
under N2 for 10 min before applying an H2 atmosphere for 2 h at room temperature. The mixture 
was filtered via a PVDF syringe filter (0.2 #M) and concentrated in vacuo to afford Boc-L-Ala-
D-isoGln-L-Lys(-Gly-Gly-NH2)-D-Ala-D-Ala-OMe a colorless film (40 mg, 95%). To Boc-L-
Ala-D-isoGln-L-Lys(-Gly-Gly-NH2)-D-Ala-D-Ala-OMe (15 mg, 0.02 mmol), was added TFA-
Gly-OH (10 mg, 0.06 mmol), HOBt-H2O (4.8 mg, 0.03 mmol) and dry DCM (2 mL) as well as 
DMF (0.5 mL), followed by DIEA (5.8 #L) and EDC (6 mg, 0.03 mmol). The mixture was 
stirred under N2 at room temperature for 30 h, during which more reagents: TFA-Gly-OH (10 
mg), HOBt-H2O (4.8 mg), DIEA (10 #L) and EDC (12 mg) were added. The progress of the 
reaction was monitored. After reaction was stirred for 48 h, 90% conversion was observed. The 
mixture was concentrated, and redissolved in 1: 1/H2O: ACN (100 #L) to apply onto a C18 
reverse phase column. The mixture was eluted using a step gradient: 0%, 10%, 20%, 30%, 40%, 
50% ACN/0.1% formic acid. Unreacted starting material Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-
NH2)-D-Ala-D-Ala-OMe was eluted in the 10% fraction; while the desired product Boc-L-Ala-
D-isoGln-L-Lys(-Gly-Gly-Gly-TFA)-D-Ala-D-Ala-OMe (5) was detected in the 20% fraction, 
which was concentrated in vacuo as a colorless film (3 mg, 16.4%). "H (500 MHz; CD3OD) 4.39 
(3 H, dd, J 7.3 and 3.3), 4.18-4.21 (1 H, m), 4.05 (1 H, m), 4.04 (2 H, s), 3.91 (2 H, s), 3.84 (2 H, 
s), 3.69 (3 H, s), 3.21 (2 H, d, J 6.5), 2.34 (2 H, d, J 6.9), 2.20 (1 H, s), 1.87-1.89 (1 H, m), 1.76-
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1.80 (1 H, m), 1.67-1.70 (1 H, m), 1.53-1.56 (3 H, m), 1.44 (9 H, s), 1.41 (3 H, d, J 7.3), 1.37 (3 
H, d, J 7.2), 1.32 (3 H, d, J 7.1); LMRS (m/z) 891.2 (M+Na+) (Figure App2.5) 
 
 
Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly-Gly-Cbz)-D-Ala-D-Ala-OMe (6). To Boc-L-Ala-D-
isoGln-L-Lys(-Gly-Gly-NH2)-D-Ala-D-Ala-OMe (40 mg, 0.056 mmol) in DME (2 mL) and 1 M 
NaHCO3 (4 mL), was added Cbz-Gly-Gly-OSu (71.2 mg, 0.196 mmol) at room temperature. The 
progress of reaction was monitored. After the reaction was stirred for 30 h, more Cbz-Gly-Gly-
OSu (50 mg, 0.14 mmol) was added. The reaction did not go to completion after 48 h, but 
significant amount of hydrolyzed products appeared. Therefore, the reaction was quenched by 
adding an excess amount of water and concentrated in vacuo. The mixture was purified on 
reverse phase C18 silica using a step gradient: 0%, 10%, 20%a, 20%b 30%a, 30%b, 40%, 60% 
ACN/ 0.1% formic acid (3 mL each). The 20% and 30% fractions were pooled and concentrated 
in vacuo, The 20%b and 30%a fractions were pooled and concentrated to afford Boc-L-Ala-D-
isoGln-L-Lys(-Gly-Gly-Gly-TFA)-D-Ala-D-Ala-OMe (6) as a colorless film (20 mg, 37%). "H 
(500 MHz; CD3OD)  7.21-7.43 (5 H, m), 5.11-5.16 (2 H, s), 4.31-4.43 (3 H, m), 4.16-4.21 (1 H, 
m), 3.98-4.10 (2 H, m), 3.91-3.98 (2 H, m), 3.84-3.89 (4 H, m), 3.62-3.72 (3 H, m), 3.17-3.21 (2 
H, m), 2.65-2.70 (1 H, m), 2.30-2.38 (2 H, m), 2.17-2.25 (2 H, m), 1.84-1.91 (2 H, m), 1.73-1.82 
(2 H, m), 1.65-1.74 (2 H, m), 1.51-1.57 (2 H, m), 1.41-1.48 (9 H, m), 1.39-1.44 (3 H, d, J 7.1), 
1.35-1.39 (3 H, d, J 7.1), 1.23-1.32 (3 H, d, J 7.1); LMRS (m/z) 964.4 (M+H) (Figure App2.6).  
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Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly-Gly-Gly-TFA)-D-Ala-D-Ala-OMe (7). To 6 (18.4 
mg, 0.02 mmol) in dry MeOH (8 mL) was added Pd(OH)2/C (10 mg). The mixture was flushed 
with N2 for 10 min before a H2 atmosphere was applied for 2 h at room temperature. The mixture 
was filtered via a PVDF syringe filter (0.2 #M) and concentrated in vacuo to afford Boc-L-Ala-
D-isoGln-L-Lys(-Gly-Gly-Gly-Gly-NH2)-D-Ala-D-Ala-OMe as a colorless film (12.4 mg, 78%). 
To Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly-Gly-NH2)-D-Ala-D-Ala-OMe (12.4 mg, 0.015 
mmol), was added TFA-Gly-OH (10 mg, 0.06 mmol), HOBt-H2O (6.8 mg, 0.05 mmol) and dry 
DCM (2 mL) as well as DMF (0.5 mL), followed by DIEA (4.5 #L) and EDC (12 mg). The 
mixture was stirred under N2 at room temperature for 72 h, during which more reagents: TFA-
Gly-OH (10 mg, 0.06 mmol), HOBt-H2O (6.8 mg, 0.05 mmol), DIEA (4.5 #L) and EDC (12 mg) 
were added. The reaction progress was monitored until starting material Boc-L-Ala-D-isoGln-L-
Lys(-Gly-Gly-Gly-Gly-NH2)-D-Ala-D-Ala-OMe was consumed. The mixture was concentrated, 
re-dissolved in a mixture of ACN/H2O (200 #L) and purified on a C18 silica column with a step 
gradient: 0%, 5%, 10%a, 10%b, 20%a, 20%b, 30%a, 30%b, 40%, 60% ACN/0.1% formic acid 
(3 mL each). Unreacted starting material Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly-Gly-NH2)-D-
Ala-D-Ala-OMe was detected in 10%a and 10%b fractions, which were recovered; while the 
desired product Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly-Gly-Gly-TFA)-D-Ala-D-Ala-OMe (5) 
was detected in 20%a fraction, which was concentrated in vacuo as a colorless film (5.1 mg, 
34.7%). "H (500 MHz; CD3OD) 4.35-4.41 (2 H, d), 4.25 (1 H, m), 4.17-4.21 (1 H, m), 4.16 (1 H, 
dd, J 2.5 and 1.5), 4.03 (2 H, dd, J 1.4 and 0.7), 3.91-3.94 (2 H, m), 3.88 (2H, m), 3.82-3.83 (2 
N
H O
CONH2
O
BocHN
H
N
O
HN
N
H
H
N
O
OMe
O
O
N
H
H
N N
H
O
O
H
N NHTFA
O
O
! 122 
H, m), 3.67 (2 H, m), 3.44 (2 H, s), 3.16 (2 H, t, J 1.6), 2.33 (2 H, t, J 0.8), 2.19 (2 H, m), 1.58-
1.62 (3 H, m), 1.51-1.56 (2 H, m), 1.43-1.48 (9 H, m), 1.39-1.41 (2 H, m), 1.31-1.37 (4 H, m), 
1.28-1.31 (3 H, m); LMRS (m/z) 983.3 (M+H) (Figure App2.7). 
 
 
Cbz-D-isoGln(Trt)-OH. To a stirring solution of D-Glu-NH2 (670 mg, 4.6 mmol) in 1 M 
NaHCO3 (1 mL) and H2O (2 mL), was added benzylchloroformate (1.33 g, 7.8 mmol) dropwise. 
The mixture was vigorously stirred for 3.5 h at room temperature. The reaction was quenched 
with 10 mL H2O. For purification, the crude mixture was extracted with diethyl ether (10 mL) 
for three times. The aqueous phase was collected, washed with 10% citric acid (10 mL), and 
extracted with EtOAc (20 mL). The organic phase was dried with Na2SO4, and concentrated in 
vacuo to afford Cbz-D-Glu-NH2 a white powder (984 mg, 76%). LRMS (m/z): 279.1 (M-H). To 
the dried Cbz-D-Glu-NH2 (192 mg, 0.685 mmol) was added triphenylmethnaol (375 mg, 1.37 
mmol). To the solid mixture, glacial acetic acid (2 mL) was added, followed by the addition of 
30 #L of conc. sulfuric acid in acetic acid (prepared by mixing 100 #L sulfuric acid and 1 mL 
acetic acid) dropwise. The mixture turned yellow upon addition. Acetic anhydride (129 #L, 1.3 
mmol) was added lastly. The reaction was completed after stirring at room temperature for 2 h. 
Cold H2O (20 mL) was added to quench the reaction, during which white solids were formed. 
The white solids were collected by filtration and purified on silica column chromatography using 
EtOAc/0.1% acetic acid and hexane/0.1% acetic acid as solvents. The Cbz-D-isoGln(Trt)-OH 
eluted in 40% EtOAc/0.1% acetic acid, and concentrated to afford a yellow oil (153 mg, 43%). 
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"H (500 MHz; CD3OD) 7.21-7.36 (20 H, mA), 5.22 (1 H, d, J 12.5), 5.05 (1 H, d, J 12.6,), 2.27 
(2 H, dt, J 7.4 and 3.7), 1.98-2.00 (2 H, m), 1.97-2.00 (2 H, m); LMRS (m/z) 521.2 (M-H) 
(Figure App2.8). 
 
 
Boc-L-Ala-D-isoGln(Trt)-L-Lys(Cbz)-D-Ala-D-Ala-OMe (9). To a stirring solution of Cbz-D-
isoGln(Trt)-OH (150 mg 0.287 mmol) in dry MeOH (25 mL) was added Pd(OH)2/C (60 mg). 
The mixture was stirred under N2 for 10 min before applying H2 atmosphere at room 
temperature. After reaction was stirred for 1 h, the reaction was filtered using a PVDF syringe 
filter and concentrated to afford H-D-isoGln(Trt)-OH as a white solid (118.3 mg, 99%). To the 
vial containing deprotected H-D-isoGln(Trt)-OH (87 mg, 0.342 mmol) in DME (4 mL) and 1 M 
NaHCO3 (8 mL), was added Boc-L-Ala-OSu (87 mg, 0.342 mmol). After being stirred at room 
temperature for 24 h, the reaction was quenched with 10% citric acid (20 mL), and extracted 
with EtOAc (60 mL) twice. The organic layer was dried on Na2SO4, concentrated and purified 
using silica column chromatography. Boc-L-Ala-D-isoGln-OH was eluted using EtOAc/0.1% 
acetic acid to afford a colorless liquid (90 mg, 47%). To a mixture of Boc-L-Ala-D-isoGln(Trt)-
OH (22 mg, 0.04 mmol) and H-L-Lys(Cbz)-D-Ala-D-Ala-OMe (437 mg, 0.04 mmol) in DCM 
(1.5 mL) and DMF (0.5 mL), was added HOBt-H2O (6.61mg, 0.04 mmol), DIEA (10 #L, 0.04 
mmol) and EDCI (8 mg, 0.04 mmol). The reaction was stirred at room temperature for 15 h. The 
mixture was concentrated, diluted with EtOAc (10 mL), washed with 10% citric acid (2 mL), the 
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organic phase was washed with H2O (2 mL), 5% NaHCO3 (1 mL), brine (1 mL), and dried over 
Na2SO4. The product was concentrated in vacuo and purified on silica column chromatography 
using EtOAc and hexane as eluent. Boc-L-Ala-D-isoGln(Trt)-L-Lys(Cbz)-D-Ala-D-Ala-OMe 
was eluted in 100% EtOAc, and concentrated to afford a colorless oil (32.2 mg, 84%). "H (500 
MHz; CD3OD) 8.49 (1 H, s), 8.18-8.30 (2 H, m), 8.18 (1 H, d, J 7.3), 8.05 (2 H, d, J 7.5), 7.18-
7.33 (16 H, m), 5.05 (2 H, s), 4.52 (1 H, ddd, J 5.0, 2.9 and 1.2), 4.33-4.38 (2 H, m), 4.14-4.16 (1 
H, m), 4.04 (1 H, dd, J 6.8 and 2.0), 3.61 (3 H, s), 3.11 (2 H, t, J 6.1), 2.21-2.25 (3 H, m), 1.74-
1.79 (2 H, m), 1.66-1.72 (1 H, m), 1.50 (2 H, d, J 6.8), 1.38-1.40 (9 H, m), 1.36 (3 H, d, J 3.3), 
1.34-1.35 (3 H, m), 1.27 (3 H, t, J 9.5) (Figure App2.9). 
 
 
Boc-L-Lys(-Gly-Gly-Gly-Gly-NH2)-D-Ala-D-Ala-OMe (10). To a solution of Boc-L-Lys-D-
Ala-D-Ala-OMe (137.2 mg, 0.34 mmol) in DME (2 mL) ad 1M NaHCO3 (4 mL), was added 
Cbz-Gly-Gly-OSu (363.33 mg, 0.85 mmol). The mixture was stirred at room temperature for 4 h. 
The reaction was concentration in vacuo and dissolved in MeOH (3 mL). The Boc-L-Lys(-Gly-
Gly-Cbz)-D-Ala-D-Ala-OMe was purified on HPLC to afford a white solid (115.6 mg, 50%). To 
a solution of Boc-L-Lys(-Gly-Gly-Cbz)-D-Ala-D-Ala-OMe (115.6 mg, 0.18 mmol) in dry MeOH 
(8 mL), was added Pd(OH)2/C (40 mg). The reaction mixture was stirred under N2 for 10 min 
before applying a H2 atmosphere. After being stirred under H2 for 2 h, the mixture was filtered 
using PVDF syringe filter and concentrated to afford Boc-L-Lys(-Gly-Gly-NH2)-D-Ala-D-Ala-
OMe as a colorless film (89 mg, 96.8%). The Boc-L-Lys(-Gly-Gly-NH2)-D-Ala-D-Ala-OMe (81 
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mg, 0.16 mmol) was stirred in DME (1.5 mL) and 1 M NaHCO3 (3 mL), to which Cbz-Gly-Gly-
OSu (142 mg, 0.39 mmol) was added. After the mixture was stirred at room temperature 
overnight, more Cbz-Gly-Gly-OSu (100 mg, 0. 27 mmol) was added with DME and 1 M 
NaHCO3. The reaction was stirred for another 12 h before quenching with 10% citric acid. The 
mixture was concentrated in vacuo and purified on HPLC to afford Boc-L-Lys(-Gly-Gly-Gly-
Gly-Cbz)-D-Ala-D-Ala-OMe. Purified Boc-L-Lys(-Gly-Gly-Gly-Gly-Cbz)-D-Ala-D-Ala-OMe 
from a few runs were pooled and subjected to hydrogenation to afford Boc-L-Lys(-Gly-Gly-Gly-
Gly-NH2)-D-Ala-D-Ala-OMe as a colorless film. "H (500 MHz; CD3OD) 4.38-4.41 (2 H, m), 
3.92-3.96 (4 H, m), 3.78-3.87 (2 H, m), 3.68 (3 H, d, J 11.7), 3.20 (2 H, s), 1.61-1.70 (2 H, m), 
1.53 (2 H, d, J 0.7), 1.39-1.43 (11 H, m), 1.35-1.39 (5 H, m); LMRS (m/z) 631.3 (M+H) (Figure 
App2.10). 
 
 
Boc-L-Lys(-Gly-Gly-Gly-Gly-Gly-TFA)-D-Ala-D-Ala-OMe (11). To a stirring solution that 
contains compound 10 (84 mg, 0.13 mmol) and TFA-Gly-OH (113 mg, 0.7 mmol) in 
DCM/DMF (3 mL/ 0.5 mL), was added HOBt-H2O (30 mg, 0.2 mmol), DIEA (35 #L, 0.2 mmol) 
and EDC (38 mg, 0.2 mmol). The reaction mixture was concentrated and purified by HPLC. The 
product Boc-L-Lys(-Gly-Gly-Gly-Gly-Gly-TFA)-D-Ala-D-Ala-OMe (11) was afforded as a 
colorless film (80 mg, 75%). "H (500 MHz; CD3OD)  4.38-4.42 (1 H, m), 4.21 (1 H, dd, J 5.6 
and 3.1), 4.03-4.07 (1 H, m), 3.88-3.97 (2 H, m), 3.81-3.83 (1 H, m), 3.68 (3 H, dd, J 20.6 and 
15.2), 3.34-3.37 (1 H, m), 3.19-3.21 (1 H, m), 1.65-1.73 (1 H, m), 1.57-1.64 (1 H, m), 1.54 (1 H, 
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ddtd, J 9.9, 5.1, 2.1 and 0.9), 1.39-1.45 (4 H, m), 1.32-1.39 (4 H, m), 1.28-1.31 (2 H, m), 0.90-
0.96 (2 H, m); LMRS (m/z) 806.1 (M+Na+) (Figure App2.11). 
Gly-Lipid I (12). MurNAc-PP-heptaprenyl lipid (4 mg, 3 #mol) was evaporated twice with 0.5 
M DIEA in MeOH (prepared by 274 #L DIEA in 3 mL MeOH) for ammonium salt exchange 
and dried under high vacuum for at least 1 h. While compound 3, Boc-L-Ala-D-isoGln-L-Lys(-
Gly-TFA)-D-Ala-D-Ala-OMe (4 mg, 6 #mol) was stirred in 4 M HCl (3 mL) under N2 for 20 
min. The solution was concentrated to dryness and concentrated twice more from toluene to 
remove trace HCl, yielding HCl NH2-L-Ala-D-isoGln-L-Lys(-Gly-TFA)-D-Ala-D-Ala-OMe 
which was used without further purification. The protected peptide was dissolved in dry MeOH 
(500 #L) and was transferred to the vial containing dried MurNAc-PP-heptaprenyl residue under 
N2. The mixture was treated with DIEA (0.5 M in MeOH, 10 #L, 9 #mol) followed by 
dimethoxytriazine-N-methylmorpholinium chloride (DMTMM, 2.5 mg, 9 #mol). After being 
stirred at room temperature for 5 h, the reaction was concentrated in vacuo, and purified on 
reverse phase C18 silica using a step gradient: 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 
90% ACN/ 0.2% NH4COO3H. The 60% fraction contained the protected Gly-Lipid I product 
(0.7 mg, 7.3%). LRMS (m/z): 1565.7 (M-H), 781.4 (M-2H)2- (Figure App3.12). The protected 
compound (0.7 mg, 0.4 #mol) was dissolved in 100 #L 1:1 dioxane/H2O and 20 #L 1 M LiOH in 
H2O was added under stirring. Global protecting hydrolysis was observed after 30 min by ESI-
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MA. The reaction was neutralized with NH4Cl (100 #L), and then concentrated in vacuo. The 
residue was purified on reverse phase C18 silica using a step gradient: 0%, 10%, 20%, 30%, 
40%, 50%, 60%, 70%, 80%, 90% ACN/ 0.2% NH4COO3H. The 50% fraction was concentrated 
in vacuo to give Gly-Lipid I (12) as a colorless film (0.3 mg). LRMS (m/z): 1454.7 (M-H), 726.9 
(M-2H)2- (Figrue App2.13). HRMS (m/z): calcd for C68H115N9O21P2 (M-2H)2- 726.8769, found 
726.8769 (Figure App2.14). 
 
Gly3-Lipid I (13). MurNAc-PP-heptaprenyl lipid (3.5 mg 3 #mol) was evaporated twice with 
0.5 M DIEA in MeOH for ammonium salt exchange and dried under high vacuum for at least 1 
h. While compound 5, Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly-TFA)-D-Ala-D-Ala-OMe (5 
mg, 6 #mol) was stirred in 4 M HCl (3 mL) under N2 for 20 min. The solution was concentrated 
to dryness and concentrated twice more from toluene to remove trace HCl, yielding NH2-L-Ala-
D-isoGln-L-Lys(-Gly-Gly-Gly-TFA)-D-Ala-D-Ala-OMe which was used without further 
purification. The protected peptide was dissolved in dry MeOH (500 #L) and was transferred to 
the vial containing dried MurNAc-PP-heptaprenyl residue under N2. The mixture was treated 
with DIEA (0.5 M in MeOH, 10 #L, 9 #mol) followed by dimethoxytriazine-N-
methylmorpholinium chloride (DMTMM, 2.5 mg, 9 #mol). After being stirred at room 
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temperature for 4 h, the reaction was concentrated in vacuo, and purified on reverse phase C18 
silica using a step gradient: 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% ACN/ 0.2% 
NH4COO3H. The 60% fraction contained the protected Gly3-Lipid I product (1.8 mg, 18.8%), 
while the 10% fraction contained unreacted peptide material, and the 70% fraction contained 
unreacted MurNAc-PP-lipid. LRMS (m/z): 838.7 (M-2H)2- (Figure App3.15). The protected 
compound (1.8 mg, 1.1 #mol) was dissolved in 500 #L 1:1 dioxane/H2O and 40 #L 1 M LiOH in 
H2O was added under stirring. Global protecting hydrolysis was observed after 30 min by ESI-
MS. The reaction was neutralized with NH4Cl (200 #L), and then concentrated in vacuo. The 
residue was purified on reverse phase C18 silica using a step gradient: 0%, 10%, 20%, 30%, 
40%, 50%, 60%, 70%, 80%, 90% ACN/ 0.2% NH4COO3H. The 50% fraction was concentrated 
in vacuo to give Gly3-Lipid I as a colorless film (1.2 mg, 70 %) LRMS (m/z): 783.6 (M-2H)2- 
(Figure App2.16). HRMS (m/z): calcd for C72H121N11O23P2 (M-2H)2- 783.8983, found 
783.8987(Figure App2.17). 
 
Protected Gly5-Lipid I (14). MurNAc-PP-heptaprenyl (2.5 mg 3 #mol) was evaporated twice 
with 0.5 M DIEA in MeOH for ammonium salt exchange and dried under high vacuum for at 
least 1 h. While compound 7, Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly-Gly-Gly-TFA)-D-Ala-
D-Ala-OMe (5 mg, 5 #mol) was stirred in 4 M HCl (3 mL) under N2 for 20 min. The solution 
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was concentrated to dryness and concentrated twice more from toluene to remove trace HCl, 
yielding NH2-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly-Gly-Gly-TFA)-D-Ala-D-Ala-OMe which 
was used without further purification. The protected peptide was dissolved in dry MeOH (500 
#L) and was transferred to the vial containing dried MurNAc-PP-heptaprenyl residue under N2. 
The mixture was treated with DIEA (0.5 M in MeOH, 10 #L, 9 #mol) followed by 
dimethoxytriazine-N-methylmorpholinium chloride (DMTMM, 2.5 mg, 9 #mol). The reaction 
progression was monitored over 5 h, but no product was observed on MS. The reaction was 
concentrated in vacuo, and purified on reverse phase C18 silica using a step gradient: 0%, 10%, 
20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% ACN/ 0.2% NH4COO3H. The 60% fraction was 
analyzed, and contained small amount of product. LRMS (m/z): 895.8 (M-2H)2- (Figure 
App2.18). 
 
Gly-Lipid II (15). Gly-Lipid I was converted to Gly-Lipid II using a previously described 
enzymatic method.10 A radiolabeled reaction was carried out in parallel. Briefly, to a tube 
containing Gly-Lipid I (75 #g, 50 nmol) dissolved in MeOH (24 #L), 50 mM HEPES buffer, 10 
mM MgCl2 in H2O and incubated with 1 U/#L alkaline phosphatase and 0.5 mg/mL E. coli 
MurG in a final reaction volume of 160 #L for 1 h at room temperature. An additional aliquot of 
MurG (8 #L of 5 mg/mL stock) was added. After 1 h, the reactions were quenched with 160 #L 
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ice cold H2O, and purified on a reverse phase C18 SPE column. After washing with 0.1% 
ammonium hydroxide, the desired compound was eluted with 0.1 % ammonium hydroxide in 
methanol. Fraction from non-radiolabeled experiments were analyzed by ESI-MS. Vacuum 
centrifugation afforded non-radiolabeled Gly-Lipid II; HRMS (m/z): calcd for C76H128N10O26P2 
(M-2H)2- 828.4165, found 828.4146 (Figure App2.19). 
Gly3-Lipid II (16). A similar approach was used to Gly3-Lipid I was converted to Gly3-Lipid II 
using MurG reaction as described above. HRMS (m/z): calcd for C80H134N12O28P2  (M-2H)2- 
885.4380, found 885.4347 (Figure App2.20). 
 
3.6.2 Small-scale extraction of S. aureus Lipid II 
The small-scale lipid extraction was modified from a previously published protocol.17 An 
overnight culture (20 mL) of S. aureus RN4220 was diluted to an OD600 = 0.1, and allowed to 
grow to mid-exponential phase at 37 °C. The culture was divided into two partitions (10 mL 
each). One culture was treated with moenomycin (0.6 #g/mL) and the other was not. At the 
indicated time, 1 mL aliquot S. aureus taken out from each culture to read O.D. and then 
transferred to a glass tube containing 3.5 mL of a 2:1/CHCl3: MeOH. The mixture was vortexed 
for 10 min at 25  °C, and any cell debris was removed by centrifugation for 10 min at 4,000 x g. 
The supernatant was collected and transferred to a new glass tube with 2 mL CHCl3 and 1.5 mL 
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PBS. The mixture was vortexed for 10 min, and centrifuged for 10 min at 4,000x g to achieve 
phase separation. The bottom organic layer was collected and dried under N2. The dried fractions 
were resuspended in 12 #L DMSO. Each fraction (2 #L) was analyzed by in Western blot 
analysis of BDL-labeled Lipid II (Figure 3.1).  
 
3.6.3 Large-scale extraction of S. aureus Lipid II   
Large-scale lipid extraction was performed on 6 L (4x 1.5L) of S. aureus RN4220 
cultures. An overnight culture of S. aureus RN4220 in TSB media (15 mL) was used to inoculate 
each 1.5 L culture. The cultures were grown at 37 °C with shaking at 220 rpm. Moenomycin was 
added at a final concentration of 0.6 µg/mL to each 1.5 L culture when OD600 = 0.5-0.6 for 
accumulation of Lipid II. The moenomycin-treated cultures were grown for another 30 min 
before harvesting cell pellets. The pellets from 6 L (4 x 1.5 L) cultures were resuspended in 60 
mL PBS (pH 7.4), and divided equally into 4 x 125 mL Erlenmeyer flasks, each of which 
contains a mixture of 52.5 mL 2: 1 MeOH: chloroform solvents. The mixture was stirred for 1 h 
at room temperature to ensure cell lysis. The mixture (about 70 mL) from each Erlenmeyer flask 
was poured into two Teflon tubes, which were spun down at 4000 x g for 10 min at 4 °C. The 
cell debris was visible as a pellet at the bottom of the tube, while the supernatant that contains 
the solubilized cellular contents were collected. The supernatants from two tubes were combined 
and poured into a 125 mL Erlenmeyer flask containing 30 mL chloroform and 22.5 mL PBS. The 
mixture was stirred at high speed for an hour for thorough mixing of the layers. The 
homogenized mixture was quickly poured into three clean Teflon tubes and centrifuged at 4000 x 
g for 10 min at 4 °C. It is important to quickly transfer the heterogeneous mixture into three 
tubes so that the composition of the mixture in each tube is roughly the same. In each Teflon 
! 132 
tube, a white interface layer was observed between the top aqueous and bottom organic layer. 
The top aqueous layer may appear hazy at first, but the haziness settles into the interface when 
the Teflon tube warms up to room temperature, giving a clear aqueous layer. The interface layer 
was collected by first removing the aqueous layer slowly using a Pasteur pipette. It is 
unavoidable to take up some volume of the aqueous layer while transferring the interface. The 
interface layer and the remaining organic layers are dried and analyzed by Western blot analysis 
of BDL-labeled Lipid II (Figure 3.2a). 
For the second extraction to remove the Park nucleotide from the interface, the dried 
interface (from 4 x 1.5 L cell culture) was dissolved in 15 mL organic mixture of 1: 2 6M 
pyridinium acetate: n-butanol (prepared by mixing 51.5 mL glacial acetic acid with 48.5 mL 
pyridine), and washed with 15 mL of aqueous solvent (n-butanol saturated water) in a separation 
funnel. The aqueous layer was extracted again with 10 mL organic solvent (1: 2 6M pyridinium 
acetate: n-butanol) to maximize Lipid II extraction. The organic layers were combined and 
washed with aqueous solvent (n-butanol saturated water) (10 mL x 3) to remove the water-
soluble Park nucleotide (Figure 3.2a). The clean organic layer was concentrated by rotary 
evaporation, and dissolved in MeOH for LC/MS quantification. For biochemical assays, the 
dried Lipid II was dissolved in DMSO, and was referred to as lipid extract.  
 
3.6.4 Thin layer chromatography (TLC) analysis of phospholipids  
Lipid extract dissolved in MeOH or phospholipids standards (CL: cardiolipin, PG: 
phosphotidylglycerol, LPG: lysyl-phosphotidylglycerol) in MeOH (at 5 mg/mL) were spotted on 
a TLC plate. The TLC was eluted in solvent CHCl3: MeOH: CH3COOH of 60: 30: 10, and 
detected by spraying with a solution of CuSO4 in 8% phosphoric acid, and heating at 180 °C for 
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10 min until brown spots indicating phospholipids appeared (Figure 3.2b). 
 
3.6.5 Western blot analysis of BDL-labeled Lipid II 
The crude extract containing Lipid II was diluted in DMSO, and added to a mixture 
containing PBP4 (4 µM), BDL (3 mM) in a reaction buffer (12.5 mM HEPES (pH = 7.5), 2 mM 
MnCl2, and 250 µM Tween-80) to reach a total volume of 10 µL with a final DMSO 
concentration of 20%. The reaction was incubated at room temperature for 1 h, and quenched 
with 10 µL of 2x SDS loading buffer. The final mixture (3 µL) was loaded onto a 4-20% gradient 
polyacrylamide gel and let run at 200 V for 40 min. The products were transferred to Immun-
Blot PVDF membrane (BioRad) at 25 V (fixed) 1.3 A (variable) for 15 min. BDL-Lipid II was 
detected by blotting with streptavidin-HRP (1:10000 dilution), visualized using ECL Prime 
Western Blotting Detection Reagent (GE Ambersham) on Azure C400 imaging system (Figure 
3.2b). 
 
3.6.6 LC/MS analysis of delipidated S. aureus Lipid II 
A small amount of the interface lipid extract in DMSO (10 µL) was incubated with H2O 
(80 µL) and 100 mM ammonium acetate at pH 4.2 (10 µL). The mixture was heated at 100 °C in 
a heating block for 30 min. Under these conditions, the Lipid II is hydrolyzed at the 
phosphodiester linkage. The mixture was lyophilized, resuspended in 20 µL H2O, and subjected 
to LC/MS analysis, conducted with ESI-MS operating in negative mode. The instrument was 
equipped with a Waters Symmetry Shield RP18 column (5 µM, 3.9 x 150 mm) with a matching 
column guard. The fragments were separated using the following method: 0.5 mL/min H2O 
(0.1% formic acid) for 5 min followed by a gradient of 0 % acetonitrile (ACN) (0.1% formic 
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acid)/H2O (0.1% formic acid) to 20% ACN (0.1% formic acid)/H2O (0.1% formic acid) over 40 
min. The molecular ion corresponding to expected disaccharide muropeptide monophosphate 
fragment was extracted from chromatograms (Figure 3.3).  MS/MS chromatograms of 
delipidated S. aureus Lipid II were shown in Figure App2.21.  
 
3.6.7 Quantifications of delipidated S. aureus Lipid II 
The interface lipid extract in DMSO (4 µL) was mixed with varying concentrations of 
synthetic Lys-Lipid II in DMSO (4 µL of 200 µM, 100 µM or 50 µM) respectively, which was 
then subjected to heat degradation in buffer (10 mM ammonium acetate, pH 4.2) at 100 °C for 30 
min. The mixture was lyophilized, redissolved in 20 µL H2O, and subjected to LC/MS analysis, 
conducted with ESI-MS operating in negative mode. The LC/MS run method was indicated 
above. The molecular ions corresponding to both degraded fragments (from synthetic Lys-Lipid 
II and native S. aureus Lipid II) were extracted from chromatograms. The amount of native Lipid 
II was estimated using a standard curve of the synthetic Lys-Lipid II (Figure App2.22).  
An alternative quantification method was performed by biotinylation of Lipid II. In this 
method, the interface extract in DMSO at various dilutions were labeled with BDL using S. 
aureus PBP4, and the BDL-labeled Lipid II was then subjected to Western blot detection, as 
previously discussed. Densitometry analysis of the BDL-Lipid II (from the interface extract) was 
done using BDL-labeled Lys-Lipid II (Lys-Lipid II of known concentrations were labeled with 
BDL using S. aureus PBP4) as a standard curve on ImageJ (Figure App2.22). 
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4.1 Introduction 
 
This chapter describes the reconstitution of the transpeptidase activity of S. aureus PBP2, 
the only essential Class A PBP in S. aureus.a Access to useful quantities of native S. aureus 
Lipid II, as discussed in Chapter Two and Three, has enabled the development of in vitro TP 
assays. This allows us to characterize beta-lactam antibiotics by directly monitoring their 
inhibition of TP activity in vitro for the first time. The work in this chapter lays the groundwork 
for future discovery of novel classes of TP inhibitors such as non-covalent inhibitors. 
 
4.1.1 PBP2 is the essential Class A PBP in S. aureus  
 
S. aureus PBP2 is an essential bifunctional PBP (Class A) that has both a peptidoglycan 
glycosyltransferase (PGT) and a transpeptidase (TP) domain. The PGT domain couples Lipid II 
monomers to make glycan strands, while the TP domain crosslinks adjacent strands via a short 
peptide. The identity of PG crosslinks is distinct in different bacteria; in S. aureus, the peptide 
cross-link is a pentaglycine bridge (Figure 4.1).1 The cellular importance of the PGT and TP 
domains of S. aureus PBP2 has been probed by genetic inactivation of each active site residue.2,3 
Its TP domain was found essential for viability in methicillin-sensitive S. aureus (MSSA), and 
can only be replaced by PBP2a in methicillin-resistant S. aureus (MRSA) strains.2 However, the 
PGT domain of PBP2 is required for the full expression of methicillin resistance in MRSA, 
suggesting a cooperation between the PBP2 PGT activity and PBP2a TP activity.3 In addition, 
the PBP2 TP domain has been suggested to cooperate with PBP4 to produce highly cross-linked 
PG in S. aureus.4 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!"!Class A PBP refers to bifunctional PBP, which has both PGT and TP domains.!
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Figure 4.1. Schematic depiction of S. aureus PG biosynthetic pathway. S. aureus Lipid II contains a 
unique peptide. The PGT and TP domains of penicillin-binding proteins (PBPs) accomplish the final 
stages of PG assembly and are good antibiotic targets. PBP2 is the major PBP in S. aureus.  
 
The PGT activity of S. aureus PBP2 was characterized in vitro by Barrett et al. (2005) 
using synthetic Lys-Lipid II substrate, which was the first reconstitution of a Gram-positive 
Class A HMW PBP.5 In this work, a full-length construct of S. aureus PBP2 was heterologously 
overexpressed and purified. This construct exhibited optimal activity at pH 4.5-5.5, while the 
activity decreased in the presence of any detergent and did not depend on the presence metal 
ions. Under such optimal condition, S. aureus PBP2 PGT had a catalytic efficiency (kcat/Km: 2.4 
x 103 M-1s-1) comparable to that of the well-characterized E. coli PBP1b (kcat/Km: 3.5 x 104 M-1s-
1).6 However, it was proposed that the native pentaglycine-containing Lipid II may enhance the 
catalytic efficiency of S. aureus PBP2. Wang et al. (2008) showed that purified PGTs from 
different organisms could produce PG polymers of variable lengths. The full-length S. aureus 
PBP2 produces glycan polymers of about 15 disaccharide units in vitro.7 PG polymers of proper 
lengths in S. aureus are thought to be important for the placement of the division plane to ensure 
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orthogonal divisions.8 A moenomycin-resistant S. aureus mutant, which contains a point 
mutation in the PGT domain of PBP2 protein (PBP2 Y196D), manifests aberrant cell divisions.8 
Compared to wildtype PBP2 protein, PBP2 Y196D mutant protein displayed a distributive 
mechanism in vitro where short PG polymers were released after each coupling.8 Several crystal 
structures of different bacterial PGTs in complex with moenomycin have been reported, in which 
moneomycin binds in the extended PGT active site.9-11 The Y196D mutation in PBP2 resides in 
the distal region of the PGT active site cleft, which is proximal to the A, B rings of moenomycin. 
The fact that a point mutation in the PGT domain of S. aureus PBP2 confers a 25-fold increase in 
the MICs of moenomycin (0.5 !g/mL to 12.5 !g/mL) establishes that PBP2 is the lethal target of 
moenomycin.8  
While much is known about S. aureus PBP2 PGT activity, its TP activity remains to be 
demonstrated. In the crystal structure of S. aureus PBP2, the C-terminal TP domain is separated 
from the N-terminal PGT domain by a small linker region.11 The active site of the TP domain 
contains the characteristic motifs (SXXK, SXX, KTG) with S398 (underlined) being the active 
site residue.12 Several beta-lactam resistant S. aureus strains that bear mutations in the PBP2 TP 
domain have been isolated clinically or in laboratory conditions.4,13 However, despite its 
importance as the target of beta-lactams, S. aureus PBP2 TP activity has not been characterized 
due to the lack of an appropriate substrate. Notably, the Ac2-L-Lys-D-Ala-D-Ala tripeptide 
substrate, which has been used for probing LMW PBPs, is not suitable for studying the TP 
activities of HMW PBPs, since the TP domain and the PGT domain are coupled in HMW 
PBPs.14 The TP activities of E. coli HMW PBPs (PBP1a and PBP1b) have been shown to require 
ongoing PGT activities.14,15  
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In this chapter, we used native S. aureus Lipid II substrate to characterize PBP2 activity 
in vitro. The composition of PG assembled by PBP2 in vitro greatly resembles that of the 
isolated sacculus from S. aureus. This observation is in line with the fact that PBP2 is the major 
TP in S. aureus. In this work, we have developed a facile activity assay that directly reports on 
the TP-mediated cross-linking and D-amino acid exchange reaction, enabling studies of beta-
lactam inhibition of transpeptidation. 
  
4.1.2 Traditional competition binding assays to study beta-lactams 
 
In the absence of a transpeptidase activity assay, competition binding assays have been 
the prevalent approach to study beta-lactam interaction with bacterial PBPs, in which the 
concentration of a beta-lactam of interest needed to prevent binding of a labeled penicillin is 
assessed.16 Different beta-lactams display greatly varied affinities to PBPs in a given organism. 
For instance, mecillinam, a broad-spectrum beta-lactam, demonstrates specific binding to E. coli 
PBP2, an essential enzyme involved in cell elongation of the rod-shaped E. coli.17 S. aureus 
PBP3, which has a high homology to E. coli PBP2, also demonstrates high affinity for 
mecillinam.18. Consistent with the fact of S. aureus PBP3 is non-essential, mecillinam exhibits 
poor antibacterial activity against S. aureus. Although competition binding assays have allowed 
one to delineate the possible target(s) for a beta-lactam drug in bacteria, such assays are not 
desirable for studying non-covalent PBP inhibitors or beta-lactams with a fast rate of release 
from the enzyme, since a large excess of penicillin is necessary for labeling in the experiment 
and may result in an underestimation of the inhibitor’s binding affinity. For instance, the 
cefaclor-bound PBP2 species has a high deacylation rate at 37 °C, despite cefaclor having a high 
affinity for the enzyme.19 If the incubation time exceeds the half-life of the covalent adduct 
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(penicilloyl-PBP), S. aureus PBP2 can be labeled by the excess penicillin to result in a 
misleading readout.20 Therefore, a direct activity assay to study beta-lactam inhibition of PBPs is 
needed.  
Using the TP assays developed in this chapter, we characterized the inhibitory activities 
of a panel of beta-lactams on S. aureus PBP2. We showed that the TP activity assay is useful for 
studying inhibitors that show reversible binding, such as cefaclor. We also investigated the TP 
activities of PBP2 mutant proteins that are implicated antibiotic resistance and confirmed their 
resistance to be associated with specific beta-lactams. Furthermore, we analyzed the substrate 
specificity of S. aureus PBP2 and revealed that it required a certain length of glycine branch for 
transpeptidation in vitro. These results provide a platform for studying the activities of other 
bacterial PBPs and for the continuing search of new classes of TP inhibitors. 
 
4.2 Purification of S. aureus PBP2 
 
Like other HMW PBPs, S. aureus PBP2 is a transmembrane (TM) protein with an N-
terminal TM helix that anchors it to the cytoplasmic membrane. We have previously cloned, 
overexpressed and purified a full-length construct of S. aureus PBP2, and reconstituted its PGT 
activity using synthetic Lys-Lipid II.5 However, an anionic detergent, sodium lauryoyl 
sarcosinate, was necessary to solubilize the full-length PBP2 from the membrane fraction during 
purification. The purified full-length protein appeared aggregated on size-exclusion 
chromatography (SEC) analysis. As a result, the observed activity may come from only a small 
percentage of the well-folded protein in the purification preparation. To obtain a soluble S. 
aureus PBP2 construct, we cloned a PBP2 [M59-S716] construct with its N-terminal TM helix 
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truncated.b To facilitate solubilization of S. aureus PBP2 protein, we added 40 mM of CHAPS 
detergent (CMC of CHAPS is about 8 mM) to the purification buffer. A significant amount 
PBP2 [M59-S716] was solubilized under this condition. During the Ni-NTA column 
chromatography step, we exchanged the detergent to 0.28 mM LDAO (CMC of LDAO is about 
1 mM), a common zwitterionic detergent for membrane protein purification and crystallization.21 
The PBP2 [M59-S716] appeared well-folded in this storage buffer at pH 8.0 based on SEC 
analysis. From 1 L of E. coli culture for protein expression, 5-10 mg of S. aureus PBP2 [M59-
S716] was obtained after Ni-NTA and SEC purifications. This was a major improvement from 
the previous purification of the full-length construct, where only 1-2 mg PBP2 protein (that was 
aggregated) was obtained per liter of culture.5 Since the protein demonstrated desirable purity 
(Figure 4.2), we subjected it to biochemical studies without additional steps of purification.  
 
 
 
 
 
 
 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
b This work was done in collaboration with a graduate student, Jeep Veerasak Srisuknimit and two 
undergraduate students, Alan Yang and Akeem Pinnock. The purification protocol was modified from 
Lovering et al. (2007). 
Figure 4.2. Purification of S. aureus PBP2 [59-716] construct and mutants. Coomassie gel showing PBP2 
was purified in homogeneity (left), size-exclusion chromatography (SEC) trace of S. aureus [59-716] 
wildtype. A small aggregated peak was eluted in the void volume, a small peak that represents the dimer 
and the predominant monomeric peak. The red dotted line indicated the fractions that were collected.  !
1: PBP2 wildtype 
2: PBP2 S398G 
3: PBP2 D606V 
4: PBP2 P458L 
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4.3 Reconstitution of the PGT and TP activities of S. aureus PBP2  
To reconstitute the activities of S. aureus PBP2, we used native Lipid II substrate 
prepared by direct isolation from S. aureus (see Chapter Three). As mentioned earlier, the PGT 
activity of S. aureus PBP2 has been studied using model Lys-Lipid II substrate,5 but 
characterization of its TP activity has not been possible due to a lack of the appropriate Lipid II 
substrate. The presence of the pentaglycine branch on native Lipid II allows us to study S. aureus 
PBP2 TP activity for the first time. We adopted the LC/MS assay that was used to study PBP4 
activity as described in Chapter two for investigating PBP2 PGT and TP activities.22 The purified 
S. aureus PBP2 protein was incubated with native Lipid II substrate at room temperature. After 
one hour of incubation, the product was digested with mutanolysin to give the disaccharide 
muropeptides, which were further reduced by NaBH4 to prevent anomerization of the reducing 
end on MurNAc.c The mixture was then subjected to LC/MS analysis (Figure 4.3a). We 
identified monomeric muropeptide (A), as well as dimeric (B) and trimeric (C) muropeptides. 
The presence of peak A indicated the PGT activity of S. aureus PBP2, while the presence of 
peak B and C suggested successful TP activity of PBP2. Incubation of S. aureus PBP2 TP active 
site mutant with Lipid II resulted in only monomeric muropeptide (A), identical to what was 
observed when the monofunctional PGT SgtB was used for Lipid II polymerization (Figure 
App3.1). The composition of muropeptides from PG produced by PBP2 in vitro closely 
resembles that produced by digestion of the isolated S. aureus sacculus (Figure 4.3b). Hence, 
using native Lipid II substrate, we have reconstituted both glycan polymerization and strand 
cross-linking by the essential enzyme S. aureus PBP2. It should be mentioned that acidic buffer 
condition (pH 5.5) that was used previously for the full-length PBP2 construct was not optimal 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
c Reduction of the anomeric carbon on MurNAc increases its ionization on mass spectrometry. 
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for our studies here, since the truncated PBP2 demonstrated better in vitro activity at neutral pH 
and the acidic buffer interfered with the LC/MS analysis. 
 
 
 
 
 
 
 
 
 
 
We next sought to develop a faster assay to monitor PBP2 activity. The LC/MS analysis 
of transpeptidation relies on a high-resolution mass spectrometer to detect the cross-linked 
products, and the throughput is slow (i.e. each LC/MS run takes 50 min). We examined whether 
S. aureus PBP2 can incorporate exogenous D-amino acids during in vitro PG assembly. If so, D-
amino acid incorporation can provide a facile assay to study S. aureus PBP2 TP activity in vitro.  
It is known that several HMW PBPs in E. coli and B. subtilis are capable of incorporating a 
variety of D-amino acids into PG in vitro.23,24 We recently demonstrated that the LMW S. aureus 
PBP4 can incorporate a variety of functionalized D-amino acid derivatives into either pre-formed 
Figure 4.3. S. aureus PBP2 uses native Lipid II to make cross-linked PG in vitro. (a) Schematic of 
PBP2 reaction to produce PG and muropeptide fragments resulting from degradation. (b) LC/MS EICs 
of the degraded products from PBP2 reaction (top) and from degraded sacculus (bottom). Peak A, 
monomeric muropeptide; peaks B and C, cross-linked dimeric and trimeric muropeptides, respectively. 
The following ions were extracted: A: 1254.5856 (m+H); B: 1029.0617 ([m+2H]2+); and C: 1194.2204 
([m+3H]3+). (See materials and methods for detailed protocols).  
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PG or monomeric Lipid II in vitro; in particular, the incorporation of biotinylated-D-lysine 
(BDL) has led to a simple and sensitive assay to detect the cellular pools of Lipid II in bacteria.22 
Therefore, we chose BDL as a probe to investigate S. aureus PBP2 TP activity in vitro. Here, the 
purified PBP2 protein was incubated with native Lipid II and BDL at room temperature for one 
hour, and then the reaction was quenched and loaded onto an SDS-PAGE gel for separation, 
followed by Western blot analysis using a streptavidin-HRP conjugate. Surprisingly, the only 
signal detected was found at a location that corresponded to the loading well of the gel (Figure 
4.4a, left lane), suggesting that the product was too highly cross-linked to enter the SDS-PAGE 
gel matrix.25,26 To resolve the cross-linked product, we added lysostaphin to the reaction mixture 
prior to analysis by gel electrophoresis. Lysostaphin is an endopeptidase that specifically cleaves 
cross-linked pentaglycine bridges in S. aureus PG.27 In the lysostaphin-treated sample, we 
detected strong signals across a wide range of molecular weights on the blot (Figure 4.4a, right 
lane). When the reaction sequence was carried out using PBP2 TP active site mutant, no signal 
was observed in the presence or absence of lysostaphin, indicating that BDL labeling was 
specific to PBP2 TP activity (Figure App3.2). Therefore, we conclude that PG polymers 
produced by the PGT domain of S. aureus PBP2 undergo TP-mediated cross-linking as well as 
BDL incorporation, resulting in a cross-linked macromolecule labeled with BDL. 
As S. aureus PBP2 mediate PG cross-linking and D-amino acid incorporation (into PG) 
via the same acyl-enzyme intermediate (i.e. the activation step is identical), the two reactions are 
competing reactions (Figure 1.6). Indeed, we observed that as the concentration of Lipid II 
increases from 5 !M to 20 !M in the reaction, while keeping the concentrations of PBP2 (1 !M) 
and BDL (3 mM) constant, the signal of BDL-labled PG became fainter (data not shown). This 
implied that PG cross-linking was favored over BDL incorporation by S. aureus PBP2 when 
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higher concentration of Lipid II substrate was used in the reaction. Although the concentration of 
exogenous BDL used was orders of magnitude higher than that of the Lipid II substrate, we 
assume that the close proximity of the pentaglycine branch in PG to the donor peptide may 
dramatically enhance the effective concentration for cross-linking as the Lipid II substrate 
concentration increases in the reaction mixture. However, at a lower concentration of Lipid II 
substrate, cross-linking and BDL labeling of PG by PBP2 can both occur readily; lysostaphin 
treatment allows cleavage of PG cross-links to yield linear PG polymers labeled with BDL for 
the ease of analysis. In summary, BDL labeling of PG by S. aureus PBP2 provides a facile and 
qualitative readout for PBP2 transpeptidation reaction.  
 
4.4 Assessing the inhibitory effects of beta-lactams  
To demonstrate the utility of this activity assay, we investigated the inhibitory effects of a 
panel of beta-lactams. As mentioned earlier, studies of beta-lactams have relied on competition 
binding assays in which a radiolabeled or fluorescent penicillin is used as a probe.16,28,29 Beta-
lactam inhibition of the TP enzymatic activity of PBPs, however, has not been directly 
demonstrated. Here, we briefly incubated S. aureus PBP2 with an increasing concentration of 
different beta-lactams prior to running the reactions (Figure 4.4 and Figure App3.2). Cefalor, a 
second-generation cephalosporin, has been considered to be a weak binder of S. aureus PBP2 in 
the competition binding assay.20 It was subsequently determined that cefaclor actually has a high 
affinity for PBP2 but undergoes rapid deacylation,19 resulting in a misleading readout by this. 
The half-life of cefaclor acyl-PBP2 was approximately 10 min at 37 °C.19 Therefore, the 
incubation time and the temperature of the reaction are important variables in the binding assay. 
If the time of radiolabeling exceeds the half-time of the acyl-enzyme intermediate, the binding of 
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the antibiotic to PBP will be significantly underestimated. In our activity assay, we found that 
cefaclor potently inhibited PBP2 activity at a concentration 5x that of the enzyme (5 !M of 
cefaclor versus 1 !M of PBP2). We did not observe significant differences in cefaclor inhibitory 
activities with either shorter (10 min) or longer (60 min) incubation time, but the amount of 
cefaclor required to inhibit S. aureus PBP2 activity in vitro varies with the concentration of PBP2 
used in the reaction. In addition, mecillinam, an extended spectrum beta-lactam, which 
demonstrates poor antibacterial activity against S. arueus, has been reported to have poor affinity 
for S. aureus PBP2.20 Indeed in our assay, it showed no detectable inhibition of PBP2 activity up 
to 20-fold excess of PBP2 concentration. Other beta-lactams including penicillin G, methicillin, 
and imipenem also demonstrate potent inhibitory activities in line with their binding data (Figure 
App3.2).20,30,31 The direct in vitro activity assay allows us to evaluate the inhibitory activities of 
beta-lactams in a purified system conviently.  
We next examined whether the TP activity assay would be useful for assessing the 
activities of resistance mutations upon beta-lactam inhibition. Several laboratory and clinical 
isolates of S. aureus strains that display resistance to certain beta-lactams have been identified, 
and the mutations are mapped to the pbp2 gene.4,13 In the case of a ceftizoxime-resistant S. 
aureus strain, a PBP2 P458L substitution has been shown to be responsible for resistance. The 
P458L mutation occurs in the TP cleft of S. aureus PBP2 (which is close to the TP active site 
residue). The mutant protein demonstrates a lower binding affinity for ceftizoxime than the 
wildtype enzyme.4 However, it is not known if the P458 residue in PBP2 specifically interacts 
with ceftizoxime, due to a lack of the crystal structure of S. aureus PBP2 in complex with 
ceftizoxime. Moreover, the TP activity of PBP2 P458L mutant has not been characterized 
previously. We overexpressed and purified the S. aureus PBP2 P458L mutant protein, and 
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analyzed its activity. We found that the TP domain of PBP2 P458L variant active and its 
tolerance to ceftizoxime was about ten fold higher than the wildtype enzyme (Figure 4.4d). The 
mutant enzyme remained susceptible to oxacillin inhibition, consistent with the observation that 
the strain containing this mutation was more susceptible to oxacillin killing (Figure App3.2).4 In 
contrast, a PBP2 D606V variant, found in several borderline oxacillin resistant S. aureus 
isolates,13 tolerated more oxacillin than the wildtype enzyme did in the activity assay (Figure 
App3.2). Our observation establishes the mechanistic basis of the observed resistance. 
 
Figure 4.4. Beta-lactams inhibit S. aureus PBP2 TP activity. (a) Lysostaphin allows entrance of the BDL-
labeled PG into the gel. (b) Structures of beta-lactams examined in c-d. (c) Cefaclor has potent inhibitory 
activity against PBP2, while mecillinam does not. The signal at 25 kD derives from non-specific binding 
of the conjugate to lysostaphin. (d) PBP2 resistant mutant P458L TP variant shows TP activity in the 
presence of higher doses of ceftizoxime. (See materials and methods for detailed protocols). 
 
Given bacterial TP is an important antibiotic target, it is surprising that beta-lactams 
represent the only class of TP inhibitors in the clinic. Discovery of non-covalent TP inhibitors 
!! 151 
has not been possible with the current competition binding assays. We showed that our activity 
assay is compatible with inhibitors that have a fast rate of release from the enzyme, such as 
cefaclor.19 Therefore, we expect the assay to greatly facilitate the discovery of novel non-
covalent TP inhibitors. 
 
4.5 Investigating the substrate specificity of S. aureus PBP2 
 
We also analyzed the substrate specificity of S. aureus PBP2 with Gly- and Gly3-Lipid II 
variants that were isolated from the S. aureus !femA and !femB mutant respectively (see 
Chapter Three). As introduced in Chapter One, FemA and FemB are enzymes involved in the 
synthesis of the pentaglycine branch in Lipid II in S. aureus, where FemA attaches the second 
and third glycines, FemB attaches the last two glycines.32 Analysis of PG structures in !femA 
and !femB mutants revealed a dramatic reduction in the level of PG cross-linking, with 
monoglycine bridges in the !femA mutant and triglycine bridges in the !femB mutant.33 This 
observation suggests that one or more PBPs in S. arueus must be able to cross-link the shorter 
glycine branches in both mutants. Using similar reaction conditions to those described in Chapter 
4.3, we incubated Gly- or Gly3-Lipid II with purified S. aureus PBP2 protein, followed by 
mutanolysin/NaBH4 treatment and LC/MS analysis (Figure 4.5). With Gly-Lipid II, the un-cross-
linked Gly muropeptide peak (Ax=1) was observed predominantly, while a small peak 
corresponding to the dimer product was found. However, with Gly3-Lipid II, both monomeric 
(Ax=3) and dimeric muropeptides (Bx=3) were present. This indicates that S. aureus PBP2 can use 
triglycine branch as a nucleophile for cross-linking, but not the monoglycine branch under the in 
vitro experimental condition. Whether S. aureus PBP2 is responsible for PG cross-linking in 
!femA and !femB mutants in vivo remains to be answered. In addition, we observed S. aureus 
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PBP2 could incorporate D-amino acids during PG assembly with Gly- or Gly3-Lipid II substrate. 
Taken together, S. aureus PBP2 demonstrates stringent substrate requirement for acceptors in 
cross-linking, where Gly-Lipid II substrate cannot be used efficiently in vitro. Nevertheless, the 
identity of the glycine branch on Lipid II does not affect its suitability as a donor substrate for S. 
aureus PBP2 TP activity. 
 
4.6 Conclusion and future studies  
In summary, we have reconstituted the TP activity of S. aureus PBP2 for the first time 
using native Lipid II substrate and developed a facile activity assay to study beta-lactam 
inhibition in vitro. The availability of a TP activity assay opens up the possibility to screen for 
novel classes of PBP inhibitors. TPs are important antibiotic targets; however, beta-lactams 
represent the only class of antibiotics that target these enzymes. Although there were several 
Figure 4.5. S. aureus PBP2 demonstrates substrate specificity in transpeptidation. (a) Schematic of PBP2 
reaction to produce PG and muropeptide fragments resulting from degradation. (b) LC/MS EICs of the 
degraded products from PBP2 reaction with Gly-Lipid II (top) and with Gly3-Lipid II (bottom). Peak A, 
monomeric muropeptide; peak B, cross-linked dimeric muropeptide. The following ions were extracted: 
A(x=1): 1205.4997 (m+H); B(x=1): 1960.9445 ([m+H]+); and A(x=3): 1139.5426 (m+H); B(x=3): 
1095.0188 ([m+2H]2+). (See methods and materials for detailed protocols). 
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attempts to identify new classes of TP inhibitors using computational docking methods 
recently,34  a systematic approach to discover potential TP inhibitors is lacking. We are currently 
working towards adopting our Western blot-based TP activity assay into a high-throughput 
screening assay to enable systematic discovery of new classes of PBP inhibitors. The fact that 
practical quantities of native Lipid II substrate can be readily accumulated and isolated from 
bacteria makes its cost-effective to develop a high-throughput screening assay.  
In our efforts to reconstitute S. aureus PBP2 activity, we have established a reliable and 
generalizable route to obtain native Lipid II substrate (see Chapter Three), which provided 
important foundations for future in vitro studies of other bacterial TPs. We are currently 
continuing the investigation of the substrate specificity of S. aureus PBPs. If S. aureus PBP2 has 
an intrinsic preference for Gly5- and Gly3- over Gly-Lipid II, there must be another S. aureus 
PBP that can cross-link the Gly-Lipid II, since the S. aureus !femA mutant is still viable and its 
PG contains monoglycine cross-bridges. Moreover, the TP activities of Class B HMW PBPs, 
such as S. aureus PBP1, PBP2a and PBP3, are not well understood. Banzhaf et al. (2012) 
showed that the presence of E. coli PBP2 (a Class B HMW PBP) stimulates the TP activity of E. 
coli PBP1a (a Class A HMW PBP), as measured by the attachment of in vitro radiolabeled PG to 
sacculi.35 However, E. coli PBP2 did not demonstrate any TP activity alone or with a PBP1a TP 
mutant. Therefore, characterization of Class B HMW PBPs still awaits, and understanding their 
activities may enable better strategies to target them.  
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4.7 Materials and Methods  
4.7.1 General Methods 
S. aureus strain was grown at 37 °C in Tryptic Soy Broth (TSB) media under aeration 
with shaking. Native S. aureus Lipid II was obtained by direct isolation from S. aureus culture as 
described in Chapter Three. LC/MS chromatograms were obtained on an Agilent Technologies 
1100 series LC-MSD instrument using electrospray ionization (ESI). HRMS data was obtained 
on a Bruker Maxis Impact LC-q-TOF Mass Spectrometer using ESI. Western blots were 
developed using Biomax Light Film (Kodak) or imaged using Azure C400 imaging systems. 
ImageJ was used to quantify blots. 
 
4.7.2 Cloning of S. aureus PBP2[M59-S716] and mutants 
The S. aureus pbp2[M59-S716] construct was cloned into pET42a(+) plasmid using 
Gibson assembly protocol. Briefly, the nucleotide region of S. aureus pbp2 gene encoding amino 
acid 59 to 716 was amplified using the following primer pair:  
5’- TTTTGTTTAACTTTAAGAAGGAGATATACATATGAAAGCACCTGCTTTTACCGA-3’ and  
5’- TGGTGGTGGTGGTGGTGCTCGAGAGATTGTTGAGATCTAGTATTGTTATTTGAT -3’, where 
the underlined regions indicate sequences annealing to the PBP2 gene, and the W59 was mutated 
to become the new N-terminal methionine. The PCR product was analyzed and purified using 
agarose gel electrophoresis. The pET42a(+) plasmid was double-digested using restriction 
endonucleases NdeI and XhoI in the CutSmart buffer, followed by heat inactivation of the 
restriction endonucleases. The purified PCR product and the linearized vector were assembled 
using Gibson assembly protocol. The inserted pbp2[M59-S716] gene was confirmed by 
sequencing (Beckman Coulter Sequencing Facility). E. coli NovaBlue strain was used for 
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cloning. Point mutants of pbp2[M59-S716] were made with the appropriate in the parent plasmid 
using QuickChange site-directed mutagenesis kit (Stratagene). The constructs were confirmed by 
sequencing.  
pbp2[M59-S716] S398G mutant was made using the following primer pair:  
5’-CAACAGATCCTCACCCTACTGGTGGATCTTTAAAACCTTTCTTAGCGTAT-3’ and  
5’-ATACGCTAAGAAAGGTTTTAAAGATCCACCAGTAGGGTGAGGATCTGTTG-3’  
pbp2[M59-S716] P458L mutant was made using the following primer pair:  
5’-GACAAAGTTTCAATATCCTAGCTTTAAAAG-3’ and  
5’-CTTTTAAAGCTAGGATATTGAAACTTTGTC-3’  
pbp2[M59-S716] mutant was made using the following primer pair:  
5’-AATGCAGCGAAAGTCGTGTGG-3’ and  
5’-CCACACGACTTTCGCTGCATT-3’ (Mutagenized codon is underlined). 
 
4.7.3 Overexpression and purification of S. aureus PBP2 and mutants.  
The plasmid encoding S. aureus PBP2[M59-S716] collected from the NovaBlue cloning 
strain was transformed into E. coli BL21(DE3) culture for overexpression and purification. A 15 
mL culture of E. coli BL21 (DE3) harboring the plasmid encoding for S. aureus PBP2[M59-
S716] grown in LB supplemented with 50 µg/ mL kanamycin was grown overnight, which was 
then used to inoculate 1.5 L LB medium (1:100) supplemented with 50 µg/mL kanamycin. The 
culture was grown at 37 °C with shaking until OD600 reached 0.4-0.5, and then cooled down to 
17 °C before induction with 0.5 mM IPTG for 17 h with shaking. Cells were harvested by 
centrifugation (5250 x g, 20 min, 4 °C) and pellets were resuspended on ice with 30 mL of lysis 
buffer (10 mM Tris pH 8.0, 1M NaCl, 10 mM MgCl2, 10% v/v glycerol and 40 mM CHAPs) 
supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF) and 100 µg/mL DNase 
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inhibitor. The resuspended cells were passed through a cell disrupter (3 x 10,000 psi, 4 °C) for 
three times. The cell lysate was then pelleted by ultracentrifugation (100,000 x g, 30 min, 4 °C). 
The resulting supernatant containing PBP2[M59-S716] protein was applied to 1.5 mL pre-
washed Ni-NTA resin (Qiagen) at 4 °C (the Ni-NTA resin was washed with dH2O and 
equilibrated with lysis buffer). After collecting flow through (FT), the resin was washed with 
buffer A (10 mM Tris pH 8.0, 0.2 M NaCl, and 0.28 mM LDAO) to facilitate detergent exchange 
(20 mL, W1). The resin was then washed with buffer A containing 60 mM imidazole (20 mL, 
W2). The protein was eluted with buffer A containing increasing imidazole concentrations (10 
mL of 100 mM, 200 mM and 500 mM each, E1-E3). The fractions were analyzed on SDS-PAGE 
electrophoresis.  The fractions containing PBP2 protein (E1- E3) were combined and 
concentrated to ~ 10mg/mL using a 50 kD MWCO Amicon Ultra Centrifuge Filter Device 
(Millipore). The concentrated PBP2 sample was further purified using size-exclusion 
chromatography with a Superdex S200 column equilibrated in buffer A. The fractions indicating 
monomeric protein were combined and concentrated using the 50 kD MWCO Amicon Ultra 
Centrifuge Filter Device, while the concentration was measured on nanodrop using the 
calculated extinction coefficient of PBP2 [M59-S716]. The final yield was approximately 10 mg 
per 1.5 L culture. S. aureus PBP2 [M59-S716] is referred to PBP2 subsequently. PBP2 S398G, 
PBP2 D606V, PBP2 P458L were purified using the same protocol. Coomassie stained gel and 
FPLC spectra of purified PBP2 are shown in Figure 4.2.  
 
4.7.4 LC/MS assay analysis of PBP2 TP activity in vitro. 
The procedure was modified from our previous report.36 Native S. aureus Lipid II in 
DMSO (40 µM) was incubated with purified PBP2 (1 µM) in 1x reaction buffer (50 mM HEPES, 
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pH 7.5, 10 mM CaCl2) in a total of 10 µL reaction volume for 1 h at 25 °C. The reaction was 
quenched at 95 °C for 5 min, and then treated with mutanolysin (from Streptomyces globisporus, 
Sigma, 1 U) for 1.5 h at 37 °C followed by another 1 U aliquot for 1.5 h. The resulting 
disaccharides were reduced with sodium borohydride (10 !L of 10 mg/mL solution, 30 min) to 
resolve the MurNAc anomers. Phosphoric acid (20%, 1.2 µL) was then added to adjust the pH to 
~4. The reaction mixture was the lyophilized, redissolved in 12 µL H2O and subjected to 
LC/HRMS analysis, conducted with ESI-MS operating in positive mode on a Bruker qTOF mass 
spectrometer. The instrument was equipped with a Waters Symmetry Shield RP18 column (5 
µM, 3.9 x 150 mm) with a matching column guard. The fragments were separated using the 
following method: 0.5 mL/min H2O (0.1% formic acid) for 5 min followed by a gradient of 0% 
acetonitrile (ACN) (0.1% formic acid)/H2O (0.1% formic acid) to 40% ACN (0.1% formic 
acid)/H2O (0.1% formic acid) over 25 min. Molecular ions corresponding to the expected 
disaccharide fragments were extracted from chromatograms. The reactions with PBP2 S398G or 
SgtB were carried out using identical conditions (Figure App3.1).  
For substrate specificity studies, the reaction was performed similarly except for native 
Lipid II replaced by either Gly-Lipid II or Gly3-Lipid II (Figure 4.5). 
 
4.7.5 Degradation of isolated S. aureus sacculi 
Isolation and degradation of S. aureus sacculi were modified from a previous reported 
procedure.37 Briefly, an overnight culture of S. aureus (2 mL) was centrifuged at 10,000 rpm for 
5 min. The pellet was resuspended in 1 mL 0.25% SDS in 0.1 M Tris/HCl, pH~7.0, and boiled at 
100 °C for 20 min. The suspension was spun down at 10,000 rpm for 5 min, and the pellet was 
washed with 1.5 mL H2O for at least three times to remove SDS. The washed pellet was 
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resuspended in 1 mL H2O and let to sonicate in a water bath for 30 min, after which, 500 µL of a 
solution containing 15 µg/mL DNase, 60 µg/mL RNase in 0.1 M Tris-HCl, pH 6.8 was added. 
After shaking at 37 °C for 2 h, the mixture was boiled at 100 °C for 3 min to inactivate enzymes, 
spun down (5 min, 10,000 rpm) and washed with water once (1 mL). To release wall teichoic 
acid (WTA), the pellet was suspended in 500 µL of 1 M HCl and allowed to shake at 37 °C for 4 
h. The pellet was spun down (5 min, 10,000 rpm) and washed with water until pH is 5~6. The 
pellet was resuspended in a 100 µL digestion buffer of 12.5 mM NaH2PO4, pH 5.5, and treated 
with 10 µL of mutanolysin (5 U/mL in dH2O), and allowed to shake at 37 °C for 16 h. After 
digestion, the sample was boiled at 100 °C for 3 min to inactivate enzymes. The sample was 
spun down (5 min, 10,000 rpm), and added 50 µL NaBH4 (10 mg/mL) at room temperature for 
30 min. The sample was adjusted to pH ~4 with 20% phosphoric acid, and lyophilized. The 
lyophilized materials were resuspended in 500 µL H2O, and 20 µL was used for LC/MS analysis 
of the muropeptides. The LC/MS condition is the same as above for PBP2 in vitro reaction 
(Figure 4.3).   
 
4.7.6 Western blot analysis of S. aureus PBP2 TP activity  
The procedure is similar to the Western blot analysis of Lipid II described in Chapter 
Two,22 but PBP4 is replaced by PBP2. Briefly, Lipid II (1 µL of 100 µM stock in DMSO) was 
incubated with PBP2 (1 µL of 10 µM), BDL (1.5 µL of 20 mM) and 10x reaction buffer (1 µL of 
500 mM HEPES, pH 7.5, 100 mM CaCl2) to reach a total volume of 10 µL. The reaction was 
incubated at room temperature for 15 min, and heat quenched briefly at 100 °C for 1 min. 
Lysostaphin (0.5 µL of 1 mg/mL) was added to the reaction mixture to resolve the cross-linked 
product. The reaction was incubated at 37 °C with shaking for 3 h. To quench the reaction, 10 µL 
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of 2x SDS loading buffer was added. 3 µL of the final mixture was loaded onto a 4-20% gradient 
polyacrylamide gel and let run at 200 V for 40 min. The products were transferred to Immuno-
Blot PVDF membrane (BioRad) at 25V fixed 1.3A variable for 15 min, detected by blotting with 
streptavidin-HRP (1:10000 dilution, Pierce), and visualized using ECL Prime Western Blotting 
Detection Reagent (GE Ambersham) and Biomax Light Film (Kodak). The same reaction 
sequence was carried out using PBP2 S398G with or without lysostaphin treatment (Figure 4.4 
and Figure App3.2a).  
 
4.7.7 Studies on beta-lactam inhibition of PBP2 TP activity 
The above gel-based assay for PBP2 TP activity was modified slightly to enable study of 
beta-lactam inhibition. Briefly, PBP2 (1 µL of 10 µM) was pre-incubated with varying 
concentrations of beta-lactams (0 - 50 µM) in a reaction mixture containing BDL (1.5 µL of 20 
mM) and 10x reaction buffer (1 µL of 500 mM HEPES, pH 7.5, 100 mM CaCl2) for 5 min 
(unless otherwise noted). Lipid extract (1 µL of 100 µM stock in DMSO) was then added to the 
reaction and let to incubate at room temperature for 15 min (unless otherwise noted), and heat 
quenched briefly at 100 °C for 1 min. Lysostaphin (0.5 µL of 1 mg/mL) was added to the 
reaction mixture to resolve the cross-linked product. The reaction was incubated at 37 °C with 
shaking for 3 h. To quench the reaction, 10 µL of 2x SDS loading buffer was added. Western 
blot analysis was performed as described above (Figure 4.4 and Figure App3.2). 
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Appendix One: Mass spectrometry (MS) analysis for studies in Chapter Two 
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Figure App1.1. S. arureus PBP4 shows TP activity in vitro. LC/MS chromatograms showing 
oligoglycine incorporation by S. aureus PBP4. !
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Figure App1.2. S. arureus PBP4 shows TP activity in vitro. LC/MS chromatograms showing D-amino 
acid incorporation by S. ausreus PBP4. 
 
! 167 
!!
Figure App1.3. Analysis of S. aureus PBP4 activities at varying concentrations of D-Tyr nucleophile. !!!!!!!!!!!!!!!!!!
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Figure App1.4. S. aureus PBP4 efficiently incorporates D-amino acids into m-Dap-Lipid II and Lys-
Lipid II in vitro. !
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Figure App.1.5. S. aureus PBP4 incorporates functionalized D-amino acids into Lys-Lipid I and Lys-
Lipid II in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Two: NMR and MS data for compounds in Chapter Three 
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Figure App2.1. 1H NMR of Boc-L-Ala-D-isoGln-OH. 
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Figure App2.2. 1H NMR (top) and LRMS (bottom) of Boc-L-Ala-D-isoGln-L-Lys(Cbz)-D-Ala-D-Ala-
OMe (1). 
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Figure App2.3. 1H NMR (top) and LRMS (bottom) of Boc-L-Ala-D-isoGln-L-Lys(-Gly-TFA)-D-Ala-D-
Ala-OMe (3). 
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Figure App2.4. 1H NMR (top) and LRMS (bottom) of Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Cbz)-D-Ala-
D-Ala-OMe (4). 
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Figure App2.5. 1H NMR (top) and LRMS (bottom) of Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly-TFA)-
D-Ala-D-Ala-OMe (5). 
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Figure App2.6. 1H NMR (top) and LRMS (bottom) of Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly-Gly-
Cbz)-D-Ala-D-Ala-OMe (6). 
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Figure App2.7. 1H NMR (top) and LRMS (bottom) of Boc-L-Ala-D-isoGln-L-Lys(-Gly-Gly-Gly-Gly-
Gly-TFA)-D-Ala-D-Ala-OMe (7). 
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Figure App2.8. 1H NMR (top) and LRMS (bottom) of Cbz-D-isoGln(Trt)-OH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 179 
 
 
 
 
 
Figure App2.9. 1H NMR of Boc-L-Ala-D-isoGln(Trt)-L-Lys(Cbz)-D-Ala-D-Ala-OMe (9). 
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Figure App2.10. 1H NMR (top) and LRMS (bottom) of Boc-L-Lys(-Gly-Gly-Gly-Gly-NH2)-D-Ala-D-
Ala-OMe (10). 
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Figure App2.11. 1H NMR (top) and LRMS (bottom) of Boc-L-Lys(-Gly-Gly-Gly-Gly-Gly-TFA)-D-Ala-
D-Ala-OMe (11). 
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Figure App2.12. LRMS of protected Gly-Lipid I. 
 
 
 
 
 
Figure App2.13. LRMS of Gly-Lipid I (12). 
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Figure App2.14. HRMS of Gly-Lipid I (12). 
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Figure App2.15. LRMS of protected Gly3-Lipid I. 
 
 
 
 
Figure App2.16. LRMS of Gly3-Lipid I (13). 
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Figure App2.17. HRMS of Gly3-Lipid I (13). 
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Figure App2.18. LRMS of protected Gly5-Lipid I (14). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
! 187 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure App2.19. HRMS of Gly-Lipid II (15). 
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Figure App2.20. HRMS of Gly3-Lipid II (16). 
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Figure App2.21. LC/MS/MS of delipidated S. aureus Lipid II. 
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Figure App2.22. Estimation of the amount of S. aureus Lipid II isolated from cells. Synthetic Lys-Lipid 
was used as a standard. a) Known amount of Lys-Lipid II was mixed with the S. aureus Lipid II sample 
for lipid cleavage and LC/MS analysis. A Lys-Lipid II standard curve was used to calculate S. aureus 
Lipid II concentration. The following equation was used: amount of S. aureus Lipid II = concentration x 
volume x Mw of S. aureus Lipid II. In this manner, 300 !g S. aureus Lipid II (from 1 L culture) was 
estimated. b) Serial dilutions of S. aureus Lipid II and Lys-Lipid II samples were prepared, biotinylated, 
and subjected to Western blot analysis. The band intensity was quantified on ImageJ. The standard curve 
of Lys-Lipid II was used to calculate the concentration of S. aureus Lipid II sample. 800 !g Lipid II (from 
1 L culture) was estimated. c) S. aureus Lipid II appeared to contain predominant one species on TLC. 
Cerium Ammonium Molybdate (CAM) stain was used. 
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Figure App2.23. LC/MS analysis of delipidated Lipid II from different bacteria: !femA S. aureus; !femB 
S. aureus; B. subtilis; E. faecalis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Three: MS and Western blots data for studies in Chapter Four 
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Figure App3.1. The TP domain of S. aureus PBP2 is responsible for PG cross-linking. S. aureus 
PBP2 TP inactive mutant (S398G) and SgtB, a monofunctional glycosyltransferase, do not produce 
dimer muropeptide products. 
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Figure App3.2. Beta-lactams inhibit S. aureus PBP2 TP activity in vitro. (a) The cross-linking and BDL-
labeling are both specific to the TP activity of PBP2. PBP2 S398G (TP inactive mutant) shows no activity 
in the presence or absence of lysostaphin. (b-c) Structures of beta-lactams and their inhibitory activities of 
PBP2. (d) PBP2 mutants demonstrate altered TP activities in the presence of specific beta-lactams.  !!
 
